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SUMMARY 
 
The Epstein-Barr virus (EBV) is one of the oldest and most successful human viruses, 
infecting over 95% of the human population. Exposure usually occurs during early 
childhood and leads to mild, or no, acute symptoms. After primary infection, the virus 
enters naive B cells, causing differentiation and proliferation, finally leading to lifelong 
persistence of the virus in these cells (latency). Infectious virions are produced during 
the lytic phase of the EBV life cycle, leading to spread of the virus via oral secretions. 
There is a strong link between EBV infection and over a dozen malignant diseases. A 
large amount of our EBV knowledge has been obtained in B cells. However, this virus 
also infects epithelial cells and is associated with a range of epithelial malignancies. 
This thesis aims to elucidate some of the ambiguity surrounding EBV lytic cycle in 
epithelial cells and to extend the knowledge surrounding the switch from latency to 
lytic cycle. For this purpose EBV was induced into lytic cycle, in the epithelial cell line 
HONE1-EBV, with the histone deacetylase inhibitor SAHA, which is used in the 
treatment of non-Hodgkin lymphoma and is in Phase II clinical trials for the treatment 
of nasopharyngeal carcinoma. The binding of the early lytic cycle protein, Zta, to the 
epithelial host cell genome was investigated using Chromatin Immunoprecipitation 
followed by high-throughput sequencing. This led to the identification of several host 
genes regulated by the lytic virus. In addition, results previously obtained in B cells 
and other public ChIP sequencing data were included in the data analysis and 
revealed a potentially significant role of the host transcription co-factor and proto-
oncogene candidate BCL3. Further experiments led to the proposal of a model for the 
regulation of Zta gene activation involving Zta, BCL3 and TORC.  
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Chapter 1: Introduction 
 
1.1 General Overview 
1.1.1 Brief Introduction to Viruses 
Any virus on its own has no metabolism and cannot replicate; it is an acellular, 
inert complex of molecules. But when viruses enter cells, they can be replicated, 
which causes harm to the host. Viruses can vary greatly in shape, size and 
content. They generally consist of some nucleic acid - single or double strand 
ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), surrounded by a 
protective protein shell, the nucleocapsid.  Many viruses also carry replicase 
enzymes and some viruses have an additional membrane [1]. The number of 
genes encoded by different types of virus can range from three to several 
hundred. Similarly their size can vary greatly, ranging from 10nm-300nm [2]. Most 
eukaryotic viruses can only infect certain cell types, depending on specific host 
cell membrane surface receptors which can be bound by the virus and lead to 
cell entry via endocytosis or direct fusion with the membrane. Cell types that lack 
specific receptors are much less prone to viral infection. Bacteriophages, which 
are often used in gene cloning, attach to the bacterial cell wall using their tail fibre 
through which they then inject their DNA into the cell [1, 3].  
Once inside the cell, some viral genomes can be integrated into the host cell 
chromosome as an additional set of genes which are only replicated as the cell 
divides. This is known as latency. Most of the symptoms attributed to a viral 
infection are caused by the active replication of the virus independent of the host 
cell chromosome. This process leads to the destruction of the host cell and is 
known as lytic cycle, which will be the focus of this thesis. Following viral 
18 
 
replication, newly formed viruses are released. This process may kill the infected 
host cell through lysis. In other cases the viral release causes no immediate 
damage but leads to the embedding of some viral proteins in the cell membrane, 
which allow the immune system to recognize infected cells. If the viral antigen is 
associated with an MHC class I molecule, natural killer cells bind to the foreign 
viral proteins and cause membrane trauma leading to cell death. In cases where 
the immune system does not recognize an infected cell, viruses can cause 
apoptosis by producing deficiency injury in infected cells. During active viral 
replication, essential metabolites are in such heavy demand that the cell cannot 
survive [1].  
Infectious diseases are the second most common cause of death worldwide [4]. 
While bacterial infections can mostly be controlled by antibiotics, finding drugs 
that effectively treat viral infections is very challenging. Viruses use the host cell’s 
resources and metabolism, so effective antiviral drugs often lead to toxicity for 
the host. As is the case in chemotherapeutic cancer treatment, some licensed 
antiviral drugs are more toxic to the virus than to the host (e.g. nucleoside 
analogues). However, the development of drug resistant viruses is common in 
this type of treatment. Some agents produced by the host itself (i.e. Interferons), 
which can inhibit cell protein synthesis, are able to target viruses by preventing 
viral spread to further cells. However, only small amounts of interferons are 
produced in response to highly virulent viruses. In addition, interferons are host-
specific, so interferons produced in one species cannot be used to treat viral 
infection in another [5].  
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1.1.2 Herpesviruses 
 
Herpesviruses make up a large family of viruses that cause many different 
diseases including cold sores, chicken pox and infectious mononucleosis. Some 
herpesviruses can remain latent in host cell for extended periods of time (years) 
and only become active in response to stress conditions. In addition 
herpesviruses, like the Epstein-Barr virus, can cause cancer. The structure of 
herpesviruses is quite complex (Figure 1) [2, 5].  
 
 
Figure 1: Schematic image and electronmicrograph of herpesvirus structure. 
Figure 1: Schematic image and electronmicrograph of herpesvirus 
structure. Figure shows an enveloped polyhedral capsids with linear double-
stranded DNA. Electronmicrograph from Goldsmith et al., 2009 [6]. 
 
Herpes viruses infect host cells by attaching to specific cell receptors, fusing the 
cell membrane with the viral envelope. This allows the nucleocapsid to be 
released into the cell before it is transported to the nucleus, where the viral DNA 
is uncoated, circularizes and latency is established [5]. When the virus enters lytic 
cycle, the genome is replicated, viral genes are expressed and the virus is 
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assembled in the nucleus. The viral envelop is obtained from the host cell’s 
nuclear membrane and the fully-formed virus exits via exocytosis or lysis.  
Herpesviruses have very high infection rates and are the most prevalent type of 
DNA virus [2]. Almost all animal species are natural hosts to at least one type of 
herpesvirus. Overall, more than 200 herpesviruses have been identified which 
have particular specificity for certain host species and are classified into three 
subfamilies: α, β and γ. In addition to this classification, a numbering system has 
been assigned to the eight known human herpesviruses (HHV) with numbers 
corresponding to the order of discovery (except HHV-7). [1, 2] 
 
1.1.3 The Epstein - Barr virus 
The Epstein-Barr virus (EBV, HHV-4) is the only γ-1 herpesvirus (or 
lymphocryptovirus) that is known to infect humans and humans are its only 
natural host [11]. EBV was first discovered in 1964 by Anthony Epstein, Yvonne 
Barr, and Burt Achong in cultured tumour cells from a Burkitt Lymphoma biopsy 
[6, 7]. Since then it has become clear that EBV is one of the oldest, most common 
human viruses which has infected mankind ever since we parted from our primate 
ancestors [7]. EBV is highly prevalent all over the world, even in remote locations. 
More than 95% of the world’s population are infected by this virus, which makes 
EBV one of the most successful human pathogens [8, 9].  
In 2012, 14 million people were diagnosed with cancer, of which 2.2 million cases 
(15.4%) were directly linked to infections [10]. EBV is one of the most common 
causes of infection associated cancer, with an estimated 200 000 new cases 
annually [11]. While EBV infection is benign and asymptomatic in the majority of 
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cases, there is a strong link between EBV infection and over a dozen malignant 
diseases in both immunocompromised and immunocompetent patients. In total, 
1.5% of cancer cases are associated with EBV [10]. The four most common 
malignancies connected to EBV infection are Hodgkin’s lymphoma, Burkitt 
lymphoma, gastric carcinoma and non-glandular nasopharyngeal carcinoma 
(NPC), which will be discussed in more detail further on in this introduction. EBV 
causes approximately 10% of gastric carcinomas, which are the second most 
common cause of cancer deaths [12]. Many factors point to the causative role of 
EBV in malignant transformation. These include viral oncogenes and the 
presence of EBV in every cancerous cell in EBV associated tumours. In 
immunocompetent hosts, cancer detection occurs several years after primary 
infection, suggesting that EBV infection is only one factor in the complex, 
multistep process of malignant transformation [6]. Cofactors which are able to 
initiate the lytic stage of the viral life cycle, thus reactivating viral replication, are 
most likely required for EBV associated oncogenesis [11]. The International 
Agency for Research on Cancer classifies EBV as a Group 1 carcinogen [12].  
In addition to the direct link between EBV and cancer, increasing evidence points 
to the implication of EBV in the pathogenesis of Multiple Sclerosis, a chronic 
inflammatory demyelination of the central nervous system which leads to 
progressive disability in affected individuals [13].  
Evolution of EBV, and other herpes viruses, has been driven by survival rather 
than the ability to cause illness. Persistence and reactivation have become key 
to the success of this group of pathogens [6]. Persistence of EBV can be detected 
as a lytic infection in the oral mucosal epithelium in immunocompromised people, 
which leads to the spread of the virus via oral secretion. EBV can also be 
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transmitted through blood transfusions. EBV exposure often takes place during 
early childhood and leads to mild, or no, acute symptoms. It has been suggested 
that persistent maternal antibodies might play a protective role in containing the 
infection at this stage [14]. The primary infection stimulates a specific immune 
response, but this is unable to rid the body completely of the virus [15]. When 
exposure is delayed to a later point in life, which is more common in developed 
countries, EBV infection leads to infectious mononucleosis in about 50% of 
primary infection cases. Infectious mononucleosis is a self-limiting 
lymphoproliferative disease characterised by fever, pharyngitis and general 
lymphadenopathy [12, 16]. After primary infection, the virus infects naive B cells 
and expresses all of the EBV genes associated with latency including 10 proteins 
and two small RNAs (latency type III), which drive B cell transformation and 
proliferation but also initiate an immune response which leads to the elimination 
of infected B cells by EBV-specific T cells. By downregulating its immunogenic 
proteins, the virus is able to survive within the host. Infected B cells enter lymph 
nodes where they are able to proliferate while only expressing three viral proteins 
(latency type II). When the infected B cells exit the lymph nodes as non-dividing 
memory B cells, all viral proteins are downregulated (latency type 0), making the 
virus undetectable to the immune system. When the infected B cells divide, the 
virus expresses one protein (latency type I) to ensure that the viral genome 
divides with the host cell genome [17]. A model of the EBV life cycle is visualised 
in Figure 2. 
Even though EBV is probably the most potent transforming human virus in cell 
culture [12], it persists in the nucleus of memory B cells for the duration of the 
host’s life, often asymptomatically as the viral genome. During this time, a 
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relatively small amount of active viral replication occurs which causes 
transmission of the virus via oral secretions [6, 18]. All γ-1 herpesvirus have a 
distinct set of genes which enables them to persist in B cells. EBV is also able to 
infect other cell types, including mesenchymal cells, T cells, and epithelial cells 
which will be particularly relevant for this thesis. 
 
EBV has a linear 172kb double stranded DNA genome (Figure3), which 
encodes >85 genes and is wrapped around an O-shaped protein core. When the 
virus infects a cell, the ends of the linear genome join together to form circular, 
episomal DNA. The genome contains long and short unique sequence domains; 
these sections are responsible for almost all of its coding capacity. Other parts of 
the EBV genome include internal and terminal tandem and reiterated direct 
repeats. The number of joined terminal repeats differs between virions due to the 
variable cleavage of the genome during the replication process. This makes it 
possible to distinguish clonal infection events. The number of terminal repeats 
stays constant in dividing, latently infected cells [6, 7].  
There are two major types of EBV, namely EBV-1 and EBV-2 (or type A and B), 
which contain substantial differences in DNA sequence, particularly in their 
nuclear antigen genes (EBNA2, EBNA3A, EBNA3B and EBNA 3C). In addition, 
there are different viral strains within each type based on heterogeneity of certain 
genomic regions. EBV strains vary between different geographical regions, but 
there can also be a range of different strains in the same area [19, 20].  
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Figure 2: Model of EBV life cycle. 
Figure 2: Model of EBV life cycle. 
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Figure 3: Map of circular, double-stranded EBV episome. 
Figure 3: Map of circular, double-stranded EBV episome. Figure shows latent 
genes. Modified from Tao et al., 2006 [21]. oriP: origin of plasmid replication, 
oriLyt: origin of lytic replication, TR: terminal repeat. The locations and 
transcription of viral latent genes are indicated. The outer arrows show the large 
EBV transcript in latency 3, during which all the EBNAs are transcribed from 
either the Cp or Wp promoter. The EBNAs arise from the same transcript that is 
differentially spliced. The inner arrow shows EBNA1 originating from the Qp 
promoter which is transcribed in latency 1 and 2.  
 
 
1.2 EBV in B cells 
1.2.1 Entry into B cells 
EBV enters B cells by interacting with the complement receptor CD21 on the cell’s 
surface via the viral envelop glycoprotein gp350/220 and binding of a second 
glycoprotein, gp42, to human leukocyte antigen class II which acts as a co-
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receptor.  When the viral molecules interact with the B cell receptors, CD21 
aggregates within the membrane and EBV is endocytosed in cytoplasmic 
vesicles [6, 15]. Fusion in this low pH compartment occurs via three proteins 
which are part of the core fusion machinery [22], common to all herpesviruses. 
The core fusion machinery is activated by the interaction of gp42 with HLA class 
II, which leads to the widening of a hydrophobic pocket on the gp42 protein [23], 
and is made up of homodimers of glycoprotein gB and a heterodimer of 
glycoproteins gH and gL. Binding of glycoprotein gp42 to gH allows the formation 
of the gHgLgp42 complex. This complex leads to the activation of gB which is 
thought to insert a fusion loop into the cell membrane and undergo a 
conformational change which leads to the fusion of the viral and cellular 
membranes. [24] 
 
1.2.2 Latency in B cells 
The unique ability of EBV to convert resting B cells into permanently latently 
infected lymphoblastoid cell lines (LCLs) has provided researchers with an 
invaluable, yet incomplete, in vitro model of the lymphomagenic potential of EBV 
[15]. A large proportion of our knowledge about EBV relates to B lymphocytes. 
When EBV is in the latent phase of its life cycle, no infectious viruses are 
produced and only a highly restricted set of latent genes are expressed, which 
contribute to the ability of the virus to evade immune detection. The expressed 
genes disrupt normal B cell growth which leads to virus-induced immortalisation 
and the establishment of LCLs [6].  
The EBV genome is maintained as a circular episome during latency with every 
LCL carrying multiple extrachromosomal copies. A limited set of viral genes is 
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constitutively expressed during latency, comprising of six viral nuclear antigens, 
EBNAs 1, 2, 3A, 3B, 3C and –LP, and three latent membrane proteins, LMPs 1, 
2A and 2B. Transcripts from the BamHIA region and non-coding EBER1 and 
EBER2 can also be detected [15]. Four distinct latency programs have been 
identified, including the above mentioned latency type 0 (no latent gene products 
can be detected), latency type 1 (EBER and BART transcripts are present and 
EBNA1 is expressed), latency type 2 (EBER and BART transcripts, EBNA1, 
LMP1 and LMP2) and latency type 3 (all latent gene product are expressed, 
including EBNAs 1, 2, 3A, 3B, 3C and –LP, all three latent membrane proteins 
LMP1, LMP2A and LMP2B, as well as the EBER and BART RNAs) [25]. In 
addition, some subsets of BL tumours express EBNA1, -3A, -3B, and -3C and a 
truncated EBNA-LP without LMPs or EBNA2. This is known as Wp restricted 
latency as transcription is limited to the Wp promoter [26]. Table 1 summarises 
the EBV latency types.  
 
Latency 
Type 
Viral Gene Expression Occurrence 
0 none Non-dividing, infected memory B 
cells 
1 EBER and BART miRNAs 
EBNA1 
Dividing, infected B cells, Burkitt’s 
Lymphoma, Primary Effusion 
Lymphoma 
2 EBER and BART miRNA, 
EBNA1, LMP1 and LMP2 
Recently infected B cells in lymph 
nodes, NPC, Gastric carcinoma, 
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Hodgkin’s lymphoma, T/NK cell 
lymphoma 
3 EBNAs 1, 2, 3A, 3B, 3C 
and –LP, LMP1, LMP2A 
and LMP2B, EBER and 
BART miRNAs 
Primary infection, AIDS_NHL (large 
cell), PT-LPD 
Wp 
restricted  
EBNA1, -3A, -3B, and -3C 
and a truncated EBNA-LP 
Subsets of BL tumours 
Table 1: EBV latency types. 
Table 1: EBV latency types. Table includes genes expressed in each latency 
type and when you would expect to see that type of latency. 
 
During latency, the viral genome is replicated by host cell DNA polymerase and 
is equally distributed to daughter cells during mitosis. Latent infection of B cells 
is essential for the life-long persistence of the virus. It has been shown that 
patients who lack B cells (X-linked agammaglobulinemia) do not show evidence 
of persistent EBV infection [27].  
The main oncogenic EBV protein is the latent membrane protein LMP1 which is 
essential for tumorigenic B cell transformation [28, 29]. LCLs express anti-
apoptotic proteins like BCL2 and A20, and high levels of B cell activation markers 
including CD23, CD30, CD39 and CD70 as well as the cell adhesion molecules 
CD11a, CD58 and CD54 which are normally expressed at very low levels in 
resting B cells until they are activated by antigenic or mitogenic stimuli. This 
indicates that EBV-induced immortalization can be achieved through the 
constitutive activation of the same pathways that drive physiological B-cell 
proliferation [15, 30]. 
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1.2.3 Lytic cycle in B cells 
Lytic replication is initiated in B cells when the latent virus is reactivated following 
physiological stimuli or chemical assault, such as foreign antigens, 
immunodeficiency, malaria, protein kinase C agonists, DNA methyltransferase 
inhibitors, histone deacetylase inhibitors or anti-IgG [12, 18]. Key early lytic 
promoters and the origins of lytic replication are in a repressive heterochromatin-
like environment during latency which has to be overcome to achieve viral 
replication [18]. During the lytic cycle, the EBV genome goes through substantial 
epigenetic modifications including chromatin remodelling and DNA methylation 
[18]. The earliest indicators of the lytic cycle are the proteins Zta and Rta which 
are key mediators in the switch from latency to lytic cycle as they act as powerful 
transactivators of later lytic cycle genes and lead to the expression of the viral 
DNA polymerase [31].  During the lytic phase of the EBV life cycle, infectious 
viruses are produced. At this stage approximately 80 viral proteins are expressed 
which include DNA replication factors, transcriptional activators and structural 
proteins. After replication, the linear genome is cleaved at the terminal repeats 
and packaged into viral capsids. Finally, the virus is enveloped and released from 
the cell [6].  
 
1.3  EBV in Epithelial cells 
1.3.1 Entry into epithelial cells 
Entry of EBV into epithelial cells occurs through separate, as yet poorly defined 
pathways, that seem to require EBV gH and gL glycoproteins but not gp42 as 
epithelial cells lack HLA class II expression [32, 33]. EBV infection of epithelial 
cells is much less efficient than B cell infection and may involve a direct transfer 
30 
 
infection from EBV-coated B cells to epithelial cells. The surface molecule α5β1 
integrin may contribute to EBV infection in this cell type [6].  It has been shown 
that tonsillar and adenoid epithelial cells express CD21 mRNA, which may 
suggest that this protein could play a similar role to infection in B cells. [34, 35] A 
viral membrane protein which is encoded by the bmrf2 open reading frame can 
bind β1 integrin and may also be involved in attachment. [36, 37] gH is likely 
involved in the fusion of the viral and cellular membrane. Fusion does not appear 
to require endocytosis, and the resulting low pH, as is the case in B cells. Due to 
the lack of HLA class II, gp42 does not seem to interact with the gHgL complex. 
Recent studies have shown that the ephrin receptor tyrosine kinase A2 
specifically binds to gHgL and is involved in the fusion of EBV to the cell 
membrane in epithelial cells. [38] 
In vitro infection of epithelial cells does not activate the full growth-transforming 
programme of EBV and rarely achieves full lytic replication. In addition the EBV 
genome is lost during prolonged culture. Hence LCLs have remained the 
dominant in vitro model for studying EBV infection [15, 39].  
 
1.3.2 Micro RNAs 
In recent years there has been an increasing focus on the presence of 
microRNAs in EBV infection which seem to play a role in the transcription of the 
cellular and viral genome. EBV was the first virus shown to encode microRNAs 
[40]. It expresses at least 22 distinct microRNAs [41]. 14 microRNAs are located 
in the introns of the viral BART gene and are expressed at high levels in latently 
infected, differentiated epithelial cells while they are almost undetectable in B 
cells. More research is required to characterise their concrete function as they 
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are likely to play important roles in the viral life cycle and may contribute to the 
infection of different human tissues [25, 42].  
 
1.3.3 Lytic Cycle in Epithelial Cells 
It has been suggested that lytic replication of EBV in epithelial cells is rare, usually 
abortive and mainly occurs in small subsets of malignant cells [39]. The early lytic 
cycle protein Zta has occasionally been detected in NPC samples, in a minority 
of tumour cells [43]. Consistent expression of other lytic proteins and linear forms 
of DNA is absent within tumour cells, suggesting that NPCs do not fully permit 
viral replication [44, 45]. However, EBV lytic replication is considered an 
oncogenic risk factor as a rise in IgA antibodies to lytic viral proteins can 
frequently be detected in NPC patients prior to treatment (e.g. VCA and Zta). The 
appearance of these antibodies precedes NPC development by several years 
and has been sown to correlate to tumour burden [43, 46, 47]. While it has not 
been possible to definitively demonstrate the presence of lytically infected 
epithelial cells in healthy EBV carriers, the virus can be detected in throat 
washings. These findings indicate that reactivation of lytic cycle is a feature of 
EBV infection in healthy carriers [39], though it is uncertain whether these virions 
are produced by B cells or epithelial cells. Cell-free DNA can be detected in the 
serum of NPC patients, but it is not clear whether this represents encapsidated 
virions or naked DNA from dead host cells. It appears resistant to DNAse 
digestion and the NPC tumour burden is relatively small in comparison to the 
serum DNA levels, suggesting that it may arise from virions rather than dying 
NPC cells. This could point to some unrecognised role of lytic EBV replication in 
the pathogenesis of NPC [6]. In addition, studies have shown a strong association 
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between the levels of circulating tumour-derived EBV DNA in the blood of patients 
with NPC and overall survival rates, with low post-treatment levels leading to a 
good prognosis for the patient. It is thought to accurately reflect the residual 
tumour load [48].  
EBV lytic replication in epithelial cells is indisputably observed in patients infected 
by the human immunodeficiency virus (HIV) with oral hairy leukoplakia, which is 
a non-malignant epithelial lesion located on the tongue where EBV replicates in 
the upper-layer of skin cells which are undergoing terminal differentiation, 
apoptosis and desquamation. This suggests that EBV replication is dependent 
on the differentiation state of epithelial cells [39]. When epithelial cells are grown 
in organotypic cultures (“rafts”), allowing the cells to differentiate and stratify as 
they do in vivo, EBV infection results in spontaneous production of large numbers 
of virions, specifically in the differentiating suprabasal cells. This may lead to the 
increase of the virus pool and increasing efficiency of transmission in vivo. [49] 
 
 
1.3.4 EBV contribution to Nasopharyngeal Carcinoma 
Certain types of EBV latency have been linked to specific cancers. 
Nasopharyngeal carcinoma (and gastric carcinoma) arises from latency 2 [50]. A 
diagram summarising the transformation of normal epithelium to NPC is shown 
in Figure 4.  
Epithelial cancers associated with EBV are relatively rare globally. The type II 
non-keratinizing nasopharyngeal carcinoma shows the most consistent 
worldwide association with EBV with a high incidence in Southeast Asian, 
Alaskan Inuit, and North African populations, reaching a peak incidence of around 
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20-30 cases per 100,000 [47-49]. The increased levels of EBV related NPCs in 
these particular populations may be due to genetic predispositions, as it has been 
shown that individuals of Chinese decent, especially Cantonese males, are more 
likely to develop EBV-associated NPC regardless of where they live. Frequent 
genetic changes found in low-grade dysplastic lesions of high-risk individuals, in 
the absence of EBV infection, include deletions of regions on chromosomes 3p 
and 9p. This supports the argument that genetic changes may predispose to 
subsequent EBV infection [50, 51]. Cultural and dietary factors may also play an 
important role in the predisposition of these populations. This is supported by the 
fact that a decline in EBV-associated NPC incidence has been shown in second 
generation Chinese American migrants [13, 52, 53]. Dietary risk factors include 
preserved food preparation such as salted fish (especially during weaning), 
Qaddid (dry mutton preserved in oil) and the spice mixture Harissa [54].  
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Figure 4: The pathogenesis of NPC. 
Figure 4: The pathogenesis of NPC. Different layers of the skin and cancerous 
states are indicated. Grey arrows show the carcinogenic changes thought to be 
associated with the above states [51]. 
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It has been shown that EBV strains isolated from NPC tumours in endemic 
regions, such as M81, can infect primary epithelial cells and induce lytic cycle 
more efficiently than others strains (e.g. B95-8 or Akata) [55]. These strains often 
have mutations in HLA epitopes in LMP1 and proteins including gp110 and Zta 
[56, 57]. 
It is possible that NPC arises from persistently infected epithelial cells which have 
undergone a second genetic event. EBV causes the methylation and consequent 
silencing of multiple tumour suppressor genes in NPC [52]. Proliferation of 
epithelial cells may lead to other oncogenic transformations, as is the case in B 
lymphocytes. Another possibility is that EBV infection of epithelial cells occurs at 
a later stage of life in at-risk individuals whose nasopharynxes have been 
exposed to carcinogens or other preneoplastic genetic changes which render the 
affected epithelium susceptible to EBV infection. This argument is supported by 
the fact that EBV has been detected in the cells of the nasopharynx in high-grade 
pre-invasive lesions but not in low-grade disease [53, 54]. Thus strain variation, 
environmental, genetic and cultural factors likely all contribute to the development 
of NPC.  
The immediate early lytic cycle protein Zta may enhances malignant 
transformation of epithelial cells by triggering the secretion of the angeogenic 
vascular endothelial growth factor and inflammatory, oncogenic cytokines (IL-6, 
IL-8, IL-10, IL-13)  [55]. A prominent lymphocytic infiltration is characteristic of 
NPC tumours. The interaction between tumour cells and lymphocytes appears to 
be crucial for the continued propagation of the malignancy. However, the EBV 
genome is located in the epithelial tumour cells and cannot be detected in the 
infiltrating lymphocytes [44].  
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NPCs are broadly classified into two types: nonkeratinizing and keratinizing. Non-
keratinizing NPC is by far the most common type, it can be poorly differentiated 
or undifferentiated and all tumour cells show evidence of clonal EBV infection. 
Non-keratinizing NPC is often accompanied by an ornate reactive T lymphoid 
response which may obscure the epithelial neoplasm leading to a 
lymphoepithelioma. However, the  lymphoepithelioma does not show evidence of 
EBV infection [6]. Keratinizing NPC is defined by the presence of keratin in 
addition to the squamous appearance of the tumour cells. Initially, no association 
could be found between EBV and keratinizing NPC [56, 57], but recent studies 
have identified EBV in some cases of the disease [58]. Whether or not EBV plays 
a significant role in keratinizing NPC remains debatable.  
While the exact point of EBV infection in NPC development is unclear, all 
cancerous cells in any EBV-associated NPC or high-grade dysplastic lesion carry 
monoclonal viral genomes, indicating that infection must occur before the clonal 
expansion of the malignancy, or that a single EBV infected clone has 
predominated [44, 59, 60]. Other EBV-associated neoplasms can arise in atypical 
cellular targets and include a subset of gastric carcinomas which share the 
histological features of undifferentiated NPCs [6, 15]. EBV infection may 
represent a rare event in these cell types. 
 
1.3.5 Latency in Epithelial Cells 
Based on the evidence to date, it has been suggested that true latency of EBV in 
epithelial cells only occurs in EBV-positive epithelial cell tumours [39]. Latency 
genes expressed in these cells appear intermediate between the latency 1 and 
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latency 2 programmes seen in B lymphocytes. EBNA1 and EBER are expressed 
in all EBV positive cases. Other EBNAs are absent. Some evidence points to 
growth-promoting effects of LMP2A on epithelial cells whose transcripts are 
amplified in most affected NPCs alongside LMP2B [25, 61]. The LMP2A protein 
can be detected in ~50% of cases. LMP1 protein can be identified in 35% of EBV 
associated tumours and is present in all pre-invasive lesions, suggesting an 
important role in early tumorigenesis that may not be required in established 
carcinomas [59, 61, 62]. It is still unclear how and when the virus infects epithelial 
cells, thus our understanding of the potential role of EBV in NPC development is 
limited. It is clear that the primary site of infection is the oral cavity and that oral 
secretions are responsible for the shedding and consequent transmission of the 
virus. However, it has not been possible to unequivocally identify EBV infection 
in oral epithelial cells of high-risk, healthy individuals; hence the occurrence of 
persistent infection in these cells is questionable [6, 15]. During in vitro 
experiments infection of B cells with EBV leads to the amplification of the EBV 
genome to>20 copies per cell, even if the infecting virus is a replication-defective 
Zta-knock out (see section 1.4 for further information about Zta). This 
amplification cannot be observed after infection of primary tonsillar epithelial cells 
(a likely site of EBN infection in vivo) in which EBNA1 expression is only detected 
in ~40% of EBER positive cells. The EBV genome is not maintained in these cells 
during culture. Conversely, the gastric carcinoma cell line AGS, which is derived 
from a malignant tumour formed of glandular structures in epithelial tissue, did 
result in maintenance of EBNA1 expression and EBV genome replication. 
However, as opposed to B cells, this replication was dependant on Zta. [39] 
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1.4 EBV Vaccines  
 
There is currently no licensed prophylactic vaccine for EBV. Most efforts to 
develop an effective vaccine focus on the EBV glycoprotein gp350. Phase 2 
clinical trials using monomeric gp350 showed a reduced susceptibility to 
infectious mononucleosis by 78% but did not reduce the rate of EBV infections. 
[63] Further phase 3 trials of the vaccine are needed to determine if the vaccine 
can indeed reduce the rate of infectious mononucleosis. Based on the fact that 
infectious mononucleosis increases the risk of developing Hodgkin lymphoma 
[64] and multiple sclerosis [65], a vaccine that reduces infectious mononucleosis 
might also reduce these associated diseases. However, due to the low rate of 
their occurrence it would require a considerably large study to determine this.  
Due to the long period of time between initial EBV infection and the development 
of epithelial cancers like nasopharyngeal carcinoma or EBV positive gastric 
carcinoma, a clinical trial targeting these conditions would be difficult. A recent 
study showed that gp350 antibody levels correlate with a reduction in 
nasopharyngeal carcinoma development [66], so a vaccine that does not prevent 
EBV infection may still be effective against these malignancies. In addition, a 
study by deBruyn et al. showed that children with inflammatory bowel disease 
have low seropositivity to EBV [67], so it would be interesting to find out if an EBV 
vaccine has an effect on this condition.  
Current efforts to develop an effective EBV vaccine include multimeric form of 
gp350, virus-like (nano-)particles and formulations including viral glycoproteins, 
lytic or latent proteins in addition to gp350. [68] Clinical trials on the effectiveness 
of such vaccines are still required. 
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The immediate-early lytic protein Zta, discussed in the following section, has been 
suggested as a vaccine target as it is produced prior to immune evasion genes. 
It is recognised more readily by CD8 T cells than early or late lytic proteins. [69] 
Zta is an important T cell target in infectious mononucleosis patients and patients 
with post-transplant lymphoproliferative disease. Destruction of cells expressing 
Zta reduces the chance of virion production. However, a recent study suggests 
Zta is not recognised in the early stages of EBV infection. [70] 
Testing the efficacy of any EBV vaccines is complicated by the lack of a suitable 
non-primate animal model for EBV infection. In addition, difficulties in selecting a 
suitable adjuvant hinders progress in this field [14]. 
 
 
1.5 Zta 
Zta (alias BZLF1, Z, ZEBRA or EB1) is a 245 amino acid, 35kDa, bZIP protein 
which is made up of an N-terminal transactivation domain, a basic DNA contact 
region, a dimerization region (zipper) and a c-terminal region [71],[72]. The 
activation of the Zp promoter, by AP1 proteins, Zta or SMAD [73], leads to the 
expression of BZLF1, which encodes Zta. It is the first viral gene to be expressed 
in the lytic cycle and coordinates the global changes in the viral transcriptome 
during the re-activation from latency as Zta activates further EBV lytic cycle genes 
[74]. It interacts with lytic promoters and origins of lytic replication, which are 
made up of a minimum of 32 sequence variants of a 7-mer sequence (ZREs), 
which resemble AP1 and C/EBPα binding elements. Most of the EBV genome, 
including the lytic promoters, is heavily methylated by the host cell during latency, 
creating a repressive chromatin environment [75]. Zta can recognize methylated 
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DNA and some CpG-containing Zta binding sites (CpG ZREs) are even 
dependent on methylation for Zta binding, which shows that Zta is able to interact 
with silenced DNA [76]. The loss of EBV genome methylation during lytic cycle 
leads to a reduction in binding of Zta to CpG ZREs, suggesting that Zta 
recognises these sites during the latency/lytic cycle transition, acting as a lytic 
cycle epigenetic switch [5, 77].  
There are three different classes of ZREs. Class 1 is unmethylated as it lacks a 
CpG motif. Class 2 can be methylated and contains CpG and Zta binding is 
enhanced by methylation. It contains a variant cAMP response element binding 
protein (CREB) /AP1 site. Class 3 can also be methylated and contains CpG, but 
Zta binding dependant on methylation [78]. 
Previous chromatin precipitation investigations carried out in Group I EBV 
positive Akata BL cells have shown that Zta interacts with many sites on the viral 
genome including origins of lytic replication and the promoters of Zta, BRLF1, 
and BMRF1 [76, 78]. Based on experiments carried out in these cells, it is known 
that Zta also interacts with certain regions on the host cell genome [31, 79]. In 
addition, Zta interacts and co-associates with many host and viral proteins [80]. 
It forms a homodimer but cannot dimerise with other cellular bZIP proteins such 
as Fos, Jun, C/EBPa and the CREB [81]. However, Zta binds to different cellular 
transcription factors through its dimerization domain, including p65, p53 and the 
retinoic acid receptor [82-84]. Through poorly understood mechanisms, 
transfection of these proteins significantly inhibits the transcriptional activation 
function of Zta and thereby decreases activation of the lytic cycle [85, 86].  
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Zta stabilizes RNA polymerase II at Zta associated promoters [87]. It interacts 
with six of the seven viral replication proteins, except BALF2 [88]. Zta-DNA 
interaction may also be influenced by other factors such as co-associating host 
or viral proteins or chromatin structures. 
An example of the Zta homodimer binding to an AP1 site is shown in Figure 5 
below. 
 
Figure 5: Model of Zta binding to DNA. 
Figure 5: Model of Zta binding to DNA. One of the bZIP helixes (yellow) bends 
towards one end of the DNA while the other (green) is straight. The Ap-1 site has 
been underlined. Figure by Petosa et al., 2006 [72]. 
 
The c-Fos, c-Jun, GCN4, and CREB protein family possess a conserved DNA-
binding domain. Zta contains a similar basic domain and binds directly to the 
consensus AP1 site [89]. The Zp promoter contains an Ap1/CREB-like binding 
site which is the main auto-activation site for Zta. There are three CREB-specific 
co-activator transducer of regulated CREB activity (TORC or CRTC) proteins; of 
these, TORC2 is the best studied. During the lytic cycle, TORC2 is translocated 
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from the cytoplasm to the nucleus [90]. TORC1, 2 and 3 have been identified as 
co-activators of Zta on the Zp promoter [90]. One example is that, in reporter 
assays, co-expression of Zta and TORC2 enhances Zp transcription up to 108-
fold in comparison to Zta expression alone [90]. This activation is complex. It is 
dependent both on ZREII (ZII) and ZREIII (ZIII) cis elements – ZREII (ZII) via 
CREB and ZREIII (ZIII) via Zta (Figure 5). siRNA knock-down of TORC2 reduces 
the levels of lytic proteins following induction, including Zta. Zta has been shown 
to form a complex with TORC proteins. In addition, both TORC2 and CREB have 
been shown to have some association with Zp. This interaction is significantly 
increased in the presence of Zta. TORC can associate with BCL3 which has been 
shown to recruit histone deacetylases that inhibit transcription [91] [92]. CREB 
has also been shown to be associated with Zp. Neither of these associations 
require Zta, but the effect of TORC2 is significantly higher when Zta is also 
present. The activation of Zp by TORC2 is increased by calcineurin, which is 
activated by calcium signalling following B cell receptor activation and leads to 
the dephosphorilation and consequent activation of TORCs. A model of the 
proposed mechanism of Zta interaction with TORC and CREB is shown in Figure 
6 below [92].  
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Figure 6: The proposed model for EBV Zp activation by Liang et al. 2002 
Figure 6: The proposed model for EBV Zp activation by Liang et al. 2002 
[92].  TORC is activated by calcineurin. It is able to associate with CREB or Zta 
(BZLF1) and enhances Zp activity through binding to ZII and 
ZIII cis elements. PLC: phospholipase C, PKC: protein kinase C, DAG: 
diacylglycerol, CaM: calmodulin, BCR: B-cell receptor, MEF2D: myocyte 
enhancer factor 2D [90].  
 
TORC is dephosphorylated in response to B cell receptor signalling which leads 
to its translocation into the nucleus where it increases the occupancy of pCREB 
44 
 
over certain binding sites [93]. It has been suggested that this allows for the 
specific activation of certain genes in response to signals which lead to both 
CREB phosphorylation and TORC dephosphorilation (Figure 7A). It is not clear if 
CBP is part of an alternative or cooperative pathways for target gene induction 
[94]. Nevertheless, TORC2 has been shown to interact cooperatively with CBP 
[95]. In addition, CBP has been shown to form a complex with Zta (and Rta [96]) 
and cooperates with it to significantly increase Zta-dependent transcription, 
including the lytic cycle, independent of its histone acetyltransferase activity. 
TORC2 has also been shown to interact with Zta and the TORC2/Zta complex is 
recruited to Zp. (Figure 7C) [97, 98]. In addition, Zta significantly increases CBP-
mediated acetylation of nucleosomal histones [99]. CBP can also bind to cellular 
transcription factors including p65, p53 and the retinoic acid receptor. The 
association of these proteins with CBP correlates with transcription activation 
function [100, 101]. Interestingly p65, p53 and the retinoic acid receptor inhibit 
Zta transcriptional activity, and the over-expression of CBP relieves the 
antagonistic interactions between different classes of activators such as nuclear 
receptors and AP1 [100]. It has been suggested that competition for CBP may 
control the transcription output from a range of signal inputs. Figure 7B shows 
two potential mechanisms of this inhibition [98].  
Zta has been shown to decreases the transactivation function of CREB in reporter 
assays. This effect can be partially reversed by the over-expression of CBP 
(Figure 7D) [97].  
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Figure 7: Model of cAMP response element binding protein (CREB) binding protein (CBP), Zta and phosphorylated CREB (pCREB) interaction. 
Figure 7: Model of cAMP response element binding protein (CREB) binding 
protein (CBP), Zta and phosphorylated CREB (pCREB) interaction. A: 
interaction of TORC, CBP and Zta increases Zta-dependant transcription of 
ZREs. B: Competition for CBP has been suggested to control transcriptional 
output of associated targets. Certain proteins may block binding of CBP to Zta by 
associating with CBP (left), alternatively competing proteins may associate with 
Zta thus hindering CBP-Zta interaction (right). C: TORC2 has also been shown 
to interact with Zta and the TORC2/Zta complex is recruited to Zp. D: Interaction 
of Zta with CREB decreases transactivation of CREB targets but has been 
suggested not to decrease the amount of pCREB-CBP complexes. 
Overexpression of CBP reverses this effect.  
46 
 
1.5 Project Context 
My early work focussed on HONE1-EBV cells, originally described as a poorly 
differentiated nasopharyngeal carcinoma cell line, but now thought to be a HeLa 
derivative [102]. These cells are prone to lytic cycle reactivation and have been 
re-infected with recombinant Akata EBV strain, containing neomycin-resistance 
and GFP genes [103]. 
As mentioned previously, it has been shown that there may be certain 
epitheliotropic EBV subtypes which lead to spontaneous lytic replication of EBV 
in epithelial cells and which are associated specifically with EBV related epithelial 
cancer [104]. Sequence analysis of Akata and the epitheliotropic EBV subtype 
M81, showed complete sequence homology between Zta proteins in both EBV 
strains (Figure 8). 
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Figure 8: Clustal 2.1 multiple sequence alignment of the Zta protein 
sequence of Akata and M81 EBV strains. No differences in the Zta protein 
could be detected. The top line is showing the Akata Zta protein sequence, the 
bottom line is showing the M81 Zta sequence. 
 
1.6 Aims 
 
My work aims to extend the knowledge surrounding the switch from latency to 
lytic cycle of the Epstein-Barr virus by: 
 Identifying Zta binding sites in chromatin and making comparisons 
between epithelial and B cells 
 Investigating histone modification and transcription factor binding in 
various cell types (ENCODE database) to identify common factors 
 Exploring any relationship between cell factors and Zta function 
 
Figure 8: Clustal 2.1 multiple sequence alignment of the Zta protein sequence of Akata and M81 EBV strains. 
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Chapter 2: Materials and Methods 
 
2.1 Materials 
2.1.1 Cell Lines 
Cell Line Description Reference Application 
Akata  EBV positive B 
lymphocyte, contains 
doxycycline inducible 
BZLF1 expression vector 
[105] Western blot, ChIP 
qPCR, RNA 
quantification, 
FACS, siRNA 
transfection 
HEK 293T EBV negative, derived 
from human embryonic 
kidney cells, contains 
mutant  SV40 large T 
antigen 
[106] Luciferase assay, 
Western blot 
HEK 293ZKO derived from human 
embryonic kidney cells, 
infected with EBV lacking 
the BZLF1 gene 
[31] ChIP qPCR, 
Western blot, 
genome load, 
siRNA knock-down 
HONE1-EBV EBV positive adherent 
cell line 
[107] RNA quantification, 
western blot, FACS, 
genome load, ChIP 
qPCR, ChIP 
Sequencing 
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LCL3 EBV positive 
lymphoblastoid cell line, 
spontaneously lytic 
[108] Western Blot, 
FACS, ChIP qPCR, 
ChIP reChIP qPCR 
 
 
2.1.2 Antibodies 
Antibody Description Supplier Dilution Application 
Actin Rabbit 
polyclonal 
Sigma (A2066) 1:5000 Western 
Blot 
αIgG Rabbit 
polyclonal 
Dako (A0423) 1:800 Akata cell 
induction 
Bcl-3 (150-3.5) 
FITC 
Hamster 
monoclonal 
Santa Cruz 
Biotechnology 
(sc-32741 
FITC) 
5µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
BCL3 (c-14) Rabbit 
polyclonal 
Santa Cruz 
Biotechnology 
(sc-185, 
discontinued) 
1:200 or 10µl 
to stain 
1x106 cells 
FACS and 
Western 
Blot 
BCL3 (c-14) x Rabbit 
polyclonal 
Santa Cruz 
Biotechnology 
(sc-185 x, 
discontinued)  
10μg/1ml IP 
or 
1:2000  
ChIP and 
Western 
Blot 
BCL3 (new) Rabbit 
Polyclonal 
Abcam 
(ab27780) 
1:500 Western 
Blot  
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ChIP negative 
control 
Goat IgG Santa Cruz 
Biotech 
(sc-2028) 
10μg/IP (see 
protocol for 
volume) 
ChIP 
control 
IRDye 680CW Fluorescent 
anti-mouse 
secondary 
Li-Cor 1:5000 Western 
Blot 
IRDye 800CW Florescent 
anti-rabbit 
secondary 
Li-Cor 1:5000 Western 
Blot 
Mouse 
secondary 
Alexa Fluor 
647 
Donkey 
polyclonal 
Abcam 
(ab150103) 
5µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
normal Arm. 
hamster IgG-
FITC 
Hamster 
IgG 
Santa Cruz 
Biotechnology 
(sc-2864) 
20µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
negative 
control mouse 
Mouse IgG Sigma  
(I-8765) 
1µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
negative 
control rabbit 
Rabbit 
gamma 
globulin 
Jackson 
Immuno 
Research 
(011-000-002) 
0.2µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
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Rabbit 
Secondary 
Alexa Fluor 
647 
Goat 
polyclonal 
Abcam 
(ab150079) 
5µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
TORC2 Rabbit 
monoclonal 
Abcam 
(ab109081) 
1:1000 Western 
Blot 
TORC3 Rabbit 
monoclonal 
Abcam 
(ab91654) 
1:1000 Western 
Blot 
VCA Mouse 
monoclonal 
Millipore 
(MAB8184) 
1µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
Zta (BZ1) Mouse 
monoclonal 
Martin Rowe 
(Birmingham), 
described in 
[109] 
1:500 Western 
Blot  
Zta (EBV 
ZEBRA) 
Goat 
polyclonal 
Santa Cruz 
Biotechnology 
(sc-17503, 
discontinued) 
1µl to stain 
1x106 cells 
(see protocol 
for volume) 
FACS 
Zta (SCZ) Goat 
polyclonal 
Santa Cruz 
Biotech 
(discontinued) 
10μg/1ml IP 
(see protocol 
for volume) 
ChIP 
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2.1.3 qPCR Primers 
Primer 5’–3’ Sequence  Refe-
rence 
Appli-cation 
36B4 F: GGCCGAATRCTGTCTGTGGAGACCGATTACACC [110] RNA amount 
Normali-
sation 
R:GGCCGGATCCGACTCTTCCTTGG CTTCAACCTTAG 
BCL2A1 F: TCTTGAGCTGGCTCACCTTG [111] Zta and BCL3 
ChIP qPCR R: AAACACAGCCTACGCACGAA 
BCL2A1 
3' flank 
F: ACAGTGGTTACCTCTTGGGAGA [111] Zta and BCL3 
ChIP qPCR R:CCTGTGTTGAAACTCATGTTGGTA 
BCL2A1 
5' flank 
F: AGGAATTTGGCCTCCCAATCA [111] Zta and BCL3 
ChIP qPCR R: TTTCTCCAGCGACCATGAGTT 
beta 
globin 
F: GGCAACCCTAAGGTGAAGGC [112] Genome load 
normalisation R: GGTGAGCCAGGCCATCACTA 
 
BLLF3 F: TCCATCTGGGCACTTCTGACGCT [18] RNA 
quantify-
cation 
R: CCGTCAGCAGCGTGTTCACAA 
BNLF2a 
5' Flank 
F: CATGGCCCTGAACATGAGGT [18] Zta and BCL3 
ChIP qPCR R: GAGGCCAGCCAAGTCTACAG 
BNLF2a 
peak #2 
F: GAGGCACAGCTGTTTTCGTG [18] Zta and BCL3 
ChIP qPCR R: AGCCACACCTAACTCATGCC 
BZLF1 F: AGCCAAGGCACCAGCCTCCT [18] RNA 
quantify-
cation 
R: TGCATGAGCCACAGGCATTGCT 
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EBV 
polymer
ase 
F:AGTCCTTCTTGGCTAGTCTGTTGAC [112] Genome load 
R: CTTTGGCGCGGATCCTC 
 
EGFR 
#2 
F: GCAGCAGCCTGTGAAACATT  
n/a 
Zta and BCL3 
ChIP qPCR R: GCAACTGTTGGACTGGAGGA 
EGFR 5' 
flank 
F: TGGATGTGGGAACAGTGACG n/a Zta and BCL3 
ChIP qPCR R: TCATGGCTTCCAGGATGCAG 
FOSB F:TTGCTAAGAAGATTTGCTCAGGTA
G 
[111] Zta and BCL3 
ChIP qPCR 
R: GCTTTACAATCTCCTTCTTACTGCT 
GAPDH F: CTCATGCCTTCTTGCCTCTT [113] RNA amount 
Normali-
sation 
R: TTGATGGCAACAATATCCACTT 
OriLyt 
Flank/B
HLF1 
OL1 
flank 
F: GCGCAACAGTGCCACCAACC [76] Zta and BCL3 
ChIP qPCR 
R: CAGGACCTGGCGGTAGTGCAG 
OriLyt/B
HLF1 
(OL5/O
R4)  
F: CAGCTGACCGATGCTCGCCA [76] Zta and BCL3 
ChIP qPCR R: ATGGTGAGGCAGGCAAGGCG 
SCIMP F: CCCTCGTGCAATACTGTGAGA [111] 
 
Zta and BCL3 
ChIP qPCR R: ACAACTCATTCGCTCTGGGC 
F: TTGCACAGCAAGTTCAAGCC [111] 
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SCIMP 
3' flank 
R: CTTTCTTGAAGGCAGATGGCAA Zta and BCL3 
ChIP qPCR 
THRA 
#2 
F: ACAGGGTCACACGTAGATGC n/a Zta and BCL3 
ChIP qPCR R: GATGTCTGTGTGACTGGGCT 
THRA 3' 
Flank 
F: AGCACTTCTCGCTATGCTCC n/a Zta and BCL3 
ChIP qPCR R: TGTGTTCCCTGAGACCAAGC 
 
F: Forward, R: Reverse  
 
2.1.4 TaqMan Primers 
Primer 
Target 
Life Technologies TaqMan Assay ID Reference 
ANO1 Hs00216121_m1 [111] 
BCL2A1 Hs00187845_m1 [111] 
BCL3 Hs00180403_m1 [114] 
FOSB Hs00171851_m1 [111] 
FSCN1 Hs00602051_mH [111] 
GAPDH Hs99999905_m1 [111] 
GDF2 Hs00211913_m1 [111] 
p50 Hs00765730_m1 n/a 
p52 Hs01028890_g1 n/a 
RASA3 Hs00183698_m1 [111] 
SCIMP Hs010294_m1 [111] 
SLC6A7 Hs00204454_m1 n/a 
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2.1.5 Vectors 
Name Backbone Supplier/ 
Reference 
Application 
BCL3 flag pcDNA3 n/a BCL3 expression 
BHLF1 pCpGL-basic [111] Reporter of Zta function 
BHLF1 
mutant 
pCpGL-basic [111] Negative control reporter vector 
hisZta pcDNA3 [115] Zta expression 
pcDNA3 pcDNA3 Invitrogen Negative control expression vector 
 
 
2.1.6 siRNAs 
siRNA Supplier 
BCL3 (Attempt 2) Dharmacon (M-003874-02-0005) 
BCL3 1 Ambion (115617) 
BCL3 2 Ambion (115619) 
BCL3 3 Ambion (115618) 
CBP/p300 Dharmacon (M-003477-02-0005) 
Negative Control Ambion (AM4611) 
Negative Control 
(Attempt 2) 
Dharmacon (D-001206-13-20) 
Silencer Cy3 labelled 
negative control siRNA 
Ambion (AM4621) 
TORC1/CRTC1 Dharmacon (M-014026-02-0005) 
TORC2/CRTC2 Dharmacon (M-018947-02-0005) 
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 TORC3/CRTC3 Dharmacon (M-014210-01-0005) 
 
2.1.7 Solutions and Buffers 
Solution or Buffer Composition Application 
Blocking buffer 1x PBS,  
0.5% BSA (w/v) 
ChIP for 
sequencing 
Cell lysis buffer  85mM KCl, 0.5% (v/v) 
NP-40, 
5mM PIPES (pH 8) 
Chromatin 
preparation  
FACS Wash  0.1% NaAzide,  
5% FCS in PBS 
FACS 
High salt wash buffer 0.1% (v/v) SDS, 1% 
(v/v) Triton X- 
100, 2mM EDTA, 
20mM Tris (pH 8), 
500mM NaCl 
ChIP 
IP dilution buffer 0.01%(v/v) SDS, 
1.1%(v/v) Triton 
X-100, 1.2mM EDTA, 
16.7mM Tris 
(pH 8), 167mM NaCl 
 
 
 
ChIP 
equilibration 
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LiCl wash buffer 250mM LiCl,  
1%(v/v) NP-40, 
1%(v/v) Na-
deoxycholate, 
1mM EDTA,  
10mM Tris (pH 8) 
ChIP 
Low salt wash buffer 0.1% (v/v) SDS, 1% 
(v/v) Triton X- 
100, 2mM EDTA, 
20mM Tris (pH 
8), 150mM NaCl 
ChIP  
PBS-tween 138mM NaCl, 2.7mM 
KCL, 10mM 
Na2HPO4, 1.8mM 
KH2PO4 (pH 7.4), 
0.1%(v/v) Tween-20 
Western Blot 
PMSF (100mM) 174mg 
Phenylmethylsulfonyl- 
fluoride in 10 ml of 
100% ethanol 
ChIP (at 1mM in 
each ChIP 
buffer) 
SDS lysis buffer  1% (v/v) SDS, 10mM 
EDTA, 50mM Tris  
(pH 8) 
Chromatin 
preparation 
TE 1%SDS (Elution buffer) 10 mM Tris, 5 mM 
EDTA, 1%(v/v) SDS 
ChIP 
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TE Buffer (Elution Buffer) 10 mM Tris,  
5 mM EDTA 
ChIP 
Transfer buffer  25mM Tris-HCl 
(pH8.3),192mM 
glycine, 20% (v/v) 
methanol 
Western Blot 
Tris-Borate-EDTA (1xTBE) 89mM Tris (pH 7.6), 
89mM boric acid,  
2mM EDTA 
DNA 
electrophoresis 
 
 
2.1.8 Purchased Chemicals and Kits 
Reagent or Kit Supplier Application 
12% NuPAGE Bis-Tris SDS-
PAGE Gel 
Invitrogen Protein electrophoresis  
 
Agarose Fisher 
Scientific 
DNA electrophoresis 
Agilent High Sensitivity DNA 
Kit 
Agilent ChIP sequencing library quality 
control 
Agilent High Sensitivity DNA 
Reagents 
Agilent ChIP sequencing library quality 
control 
Bioline 1kb hyperladder Bioline DNA electrophoresis 
DharmaFECT reagent Dharma-
con 
siRNA transfection 
Dimethyl sulfoxide (DMSO) Sigma Cell Culture 
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DNA loading dye (5x) Bioline DNA electrophoresis 
Doxycycline  Sigma  Induction of doxycycline 
promoter 
Dried milk powder Co-Op  Western Blot 
Effectene Kit HEK 
transfec-
tion 
Quiagen 
Ethanol Sigma DNA purification 
FIX and PERM Cell 
Permeabilization Kit  
Invitrogen FACS 
Foetal calf serum (FCS) GIBCO Cell Culture 
Formaldehyde Sigma Chromatin Preparation 
G418 Fisher 
Scientific 
Selection of EBV positive 
HONE1-EBV 
Gel red Biotium DNA electrophoresis  
Glycine Sigma Chromatin Preparation 
GlutaMAX  GIBCO NEON siRNA transfection 
GoTaq Syber green master 
mix 
Promega qPCR 
Laemmli Protein Sample 
Buffer (PSB, 2x)  
Sigma Protein electrophoresis 
Luciferase reporter assay kit Promega Luciferase reporter assay 
NEBNext ChIP Seq Library 
Prep Reagent Set for Illumina  
New 
England 
Biolabs 
ChIP Sequencing Library 
preparation 
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NEBNext Multiplex Oligos for 
Illumina (Index Primers Set 1) 
New 
England 
Biolabs 
ChIP Sequencing Library 
preparation 
NEON 100µl kit  Invitrogen NEON siRNA transfection 
Morpholinepropanesulfonic 
Acid Buffer (20x MOPS) 
NuPAGE Protein electrophoresis 
Odyssey blocking buffer Li-Cor Western blot 
Passive lysis buffer (5x) Promega Luciferase Assay 
PBS GIBCO Washing cells 
Penicillin, Streptomycin, L-
Glutamin (PSG) 
GIBCO Cell culture 
Protein A Sepharose Beads Sigma ChIP 
Protein G Sepharose Beads Sigma ChIP 
Proteinase K Sigma DNA purification 
Qiagen DNA Mini and Blood 
Mini kit  
Qiagen DNA purification 
Qiagen MinElute Gel 
extraction kit 
Qiagen ChIP Sequencing Library 
preparation 
QIAquick PCR Purification Kit Qiagen DNA clean-up 
Qiagen RNeasy Plus Kit Qiagen RNA purification 
Qubit dsDNA HS Assay Kit Life 
Techno-
logies 
ChIP  
RPMI 1640 media  GIBCO Cell Culture 
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ROCHE complete mini 
Tablets 
ROCHE ChIP 
Suberoylanilide Hydroxamic 
Acid (SAHA) 
Sigma Lytic cycle induction 
Salmon sperm DNA Invitrogen ChIP 
SeeBlue protein marker Invitrogen Protein electrophoresis  
siRNA buffer (5x) Dharma-
con 
siRNA transfection 
SYBR gold Life 
Techno-
logies 
DNA electrophoresis 
Transcription first strand 
cDNA synthesis kit,  
Roche cDNA synthesis 
Trypsin-EDTA (0.25%), 
phenol red 
GIBCO Detaching tightly adherent cells 
 
 
2.2 Methods 
 
2.2.1 Cell Culture and Induction of EBV lytic Replication 
Every cell line used in this thesis was maintained in RPMI medium supplemented 
with 10% (vol/vol) fetal bovine serum (FBS), 100U of penicillin/ml, 100g of 
streptomycin/ml, and 2mM L-glutamine (Invitrogen) at 37°C with 5% CO2.  
HONE1 cells were kindly provided by G. Tsao. Transfection of HONE1 cells with 
EBV is not stable. The EBV plasmid contains a G418 resistance gene. EBV 
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positive HONE1-EBV cells were selected with 600µg/ml G418. For EBV lytic 
induction, HONE1-EBV cells were induced with 10μM suberoylanilide 
hydroxamic acid (SAHA) for 48hrs at 70% confluency. For EBV lytic cycle 
induction, Akata group I EBV-positive BL cells were seeded in log phase growth. 
After 24hrs the cells were concentrated and treated with 0.125% rabbit anti-
human IgG (DAKO) for a further 24hrs. Alternatively, lytic cycle in Akata cells 
which contain the bidirectional doxycycline inducible promoter B-Tet, which 
drives expression of BZLF1 and green fluorescent protein (GFP), was induced 
for 24hrs with 500ng/ml doxycycline, a kind gift from Rajaei Almohammed and 
Ijiel Barak Naranjo Perez Fernandez. Lytic cycle in HEK 293ZKO cells was 
induced by transfection of a hisZta expression plasmid.  
Akata and LCL3 cells were grown in suspension. HONE1-EBV and HEK cells are 
adherent cells. When harvesting, HEK 293T and HEK 293ZKO cell were 
detached from the flask with PBS. HONE1-EBV cells were detached using 
trypsin, or by scraping for chromatin preparation. 
 
2.2.2 DNA extraction 
Cells were re-suspended in PBS (at 37°C) and DNA was extracted using the 
Qiagen DNA Mini and Blood Mini kit (50) and accompanying protocol. The waste 
collection tube was replaced after each centrifugation. The DNA was eluted in 
50µl AE buffer and stored at -20°C or used for downstream experiments 
immediately.  
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2.2.3 Quantitative Polymerase Chain Reaction (qPCR) 
qPCR analysis was undertaken using the GoTaq qPCR master mix from 
Promega on a StepOnePlus real-time PCR machine (Applied Biosystems). Each 
reaction contained 12.5µl GoTaq (Cybr green), 0.5µl primer mix (5µM each 
forward and revers), 9.5µl PCR grade water and 2.5µl sample. Cycle conditions 
were: 10min at 95°C, followed by 40 cycles of 15sec at 95°C and 1min at 60°C. 
Data was collected and analysed with the help of the StepOne software version 
2.3 (Applied Biosystems). Resulting values are relative to a standard curve made 
by serial dilution, or a reference sample for some RNA quantifications. For ChIP 
qPCR, 4% of input, or serial dilutions of sample DNA were used to generate a 
standard curve for absolute quantification. 
 
2.2.4 Western Blot 
Cells were harvested and cells (or chromatin) were boiled in protein sample buffer 
(Sigma) at 95°C for 5min. Transfected samples were sonicated for six rounds of 
10sec pulses at 21% amplitude using a Vibra-Cell Sonicator (SONICS). Samples 
were loaded at 8-10µl per well and the protein was resolved alongside 5µl of 
SeeBlue marker ladder (Invitrogen) on a NuPAGE 12% Bis-Tris polyacrylamide 
gel (Life Technologies) and run in 1x MOPS buffer (Invitrogen) at 200V for 50min. 
The proteins were transferred onto nitrocellulose membranes (Santa Cruz 
Biotechnology), in transfer buffer, by placing the gel next to the membrane inside 
of filter papers and sponges in a cooled Bio-Rad Transfer tank at 75V for 90min. 
The nitrocellulose membrane was blocked in 5% milk for 30min, then incubated 
overnight with the relevant antibodies at 4°C in 5% milk. The membrane was 
washed three times for 5min in PBS-tween at room temperature to remove the 
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excess primary antibody. The relevant IRDye secondary antibody was added to 
Odyssey blocking buffer diluted 1:1 in PBS. This was added to the membrane for 
2hrs at room temperature. Following three 5min washes at room temperature in 
PBS-tween, the western blot was visualised by chemiluminescent on the Li-Cor 
on the 700nm and/or 800nm channel with an exposure time of 2min. All 
incubation steps during the processing of the membrane were undertaken on a 
rocker.  
 
2.2.5 Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS) 
Cells were prepared by fixation, permeabilization and staining as indicated using 
the manufacturer’s guidelines of the Fix and Perm Cell Fixation and Cell 
Permeabilization Kit by Life Technologies. Cell were sorted using the BD 
FACSCanto analyser (Beckton Dickinson) or the BD Accuri C6. Data was 
analysed and graphs generated with FlowingSoftware or FCS Express 5 Flow 
(DeNovo Sofware) respectively. 
 
2.2.6 Chromatin Immunoprecipitation (ChIP) 
Chromatin was fixed by application of 1% formaldehyde for 15min, or 10min for 
the chromatin sonication protocol II, at room temperature.0.125M glycine was 
used to halt the cross-linking. Cells were pelleted at 1x107 cells per ChIP and 
washed in PBS before being resuspended in 600µl cell lysis buffer. Cells were 
incubated for 10min at room temperature and pelleted at 3500rpm for 10min at 
4°C. The pallet was resuspended in 200μl ChIP SDS lysis buffer. 
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For the original chromatin sonication protocol, cell lysates were pooled to a 
volume of 2ml and sonicated on ice for ten rounds, with 10sec pulses and a 30% 
amplitude output on a Vibra-Cell 750 Sonicator (SONICS). For the improved 
chromatin sonication protocol II, cell lysates were sonicated in a volume of 100μl 
on ice for ten rounds, with 10sec pulses and a 21% amplitude output on a Vibra-
Cell 750 Sonicator (SONICS). Samples were vortexed after every minute. 
Sonication efficiency was checked by running the sample on a 1% agarose gel 
with 1x TBE buffer.  
100μl of mixed protein A and protein G beads of 50% (w/v) bead slurry was used 
per immune-precipitation. Beads were prepared by washing and re-suspending 
in 55µl ChIP buffer for ChIP qPCR, or blocking buffer for ChIP sequencing. Beads 
were blocked for 3min at 4°C with 55µl 10mg/ml salmon sperm for ChIP qPCR or 
blocking buffer for sequencing. Beads were then washed and re-suspended in 
55µl IP dilution buffer.  
Chromatin samples were diluted 1:10 in IP dilution buffer and pre-cleared with 
45µl of beads at 4°C for 30min. Samples were centrifuged and the supernatant 
was transferred to a new tube. 40µl was removed from the sample and frozen at 
-20°C to act as 4% input control. 
For each IP, 20µg antibody was used with chromatin from 5x106 cells. Samples 
were incubated at 4°C for 1hr while rotating. Immune complexes were then 
collected over night with 55µl 50% pre-blocked protein A/G-sepharose beads at 
4°C. 
Beads were spun down at 3000rpm for 5min at 4°C and washed with low salt, 
high salt, LiCl, and TE (2x) wash buffers for 15min at 4°C while rotating. The 
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antibody-bound complexes were eluted from the beads with ChIP elution buffer 
at 65°C for 15min. Input samples were thawed and included in further processing. 
To reverse crosslink the chromatin from the proteins, supernatant was incubated 
at 65°C over night. Samples were diluted 1:2 in TE buffer and 2.5µl proteinase K. 
Samples were incubated at 55°C for 3hrs. DNA was purified using a PCR 
purification kit (Qiagen) and eluted in 55μl. ChIP sequencing was performed 
using a 7x immunoprecipitation protocol, finally eluted into 45μl to achieve a 
sufficient DNA concentration of >10nM. 
 
2.2.7 ChIP reChIP 
The ChIP reCHIP protocol starts off like the ChIP protocol in section 2.2.6. After 
eluting the antibody-protein-DNA from the protein A beads at 65⁰C for 15min with 
TE/1%SDS, retaining the supernatant and adding TE/1%SDS to the defrosted 
input control, the ChIP protocol was repeated for the second round of ChIPs by 
following the steps from 1:5 sample dilution, with IP dilution buffer containing 
protease inhibitor and pre-clearing, to the end of the CHIP protocol.  
 
2.2.8 ChIP-Sequencing Library preparation 
The ready to sequence libraries were prepared according to the NEBNext ChIP-
Seq Library Prep Reagent Set for Illumina kit instructions (New England 
Bioscience), switching the PCR and the size selection steps. As is described in 
the workflow in Figure 9, the sonicated DNA fragments (1) were end repaired and 
the 5’ ends were phosphorylated and dA-tailed (2) to allow for adaptor ligation 
(3). U excision of the adaptor was performed to linearize the barcode binding 
region and to allow the PCR reaction to take place (4).  Barcodes (Index 4, 6 and 
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12) and primers were ligated and PCR was performed to amplify the DNA (5). 
Barcodes make it possible to sequence several different samples during the 
same run. Size selection was performed on a 2% agarose gel with Gel Red 
(Biotium) or SYBR Gold dye (Life Technologies) to exclude the adaptor from the 
sequencing process. DNA fragments in the 175-225bp size range were excised 
and purified using the Qiagen Gel Extraction kit (6). 
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Figure 9: DNA Library Preparation Workflow for Illumina. 
Figure 9: DNA Library Preparation Workflow for Illumina. Figure modified 
from NEBNext® DNA Library Prep Master Mix Set for Illumina® product 
information (https://www.neb.com/products/e6040-nebnext-dna-library-prep-
master-mix-set-for-illumina) 
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2.2.9 ChIP Library Quality Control 
Quality control was performed on the Agilent 2100 Bioanalyzer. Samples were 
prepared for this purpose following the instructions of the Agilent High Sensitivity 
DNA Bioanalyzer reagents kit. Samples were sequenced by the Eurofins 
Genomics group using Illumina HighSeq 2000 technology. 
 
2.2.10 ChIP sequencing Data Analysis 
Sequence reads were mapped to the human (GRCh37.p13) and EBV 
(NC_007605.1 GI:82503188) reference genomes by the Eurofins Genomics 
group. The bamFingerprint graph was generated with the help of the deepTools 
Galaxy platform (http://deeptools.ie-freiburg.mpg.de/) [116] to the parameters 
stated in Table 2.  
 
Input Parameter Value 
Length of average fragment 
size 
200bp 
Region of genome to limit the 
operation to 
none 
Bin size 30bp 
Number of Samples 1000000 
Minimum mapping quality 1 
 
Table 2: bamFingerprint Parameters 
Table 2: bamFingerprint Parameters 
 
Binding of Zta to the human genome was visualised in the UCSC genome 
browser (http://genome.ucsc.edu/) [117]. For this purpose, the .bam files were 
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normalize to fragments per kilobase per million reads and converted to .bigwig 
format with the help of the bamCoverage tool in deepTools Galaxy. Parameters 
for this analysis were: 200bp fragment size and 30bp bin size. 
 
MACS peaks were determined using the MACS-1.4.2 tool in deepTools Galaxy 
using the parameters outlined in Table 3. 
 
Input Parameter Value 
Control data Input 
Tag size 30bp 
Bandwidth 200bp 
p-value  10-5 - 10-9 
Do not built shifting model, 
arbitrary shift size 
100bp 
Format .wig 
MFOLD range 10,30 
Dynamic lambda 1000 -
10000 
Table 3: MACS peak Parameters 
Table 3: MACS peak Parameters 
 
MACS peaks were intersected using this “Operate on Genomic Intervals” option 
in deepTools Galaxy. Overlapping pieces of intervals were selected as return 
format (see Figure 10). 
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Figure 10: Return file options for the intersection of two MACS peak datasets. 
Figure 10: Return file options for the intersection of two MACS peak 
datasets. Return files are shown in blue. Figure modified from http://deeptools.ie-
freiburg.mpg.de/. 
 
Motif analysis was performed with the help of the MEME-ChIP suite using default 
parameters (http://meme.nbcr.net/meme/tools/meme-chip) [118].  
 
Gene list enrichment analysis was performed using the EnrichR tool 
(http://amp.pharm.mssm.edu/Enrichr/) [119].  
 
Associated genes were determined and analysed using the Genomic Regions 
Enrichment of Annotations tool, GREAT  
(http://bejerano.stanford.edu/great/public/html/) [120]. For this purpose, .bed files 
were created by the USCS genome browser from the MACS peak data sets and 
sent directly from the genome browser to GREAT. 
 
Enrichment of Zta binding sites on the EBV genome was visualised using the 
Integrative Genomics Viewer (https://www.broadinstitute.org/igv/) [121] and the 
reference genomes for EBV (NC_007605.1 GI:82503188).  
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BCL3, EZH2, SUZ12 and H3K27me3 ChIP sequencing data was obtained, 
through the UCSC genome browser, from the ENCODE Transcription Factor 
Binding Tracks database. Track and file names are listed in Table 4. 
ChIP site Track  File Name 
BCL3 GM12878 TFBS Uniform Peaks 
of BCL3 from 
ENCODE/HudsonAlpha/Analysis 
wgEncodeAwgTfbsHaibGm128
78BCL3V0416101UniPk.narrow
Peak.gz 
EZH2 GM12878 TFBS Uniform Peaks 
of EZH2_(39875) from 
ENCODE/Broad/Analysis 
wgEncodeAwgTfbsBroadGm12
878Ezh239875UniPk.narrowPe
ak.gz 
SUZ12 H1-hESC TFBS Uniform Peaks of 
SUZ12 from 
ENCODE/USC/Analysis 
wgEncodeAwgTfbsSydhH1hesc
Suz12UcdUniPk.narrowPeak.gz 
H3K27me3 GM12878 H3K27me3 Histone 
Mods by ChIP-seq Peaks from 
ENCODE/Broad 
wgEncodeBroadHistoneGm128
78H3k27me3StdPkV2.broadPe
ak.gz 
Table 4: BCL3, EZH2, SUZ12 and H3K27me3 ChIP sequencing data track and file names as stated in the UCSC genome 
browser. 
Table 4: BCL3, EZH2, SUZ12 and H3K27me3 ChIP sequencing data track 
and file names as stated in the UCSC genome browser.  
 
2.2.11 RNA Extraction 
Surfaces and equipment was cleaned with RNAse AWAY spray (Thermo 
Scientific) prior to RNA extraction. Cells were pelleted to 5x106 and the pellet was 
thoroughly loosened by vortexing. RNA was extracted from cells using the 
RNeasy Plus Mini Kit from Qiagen following the kit’sprotocol. All centrifugation 
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steps were performed at 20–25ºC in a standard microcentrifuge, ensureing that 
the centrifuge does not cool below 20ºC. Prior to transfer of the homogenized 
lysate to a gDNA Eliminator spin column, the lysate was heated to 37ºC. To elute 
the RNA, 32μl RNase-free water was added to the column and incubated at room 
temperature for 10min before centrifugation. The RNA concentration and purity 
were measured on the Nanodrop at A260 (see 2.2.12). RNA was stored at -80ºC 
or used for downstream applications immediately.  
 
 2.2.12 RNA Quantification 
RNA was extracted from cells using the Quiagen RNeasy Plus Kit. The 
concentration of the purified RNA was measured via spectrophotometry on the 
Nano Drop 2000 (Thermo Scientific) and transcribed to cDNA using the 
Transcription First Strand cDNA Synthesis Kit (Roche, see 2.2.12). 
 
2.2.13 cDNA Synthesis   
Surfaces and equipment was cleaned with RNAse AWAY spray (Thermo 
Scientific) prior to cDNA synthesis. RNA was reverse transcribed using the 
Transcription first strand cDNA synthesis kit (Roche) with its accompanying 
protocol using random hexamer primer. cDNA was stored at -20ºC or used for 
qPCR immediately. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
2.2.14 NEON siRNA transfection 
Cells were seeded in log phase and transfected 24hrs later in antibiotic free 
media containing 1% GlutaMax (GIBCO) using the manufacturers guidelines of 
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the NEON transfection system 100µl kit with buffer R. Pulse conditions were set 
as follows: Pulse voltage: 1300V, Pulse width: 30ms, Pulse number: 1. siRNA 
concentration varied and are stated with the corresponding result. 
 
2.2.15 DharmaFECT siRNA transfection 
siRNA transfection was performed as described in the manufacturer’s  
DharmaFECT Transfection Reagent siRNA Transfection Protocol for HEK 293 
cells with 1x siRNA buffer and a final siRNA concentration of 25nM. TORC1, 
TORC2 and TORC3 were transfected together at a concentration of 25nM each. 
Cells were transfected with hisZta or pcDNA3 24hrs after siRNA transfection and 
harvested a further 24-48hrs later. Samples harvested after 24hrs were also 
treated with 1µM ionomycin and 20ng/ml Phorbol 12-myristate 13-acetate (PMA) 
at the time of hisZta/pcDNA3 transfection. 
 
2.2.16 Vector Transfection 
Expression and reporter vectors were a kind gift from Kay Osborn. Cells were 
seeded into log phase growth 24hrs prior to transfection. Transfection was 
performed using the non-liposomal Effectene transfection kit (Qiagen) following 
the manufacturer’s guidelines, except the amount of effectene was altered to 
2.5µl per µg DNA. The amount of vector DNA added per experiment is shown 
with the result. HEK 293T cells were harvested 48hrs after transfection to perform 
the luciferase assay. HEK 293ZKO cells were harvested 24-72hrs after 
transfection to measure protein levels and EBV genome load. 
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2.2.17 Luciferase Assay 
HEK 293T cells were transfected with hisZta, BCL3 or pcDNA3 control 
expression plasmids together with BHLF1 or BHLF1 mutant luciferase reporter 
vectors as described in section 2.2.11. Cells were harvested in PBS after 48hrs. 
Some of the cells were used for a corresponding western blot. The other cells 
were processed using the Luciferase reporter assay kit by Promega. Cells were 
lysed in 1x passive cell lysis buffer (Promega), spun down and the supernatant 
was moved to a new tube. 10µl of each sample was pipetted into a white 96-well 
plate and 50µl of LAR (Promega) was added to the samples and bioluminescence 
was measure for 10sec with a 2sec delay by the Promega GloMax multi-detection 
system. The background fluorescence was subtracted using measurements in 
wells containing only lysis buffer.  
Results were normalised with the help of a bicinchoninic acid (BCA) assay to 
account for differences in overall protein levels across samples. For this purpose, 
a standard curve of known Bovine Serum Albumin (Pierce) concentration was 
created. The standard curve and sample lysates were added to a white 96-well 
plate followed by 200µl of working reagent (Pierce). After 30min incubation at 
37°C, the absorbance of each sample was read at 560nm on the Promega 
GloMax multi-detection system. Cell-free background readings were subtracted. 
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Chapter 3: Zta binds to the human and viral genome in epithelial cells 
 
3.1 Introduction 
 
In order to study EBV in epithelial cells, HONE1-EBV cells were used, which, at 
the time, were thought to derive from a poorly differentiated NPC tumour biopsy. 
However, shortly after key experiments were performed, it was shown that 
HONE1-EBV contains HeLa genomic material [102] and a variant of STR loci 
from HeLa [122]. This suggests that HONE1-EBV may consist of a hybrid HeLa 
as has previously been suggested for other NPC cell lines [123]. More research 
is still needed to identify the origin of the HONE1-EBV cell line. That being said, 
HeLa cells are an epithelial cell line and HONE1-EBV is infected with EBV, so 
results obtained from this study are relevant in extending the knowledge 
surrounding EBV lytic cycle in epithelial cells. 
Based on unpublished data from the Tsao laboratory (University of Hong Kong), 
who kindly provided our cells, EBV lytic cycle in HONE1-EBV cells was induced 
with 10μM suberoylanilide hydroxamic acid (SAHA, Vorinostat) for 48 hours. The 
exact mechanism by which SAHA induces lytic cycle is not known. It is a potent 
histone deacetylase inhibitor which facilitates the transcription of genes that result 
in apoptosis, differentiation and growth arrest [124]. SAHA is used in the 
treatment of cutaneous T cell lymphoma and is currently in Phase II clinical trials 
for the treatment of nasopharyngeal carcinoma [125, 126]. In addition it is widely 
used for research purposes to study gene regulation, transcription regulation and 
cell signalling.  
Zta coordinates the change during the switch from latency to lytic cycle of EBV, 
as such, it is one of the earliest indicators of lytic replication [127].  To verify our 
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method of lytic cycle induction, we looked for Zta expression in cells treated with 
SAHA. We also examined the expression of a second early lytic cycle gene, 
BLLF3, which encodes a UTPase [128].  
Once it was confirmed that the viral lytic cycle could be induced successfully, 
chromatin was prepared and sonicated to create fragments of 200-600bp for 
chromatin immunoprecipitation to ask whether Zta binds at the viral origin of lytic 
replication promoter (OriLyt, BHLF1) and the BCL2A1 promoter of the human 
genome, which encodes an anti-apoptotic BCL2 family member [129]. These loci 
are known Zta binding sites in Akata B cells [19].   
Based on the obtained results, a ChIP sequencing library was prepared. 
Following optimisation of the protocol, the samples were shown to be of suitable 
quality and sent to an external laboratory for sequencing and read alignment to 
the EBV and human genomes. 
An example of Zta binding to the viral genome with a clear peak around OriLyt in 
duplicate ChIP experiments is presented. Downstream data analysis focussed 
mainly on Zta binding to the human genome and is outlined in more detail in 
chapter 4.  
 
3.2 EBV Lytic Cycle Induction in HONE1-EBV cells using SAHA  
 
In order to find an effective way of inducing EBV lytic cycle in HONE1-EBV cells, 
induction condition received from the Tsao laboratory, who kindly provided the 
cell line, were tested. This involved investigation of the amounts of Zta protein, 
through western blotting and FACS. Zta RNA levels were examined with the help 
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of reverse transcribed complementary DNA (cDNA) quantitative polymerase 
chain reaction (qPCR). The EBV genome copy number per cell was investigated 
via qPCR.  
Zta (BZLF1) and BLLF3 RNA quantification was carried out, which showed an 
eight-fold increase in Zta RNA levels and nearly 17-fold increase in BLLF3 
transcription relative to the amount of 36B4, which was used as a cellular 
reference gene (Figure 11). 
 
 
Figure 11: qPCR result showing the amounts of Zta (BZLF1) and BLLF3 RNA relative to host cell 36B4 levels in biological triplicates (1-3). 
Figure 11: qPCR result showing the amounts of Zta (BZLF1) and BLLF3 
RNA relative to host cell 36B4 levels. EBV lytic cycle was induced (+SAHA) or 
unindicted (-SAHA) with 10μM SAHA for 48 hours. Values are represented as 
mean ± SD. The amount of BZLF1 and BLLF3 RNA is significantly higher in 
samples treated with SAHA in comparison to untreated samples (p<0.05). 
 
The increased Zta RNA amount translates into an increase of Zta protein, Zta 
expression in induced cells was determined via western blotting (Figure 12). This 
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(42kDa) 
 
(33kDa) 
showed Zta in induced cells. In contrast, no Zta can be detected in the uninduced 
control. 
 
Figure 12: Western blot showing the expression of Zta in HONE1-EBV cells. 
Figure 12: Western blot showing the expression of Zta in HONE1-EBV cells. 
Lytic Cycle was induced (+) or uninduced (-) with 10μM SAHA for 48 hours. An 
antibody specific for actin was used as a loading control.  
 
In addition to western blot analysis of Zta levels, Fluorescence-activated cell 
sorting (FACS) was also carried out to detect the percentage of cells expressing 
the Zta protein. Results are summarised in histograms shown in Figure 13. No 
clear difference between cells induced with SAHA and uninduced cells could be 
detected during this analysis. Cells that are Zta positive lie within the gated region 
of the histogram, which accounts for 6.8% of uninduced cells (-SAHA) and 7.6% 
of induced cells (+SAHA). 
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Figure 13: Histograms showing FACS analysis results of Zta levels. 
Figure 13: Histograms showing FACS analysis results of Zta levels. EBV 
lytic cycle in HONE1-EBV cells was induced with 10μM SAHA (+SAHA, D) or 
uninduced (-SAHA, C) for 48 hours, as well as an isotype control (A). The Table 
(B) shows the percentage of cells lying within the gated area, containing Zta 
positive cells, as based on the isotype mouse control. 
 
Based on RNA levels, western blot results and previous, unpublished findings by 
the Tsao laboratory, an increase in EBV genome load in induced cells of 
approximately 15 fold would be expected. However, qPCR analysis using primers 
specific for either the human or EBV genome did not lead to the expected results 
(Figure 14) and no significant difference of EBV load could be detected between 
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induced and uninduced cells. The amount of EBV per host cells was shown to be 
approximately equal to one.  
 
Figure 14: qPCR results showing the amount of EBV relative to the amount of human genome. 
Figure 14: qPCR results showing the amount of EBV relative to the amount 
of human genome. EBV lytic cycle was induced in HONE1-EBV cells with 10μM 
SAHA (with SAHA) or uninduced (no SAHA) for 48 hours. The EBV genome was 
detected using primers specific for EBV polymerase. Human genome was 
detected using primers specific for globin. Values are represented as mean ± SD. 
There is no significant difference between samples treated with SAHA in 
comparison to untreated samples (p<0.05). 
 
Two distinct populations of HONE1-EBV cells can be observed, one attached to 
the flask, as would be expected of an epithelial cell line, and one freely floating in 
the medium. The previous results have been based on the entire cell population. 
Through casual observation, it has become clear that the ratio of 
floating:adherant cells increases when SAHA is added, to a point where at least 
50% of the cells are detached from the flask after 48 hours. To determine whether 
both cell populations show evidence of lytic induction, a time course was set up 
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at two different concentrations of SAHA and the presence of the early lytic protein 
Zta was determined. The overall EBV load per cell was also assessed.  
As shown in Figure 15A, SAHA successfully induces the expression of Zta in 
adherent cells.  
 
Figure 15: Western Blots showing the expression of Zta and actin in adherent or floating HONE1-EBV cells. 
Figure 15: Western Blots showing the expression of Zta and actin in 
adherent or floating HONE1-EBV cells. Lytic cycle was induced with 0μM, 5μM 
or 10μM SAHA at 24hrs, 48hrs and 72hrs post induction. An antibody specific for 
actin was used as a loading control. A: Adherent cells, B: Floating cells. 
 
Figure 15B shows a western blot of actin and Zta levels in floating cells which 
demonstrates that Zta levels are also increasing in this population when cells are 
induced with SAHA. As opposed to adherent cell numbers, the numbers of 
floating cells increase with the addition of SAHA, as measured by actin levels. 
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Relative to actin levels, the effect of SAHA on Zta expression, and thus early lytic 
cycle, seems to be strongest at time points past 24 hours using 5μM or 10μM 
SAHA. The amount of Zta detected in floating cells is shown to be slightly lower 
when compared to adherent cells. 
As part of the same experiment, the genome copy number of EBV per host cell 
was determined at different concentrations of SAHA and an induction time of 24, 
48 or 72 hours in floating and adherent cells. Results are summarised in Figure 
17. The floating cell population shows no significant increase in EBV copy number 
under the influence of SAHA. Adherent cells show a clear increase in EBV copy 
numbers when induced with both 5μM and 10μM SAHA over time, with 
significantly more EBV present by 72 and 48 hours in floating than adherent cells. 
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Figure 16: qPCR results showing the relative amount of EBV genome copies per human genome numbers in floating or adherant HONE1-EBV cells. 
Figure 17: qPCR results showing the relative amount of EBV genome 
copies per human genome numbers in adherent and floating HONE1-EBV 
cells. Lytic cycle was induced with 0μM, 5μM or 10μM SAHA with 24, 48 and 72 
hours of induction. This experiment shows a significant increase of EBV load in 
cells treated with 5µM or 10µM SAHA in comparison to untreated cells at 48hrs 
as well as samples treated with 10µM SAHA at 72hrs (p<0.05). Averages are 
based on duplicate pipetting repeats. Values are represented as mean ± SD. 
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Figure 17: Histograms showing the percentage of HONE1-EBV cells containing Zta. 
Figure 18: Histograms showing the percentage of HONE1-EBV cells 
containing Zta. Adherent HONE1-EBV cells were induced with 10μM SAHA for 
48 hours, or not induced, and stained for Zta and a negative control antibody. A: 
Induced and un-induced cells stained with a negative control antibody showing 
background fluorescence. B: Un-induced cells stained for the detection of Zta 
levels in the cell population. C: Induced cells stained for the detection of Zta levels 
in the cell population. D: Overlay Histogram of un-induced and induced cells 
stained for Zta. 
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Based on these results, FACS was performed to detect the percentage of 
adherent HONE1-EBV cells positive for Zta.  Results are summarised in 
histograms shown in Figure 18. Staining with the control antibody shows a 
relatively high background of 5-8%. As before, Zta positive cells lie within the 
gated region of the histogram, which accounts for 7% of uninduced cells (0μM 
SAHA) and 28% of induced cells (10μM SAHA). Therefore approximately 21% of 
the cell population contain EBV which has entered into lytic cycle following 
induction, representing a 3.7 fold increase in Zta levels in comparison to un-
induced cells. These FACS results confirm a clear difference in Zta expression 
when EBV lytic cycle is induced in adherent HONE1-EBV cells with 10μM SAHA 
for 48hrs in comparison to untreated cells.  
Consequently, the following results will be based on the adherent HONE1-EBV 
cell population only. 
 
3.3 Chromatin Immunoprecipitation (ChIP) 
 
In this section the procedure for preparing chromatin from HONE1-EBV cells for 
Zta ChIP qPCR and Zta ChIP sequencing is outlined. Different amounts of 
sonication were tested and the sheared chromatin was examined for the 
presence of Zta using western blotting. ChIP qPCR was performed to investigate 
the enrichment of Zta binding regions to the viral genome, which were previously 
mapped to the viral genome in B cells [18] (BCL2A1 data not published). 
Chromatin was prepared from HONE1-EBV cells treated with 10μM SAHA for 48 
hours. To optimize the sonication of this chromatin, a range of time point samples 
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was taken and the samples were separated on a DNA gel to determine their size 
(Figure 19). As the desired size for subsequent ChIP sequencing library 
preparation is 200bp, the ideal chromatin size for efficient ChIP analysis lies 
around this size region. While we would expect to see a narrower size range of 
chromatin fractions, it is clear that some of the chromatin lies within this area. 10 
rounds of sonication were used for chromatin preparation. 
 
 
 
Figure 18:Agarose Gel of chromatin samples extracted from HONE1-EBV cells. 
Figure 19: Agarose Gel of chromatin samples extracted from HONE1-EBV 
cells. EBV lytic cycle was induced with 10µM SAHA (+SAHA) or uninduced (-
SAHA), after 0, 10 or 15 rounds of sonication in a volume of 1.5ml at 30% 
amplitude with a pulsar of 10sec on, 10sec off. 
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(42kDa) 
 
(33kDa) 
To demonstrate that lytic cycle had been induced in the HONE1-EBV cells when 
chromatin was extracted, the sample was reverse cross-linked and western blot 
analysis was undertaken to determine whether Zta is present in the induced 
sample.  
 
Figure 19: Western blot showing the expression of Zta in chromatin from HONE1-EBV cells. 
Figure 20: Western blot showing the expression of Zta in chromatin from 
HONE1-EBV cells. Lytic cycle was induced (+) or uninduced (-) with 10μM SAHA 
for 48 hours. An antibody specific for actin was used as a loading control. 
 
The western blot shown in Figure 20 demonstrates that Zta is expressed in 
induced cells. In addition, a second band has been detected by the Zta specific 
antibody. This band is approximately twice the size of the Zta protein and is 
thought to show Zta dimers which have not been completely reverse cross-linked. 
A chromatin immunoprecipitation (ChIP) assay was carried out on the sonicated 
chromatin to assess whether Zta binds to the epithelial cell and viral genome in 
HONE1-EBV cells. For this purpose, primers specific for regions of the host cell 
genome (BCL2A1) and the viral genome (OriLyt), to which Zta has been shown 
to bind in Akata B cells, were used. Results are summarised in Figure 21 and 
clearly show enhanced binding of Zta to the origin of lytic replication (OriLyt) on 
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the viral genome in comparison to an OriLyt flanking region. This flanking region 
is used as a negative control together with an IgG isotype control. A fold change 
of 2.4 can be identified between Zta binding to OriLyt in induced versus 
uninduced cells. 
In addition to the origin of lytic replication, Zta association with a second B cell 
Zta binding region, the B-cell lymphoma 2-related protein A1 gene (BCL2A1), and 
it’s flanking region, was also determined. A significant increase with a fold change 
of 8.5 in Zta binding to this region of the epithelial cell genome can be seen when 
lytic cycle is induced.  
The ChIP protocol, which was kindly provided by Rajaei Almohammed, states a 
working range of ChIP antibody between 2µg and 10µg. Both extremes of Zta 
specific antibody were used for this ChIP to investigate which amount results in 
the most efficient ChIP. Based on the results shown in Figure 21, 10µg of Zta 
antibody was used for future ChIP experiments.  
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Figure 20 :qPCR results of ChIP experiment showing Zta binding to BCL2A1 or OriLyt in comparison to flanking regions and an IgG control. 
Figure 21: qPCR results of ChIP experiment showing Zta binding to BCL2A1 
or OriLyt in comparison to flanking regions and an IgG control. HONE1-EBV 
cell were induced with 10μM SAHA (+SAHA) or uninduced (-SAHA) for 48 hours. 
ChIP was performed using either 2µl or 10µl of BZ1 antibody (200µg/ml). The 
difference of Zta binding to the peak vs flanking region in cells treated with SAHA 
is significant (p<0.05). Values are represented as mean ± SD. 
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3.4 Library Preparation and Quality Control 
Based on the results outlined in the previous section, the role of Zta in epithelial 
cells was examined more closely by coupling chromatin immunoprecipitation to 
next generation sequencing (ChIP Seq). For this purpose, the ChIP assay was 
scaled up in duplicates and the DNA concentration in the sample was determined 
using a NanoDrop. The samples were prepared for sequencing (library 
preparation) by end repair, dA-tailing, adaptor ligation and PCR enrichment, 
followed by size selection of the library.  
qPCR analysis was carried out on the large scale ChIP DNA samples to verify 
the presence of DNA in the samples going into the library preparation. This 
confirmed that DNA was present and showed enriched binding of Zta to OriLyt in 
comparison to a flanking region in both ChIP assays (Figure 22). However, a 
problem was encountered when the DNA could not be detected during the size 
selection step. Attempts to re-stain the gel with SYBRSafe did not improve the 
detection of the sample, even on an over-exposed gel (Figure not shown). Further 
investigation of the problem finally revealed an error during the PCR enrichment 
step involving the absence of a required enzyme which is required for the adaptor 
used during this experiment that contains a modified nucleotide requiring 
cleavage by this enzyme before PCR amplification can occur. 
As enough ChIP DNA was still available, a second library preparation was 
attempted. The concentration of the DNA was determined on a Qubit, which is 
more sensitive than the NanoDrop used previously. The recommended 10ng 
DNA was used to prepare the library. In addition, a higher amount of 90ng of DNA 
was used as starting material for the library preparation. The concentration of the 
end repaired, dA-tailed, adaptor ligated and PCR enriched DNA was determined 
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before loading it onto the size selection gel to avoid loss of library samples. In 
addition, the DNA stain SYBRGold was used to be able to detect a smaller 
amount of DNA. The appropriate sized samples (175-225bp) were excised from 
the TAE gel and purified. qPCR analysis of the prepared sample was carried out, 
showing a clear enrichment of DNA bound by Zta in the ChIP samples compared 
to the input control (Figure 23). The fold enrichment for the 90ng samples is equal 
to 1.16 for the Input, 13.64 for ChIP1 and 8.39 for ChIP2. The fold enrichment for 
the 10ng sample cannot be calculated as OriLyt Flank readings were too low to 
be detected during this qPCR step. All six samples were sent to an external 
laboratory (Euorofins Genomics group) for high-throughput sequencing. 
 
 
Figure 21: qPCR results of large scale ChIP experiment. 
Figure 22: qPCR results of large scale ChIP experiment. Graph shows 
significantly enhanced Zta binding to OriLyt in comparison to flanking regions 
(p<0.05) in duplicate ChIPs. HONE1-EBV cell were induced with 10μM SAHA 
(+SAHA) or uninduced (-SAHA) for 48 hours. Values are represented as mean ± 
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SD.
 
Figure 22: qPCR results showing the relative amount of OriLyt and OriLyt Flank DNA bound by Zta in a HONE1-EBV ChIP sequencing 
library. 
Figure 23: qPCR results showing the relative amount of OriLyt and OriLyt 
Flank DNA bound by Zta in a HONE1-EBV ChIP sequencing library. Lytic 
cycle was induced with 10μM SAHA for 48 hours or uninduced. 10ng (A) or 90ng 
(B) ChIP DNA were used to prepare the library. The aount of DNA bound by Zta 
in the flanking region of OriLyt in the 10ng ChIP was too low to be detected in the 
qPCR experiment. The amount of DNA bound by Zta is relative to a standard 
curve where 90ng input was assigned the value of 100. The amount of binding of 
Zta to OriLyt is significantly larger than to the flanking region in both 90ng ChIPs 
(p<0.05). OriLyt Flank readings for the 10ng ChIP were too low to be detected 
during qPCR. The Values are represented as mean ± SD. 
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To determine the quality of the ChIP library, the sample was evaluated with the 
help of a Bioanalyser by the Euorofins Genomics group. This makes it possible 
to determine the DNA fragment sizes within the samples and the corresponding 
concentrations. The resulting electropherogram (Figure 24) shows the sizes and 
concentrations of the DNA fragments in the library with the far left peak, or bottom 
band (green), and far right peak, or top band (purple), representing markers. 
Ideally, no adaptor should be present to contaminate the library sample, and the 
concentration of the immunoprecipitated DNA should be ≥10nM. The actual 
concentration of this library has been shown to be 1.6nM (244pg/µl). Hence the 
library could not be sequenced. 
 
Figure 23: High-Sensitivity Electropherogram of library sample prepared for sequencing. 
Figure 24: High-Sensitivity Electropherogram of library sample prepared for 
sequencing. Diagram representative of ChIP1, ChIP2 and input sample. The 
blue box indicated the size region of the adaptor and the red box represents the 
desired size, in base pairs, of the sample that is to be sequenced. Numbers above 
peaks represent the time, in seconds, at which the concentration at the particular 
size was measured. 
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As a result of the failed library quality control, an additional large-scale chromatin 
preparation and ChIP experiment were performed to construct a library. To 
investigate if the chromatin was sonicated sufficiently a southern blot was 
performed which is shown in Figure 25. In addition, a ChIP qPCR experiment was 
performed to demonstrate if the lytic cycle was successfully induced. As is shown 
in Figure 26, there is a significant enrichment of Zta binding to OriLyt in 
comparison to a negative control region (OriLyt Flank) suggesting that the 
chromatin fragments have been immunoprecipitated successfully. Following 
these results a library was prepared for sequencing using the recommended 10ng 
ChIP DNA.  
 
 
Figure 24: Agarose Gel of chromatin samples extracted from HONE1-EBV cells. 
Figure 25: Agarose Gel of chromatin samples extracted from HONE1-EBV 
cells. Lytic cycle was induced with 10µM SAHA, after 36 rounds of sonication in 
a volume of 1.5ml at 40% amplitude with a pulsar of 10sec on, 10sec off.  
96 
 
 
Figure 25: ChIP qPCR analysis showing the relative amount of viral DNA bound by Zta in HONE1-EBV cells. 
Figure 26: ChIP qPCR analysis showing the relative amount of OriLyt DNA 
bound by Zta in HONE1-EBV cells. Lytic cycle was induced with 10μM SAHA 
for 48 hours. The difference in binding of Zta to OriLyt and OriLyt Flank is 
significant in both ChIP experiments (p<0.05). Data shown as percentage of 
Input. Values are represented as mean ± SD. 
 
To determine the quality of this library, the samples were evaluated on a 
Bioanalyser before sending them for sequencing. Results are shown in Figure 
27.  
No ChIP sample could be detected during this Bioanalyzer run. The high-
sensitivity kit used previously is able to detect concentrations of as low as 100 
pg/µL DNA. The kit used during this run should be able to detect the required 
10nM concentration, as can be seen for the Input sample. However, if the sample 
concentrations are below the 0.5ng/μl detection limit of this kit, they would not be 
identified. This is the case for the ChIP samples. In comparison to the previous 
quality control shown in Figure 24, no adaptor contamination can be detected.  
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Figure 26: Electropherogram of library samples prepared for sequencing. 
Figure 27: Electropherogram of library samples prepared for sequencing. 
As before, the blue box indicates the size region where the adaptor would be 
present and the red box represents the desired size, in base pairs, of the sample 
that is to be sequenced.  
 
The low sample concentration at the selected size range highlights the need for 
chromatin sonication to produce as high a concentration of 200bp fragments as 
possible. For this purpose the sonication protocol was modified to achieve a more 
favourable fragment size for ChIP sequencing purposes (Material and Methods 
“Chromatin Sonication II”). In a nutshell, cells were 15x more concentrated and 
the crosslinking time was reduced from 15 to 10 minutes to prevent over-
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crosslinking. The samples were sonicated in a 15x lower volume (100μl instead 
of 1.5ml) and the sonication amplitude was lowered from 40% to 21%. In addition, 
samples were vortexed after every three cycles to ensure uniform sonication of 
the whole sample. 
The ideal fragment size for sequencing ChIP DNA is 200bp. Based on the 
results shown in Figure 28, the new chromatin lot was prepared using the 
improved chromatin sonication protocol.  
The Zta ChIP was performed as before and immunoprecipitated DNA was 
assessed using qPCR (Figure 29). 
 
 
 
Figure 27: Agarose Gel showing the size, in base pairs (bp), of sonicated HONE1-EBV chromatin fragments. 
Figure 28: Agarose Gel showing the size, in base pairs (bp), of sonicated 
HONE1-EBV chromatin fragments. Lytic cycle was induced with 48μM SAHA 
for 48 hours, using the original chromatin sonication protocol (left) in comparison 
to the altered protocol (right). 
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Figure 28: ChIP qPCR analysis showing the amount of viral OriLyt DNA or flanking region bound by Zta in new HONE1-EBV 
chromatin. 
Figure 29: ChIP qPCR analysis showing the amount of viral OriLyt DNA or 
flanking region bound by Zta in new HONE1-EBV chromatin. Lytic cycle was 
induced with 10μM SAHA for 48 hours. OriLyt represents the origin of lytic 
replication on the EBV genome, which is known to be bound by Zta. OriLyt Flank 
represents a negative control region in the vicinity of OriLyt which is not bound 
by Zta. The enhanced binding of Zta to OriLyt in comparison to the flanking region 
is significant (p<0.05). Data shown as mean ± SD. 
 
As shown in Figure 29, the chromatin was enriched for DNA specifically bound 
by Zta, as desired, and a library was constructed to prepare the DNA for 
sequencing. After the library preparation, the samples were analysed with the 
help of a high-sensitivity Bioanalyser assay. The results of this quality control step 
can be seen in Figure 30 below, which shows 8-15x higher sample concentrations 
at the desired size than required (>10nM), with no adaptor contamination. 
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Figure 29: High-Sensitivity Electropherogram of library samples sent for sequencing. 
Figure 30: High-Sensitivity Electropherogram of library samples sent for 
sequencing. As before, the blue box indicates the size region where the adaptor 
would be present and the red box represents the desired size, in base pairs, of 
the sample that is to be sequenced. Input Sample peak: 151nM, ChIP1 Sample 
peak: 81nM, ChIP2 Sample peak: 48nM. 
 
 
Figure 31 shows a number of different library preparations on agarose gels, which 
have been used during the size selection step of the library preparation process, 
and summarises the various stages and alterations made to achieve an effective 
ready-to-sequence library.  
 
101 
 
 
Figure 30: Size selection gels showing various library preparations. 
Figure 31: Size selection gels showing various library preparations. Red 
boxes represent the region of the gel selected for purification and consequent 
sequencing. A: First attempt to prepare a ready-to-sequence library using SYBR 
Safe dye to visualise the DNA. This blot shows one of the duplicate ChIPs only 
(ChIP2), but is representative of all samples. No DNA could be detected at the 
desired size as an essential enzyme had been omitted from the amplification step 
of the library preparation process. B: This blot is representative of the next two 
library preparation attempts. SYBR Gold dye was used to visualise DNA. Sample 
concentrations were too low to be sequenced. C: Size selection gel of a 
successful ready-to-sequence library using the improved sonication protocol to 
prepare chromatin. 
 
3.5 Zta binding to the viral genome 
Following the sequencing of the ChIP libraries by an external laboratory, 30.8GB 
of data was received in .bam (binary) format. This data was processed using a 
range of data analysis platforms.  
B                                               C 
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Zta ChIP sequencing enrichment was identified for several sites on the EBV 
genome. Figure 32 shows an example of high enrichment for a site around the 
42kb region of the EBV genome which is in the area of the BHLF1 gene promoter 
(OriLyt). 
 
Figure 31: Example of Zta binding to the EBV genome in HONE1-EBV cells visualised through the display of Zta ChIP sequencing data on the Integrative Genomics Viewer (IGV). 
Figure 32: Example of Zta binding to the EBV genome in HONE1-EBV cells 
visualised through the display of Zta ChIP sequencing data on the 
Integrative Genomics Viewer (IGV). Data range 0-90000 reads. Figure shows 
an example of high enrichment for a site around the 42kb region of the EBV 
genome which is in the area of the BHLF1 gene promoter (OriLyt) that is 
associated with the EBV lytic cycle.  
 
The large majority of Zta ChIP sequencing analysis focussed on the human 
genome. This is discussed in more detail in the following chapter.  
 
3.6 Discussion 
Results show that Zta and BLLF3 are upregulated at the RNA level in HONE1-
EBV cells under the influence of SAHA. In addition, it has been confirmed by 
western blotting that Zta is upregulated at the protein level, indicating that lytic 
cycle is successfully being induced. However, FACS results initially did not 
 
        30kb                               40kb                               50kb 
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support this conclusion. It is possible that induction was inefficient due to a range 
of potential causes, including unequal distribution of the SAHA in the defrosted 
stock, an inexact induction time or cell density and number in the flask at the time 
of induction. It is also possible that the antibodies used was not suitable to detect 
Zta expression in the cell line. Additionally, it is likely that only a minority of 
HONE1-EBV cells are in lytic cycle. FACS analysis takes every cell into account 
individually which may explain part of the obtained result.  
Detection of the EBV load in induced cells at first did not show the increase 
expected during lytic replication. These findings may indicate that the virus is at 
a very early stage of the lytic cycle. It is possible that, at 48 hours of induction, 
only a fraction of the cells have entered productive lytic cycle.  
Subsequent to these initial results, the induction conditions were optimised to 
achieve more efficient results for investigating the sites on the host cell and viral 
genome bound by Zta in epithelial cells.  
The amount of actin present in the sample is proportional to the number of cells, 
which leads to the conclusion that the number of adherent HONE1-EBV cells 
declines with increasing exposure to SAHA. It is possible that the floating cells 
are apoptotic due to either the direct effects of SAHA on the cell, the loss of the 
EBV plasmid (which is selected for with G418), or the completed lytic cycle. All 
six samples of floating cells which were treated with SAHA show no evidence of 
EBV replication. This may be due to the absence of lytic cycle, or its completion, 
in these cells. Alternatively it is possible that the cells detach from the flask due 
to differentiation, which has been suggested to be associated with lytic replication 
of EBV in epithelial cells [130].  
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The determination of average EBV genome number per cell revealed a significant 
lower amount of EBV in the floating compared to the adherent population. At 24 
hours the genome copy number of EBV seems higher in cells not containing 
SAHA which could be due to the spontaneous entry into lytic cycle, as HONE1-
EBV cells are not tightly latent. Based on these results, it was decided to work 
with adherent cells only in following experiments. As we are interested in the early 
lytic cycle and cell numbers decrease with time, it was decided to use cells 
induced for 48 hours with 10μM SAHA.  
Based on FACS results of HONE1-EBV cells induced in this way, approximately 
21% of the HONE1-EBV cell population have entered into lytic cycle following 
induction. Hence, any effects observed as a result of this induction, during 
experiments based on the average of the whole population, actually only 
represent less than a quarter of cells. These experiments include the EBV copy 
number per cell, RNA levels, and western blots. Zta ChIP qPCR experiments are 
not included in this, as the immunoprecipitation of the early lytic cycle protein, 
Zta, selects cells in lytic cycle. However, it does point to the necessity to increase 
the number of cells used for Zta ChIP experiments in these cells, in comparison 
to other cell types which can be induced more efficiently.   
It was shown that Zta binds to both the viral and host cell genome in HONE1-
EBV cells when EBV is induced into lytic cycle using SAHA. Based on these 
results, chromatin was prepared and Zta binding sites were immunoprecipitated. 
A ChIP sequencing library was prepared.  
The first Zta ChIP ready-to-sequence library quality controls had a too low sample 
concentration to be sufficient for sequencing. It is thought that this is due to a 
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chromatin preparation process of low quality. Adaptor contamination is most likely 
a result of poor size selection. Alternatively it could be a contamination of the 
sample in the size range of the adaptor. It was clear that these processes needed 
to be improved to achieve the desired results. Subsequent changes made to the 
chromatin preparation and sonication did indeed yield a more favourable result 
for ChIP sequencing purposes as the following Zta ChIP and library preparation 
generated over eight times more sample than required, with no adaptor 
contamination. After the optimisation of this process, as outlined in the previous 
section, the samples passed quality control and were sent to an external 
laboratory for high-throughput sequencing.  
The analysis of Zta ChIP sequencing reads mapped to the EBV genome revealed 
several clear Zta binding sites. Further analysis is necessary to reveal any 
differences and similarities of Zta binding to the viral genome in epithelial cells 
compared to B cells. Following up on these results could provide insights into the 
process of the EBV lytic cycle activation in epithelial cells, which would lead to a 
better understanding of the biology of EBV infection. 
Analysis of Zta binding to the human genome is presented in the following 
chapter.  
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Chapter 4: Zta ChIP sequencing data analysis of binding                            
to the human genome 
 
4.1 Introduction 
 
The previous chapter outlined how a HONE1-EBV Zta Chromatin 
Immunoprecipitation (ChIP) Library was prepared, in duplicate, and sent to an 
external laboratory for sequencing and mapping to the host cell and EBV 
genome. This resulted in 30.8GB of data which was received in .bam (binary) 
format. This chapter will focus on the analysis of the data to identify Zta binding 
sites on the host genome, using a range of data analysis platforms. The first steps 
in analysing the ChIP sequencing data were performed with the help of 
deepTools Galaxy which includes a public server that contains a range of python 
tools which make it easier for researchers without a background in informatics to 
analyse high-throughput sequencing data, like ChIP sequencing data [116].  
The resulting output of deepTools Galaxy enabled the use of the Genomic 
Regions Enrichment of Annotations Tool (GREAT) to analyse the functional 
significance of distal and proximal cis-regulatory elements which have been 
identified by Zta binding across the human genome [120].  
Gene lists obtained through GREAT were further analysed using EnrichR, which 
is a gene list enrichment analysis tool. The list of genes associated with Zta 
binding across the human genome was used as input for computing enrichment. 
EnrichR is based on existing lists created from prior knowledge which has been 
organized into gene-set libraries. [119, 131]. 
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Furthermore, DNA motifs of Zta binding peak regions were discovered, 
analysed and visualised using the online tool MEME-ChIP [132].  
Analysis revealed a range of host genes that are bound by Zta in epithelial cells. 
In addition comparisons of Zta binding sites between epithelial and B cells were 
undertaken. Histone modification and transcription factor binding in various cell 
types were also investigated to identify common factors. For this purpose, the 
Encyclopaedia of DNA Elements (ENCODE) database was utilised [133]. Results 
of this data analysis were followed up with further experiments. 
 
4.2 Mapped sequencing .bam file data analysis 
To analyse the semi-compressed alignment files (.bam) received from the Zta 
ChIP sequencing experiment, reads mapped to the human genome were 
transferred to deepTools Galaxy using a file transfer protocol (FTP). To assess 
the enrichment strength of the duplicate Zta ChIPs, a bamFingerprint graph was 
produced (Figure 33). This shows that approximately 18% of genomic bins 
contain the greatest fraction of reads, which is not considered to be very strong 
enrichment. The bamFingerprint graph created by our data is more characteristic 
of a broad, histone modification ChIP rather than high, narrow enrichment that 
would be expected for a transcription factor, like Zta [134].  
As we have checked the chromatin fragment size prior to ChIP sequencing, it is 
unlikely that the fragments were so long as to impair enrichment resolution and 
specificity. Consequently we investigated the possibility that many binding sites 
are close to each other, which would lead to a large fraction of bins having a high 
coverage.  
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Additionally, even the input file contains a large amount of bins with zero ready 
as indicated on the x-axis. It would be expected that the input does not map 
completely to the human genome. Due to the relatively short fragment size of 
around 200bp, the unique mapping to highly repetitive regions of the genome is 
not possible. Additionally some of the DNA present in the input sample will be of 
EBV origin. Even so, 40% of the genome containing no reads is unusual. As the 
origin of HONE1-EBV cells used in this experiment has not been identified, it is 
possible that some human genome was lost or that a cell line from a different 
species was involved in the establishment of this cell line.   
 
 
 
 
 
 
 
 
 
 
Figure 33: bam Fingerprint graph showing the enrichment of the duplicate 
HONE1-EBV Zta ChIPs and input. Cells were induced with 10μM SAHA for 48 
hours. The cumulative sum of read counts was plotted against bin read-count 
rank. When counting the reads contained in ~82% of all genomic bins, ~50% of 
the maximum number of reads are reached ~18% of the genome contain the 
greatest fraction of reads. Fragment: 200bp, Bin size: 30bp, Bins ranked: highest 
number of reads, highest rank.  
Bins containing zero reads 
Figure 32: bam Fingerprint graph showing the enrichment of the duplicate HONE1-EBV Zta ChIPs and input. 
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Figure 34 shows an example of binding sites clustering around the FOSB gene 
on the human genome. This binding pattern of Zta explains the unusual 
transcription factor enrichment profile described in the bamFingerprint graph 
above. 
 
 
  Figure 33: Example of HONE1-EBV Zta ChIP sequencing reads around the FOSB gene. 
Figure 34: Example of HONE1-EBV Zta ChIP sequencing reads around the 
FOSB gene. Peaks were visualised in the form of histograms and MACS peaks 
with the help of the UCSC genome browser. The height of the graph represents 
the amount of ChIP DNA fragments that have been uniquely mapped to the 
particular site of the human genome. Cells were induced with 10μM SAHA for 48 
hours. Gene locations are indicated below. FOSB is a known Zta binding site in 
Akata B cells.  
 
To determine the statistical significance of these enriched binding sites, model-
based analysis of ChIP Sequencing (MACS) peak calling was performing using 
the deepTools Galaxy platform [116]. The number of significant peaks at two 
different p-values is summarized in Table 5 below, together with the number of 
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peaks common to both ChIPs (intersected peaks). Peaks were detected using 
the MACS-1.4.2 program of the deepTools Galaxy platform with parameters as 
specified in the Methods section. The process of intersecting the overlapping 
pieces of intervals in both ChIPs helps to narrow down the actual binding region 
of Zta to the human genome more effectively. Further analysis was carried out 
based on MACS peaks at a p-value of 10-9. 
 
p-value ChIP and 
Input Control 
Number of 
peaks called 
Intersected 
peaks 
10
-7 CHIP1 18 280 12 378 
ChIP2 13 498 
10
-9 ChIP1 14 669 9 913 
ChIP2 10 663 
Table 5:Number of MACS peaks with p-values of 10-7 and 10-9 in HONE1-EBV Zta ChIP duplicates, and number of 
peaks present in both ChIPs (intersected peaks). 
Table 5: Number of MACS peaks with p-values of 10-7 and 10-9 in HONE1-
EBV Zta ChIP duplicates, and number of peaks present in both ChIPs 
(intersected peaks). Cells were induced with 10μM SAHA for 48 hours. 
 
Figure 34 shows the histogram of Zta binding sites around FOSB together with 
MACS peaks at a p-value of 10-9, indicating which of the regions can be 
considered statistically significant Zta binding sites (HONE1-EBV MACS peaks 
10-9). A list of MACS peaks has not been included in the appendix of this thesis 
due to its unfeasible length. However, the obtained Zta ChIP sequencing data will 
be publicly available on the Gene Expression Omnibus (GEO) genomics data 
repository from 01.01.2019 (GSE83354 - Binding site identification for the EBV 
transcription factor Zta in NPC). 
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Figure 34: Flow diagram summarising the HONE1-EBV ChIP data analysis. 
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Figure 35 gives an overview of the data analysis steps, and subsequent results, 
of the HONE1-EBV Zta ChIP data analysis. Each step will be outlined further in 
the text below. 
 
For the purpose of creating the histograms shown in Figure 34, binary .bam files 
were binned and converted to .bigwig files by normalizing to reads per kilobase 
per million reads, using the bamCoverage tool of the deepTools Galaxy platform, 
which reduces the file size so that the data can be loaded and visualised in the 
University of California, Santa Cruz (UCSC) genome browser. 
 
4.3 Zta binding and host gene regulation 
A ChIP qPCR experiment was conducted to confirm the binding of Zta to specific 
sites on the human genome, which were discovered through ChIP sequencing 
analysis and are known Zta binding sites in Akata cells. Figure 36 demonstrates 
the binding of Zta to SCIMP and BCL2A1 promoter regions of the HONE1-EBV 
cell genome (published in [111]), thus confirming the validity of MACS peak 
results. It appears that the Zta antibody binds more to non-specific regions than 
the IgG control antibody, for which no binding could be shown, despite this, 
enrichment can be seen at peak binding sites in comparison to flanking regions. 
To investigate whether genes are regulated as a result of Zta binding peak gene 
association in HONE1-EBV cells, the level of specific RNAs was quantified with 
the help of reverse-transcribed cDNA qPCR analysis. These particular genes 
have been shown to be upregulated during the EBV lytic cycle in RNA sequencing 
experiments [111] (data for SLC6A7 not published). As shown in Figure 37, the 
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binding of Zta at these sites is associated with the up-regulation of gene 
transcription in epithelial cells. 
 
Figure 35: ChIP qPCR analysis showing the amount of HONE1-EBV DNA bound by Zta when induced with 10μM SAHA for 48 hours. 
Figure 36: ChIP qPCR analysis showing the amount of HONE1-EBV DNA 
bound by Zta when induced with 10μM SAHA for 48 hours. Chromatin was 
immunoprecipitated with an antibody specific to Zta or a negative control IgG 
antibody. ChIP sequencing data analysis has revealed MACS peaks in the 
promoter region of the SCIMP and BCL2A1 genes of the human genome. The 
amount of Zta ChIP DNA in this region, and in a flanking negative control region, 
were quantified. Data represented as percentage of input. Line indicates 
background. Values are represented as mean ± SD. Increased binding to SCIMP 
and BCL2A1 in comparison to the flanking regions is significant (p<0.05). 
 
 
 
 
 
 
 
 
0
50
100
150
P
er
ce
nt
ag
e 
of
 In
pu
t
Zta
114 
 
 
 
 
Figure 36: qPCR result showing the amounts of RNA relative to GAPDH levels in HONE1-EBV cells. 
Figure 37: qPCR result showing the amounts of RNA relative to GAPDH 
levels in HONE1-EBV cells. Lytic cycle was induced (+SAHA) or unindicted (-
SAHA) with 10μM SAHA for 48 hours. The increased gene expression in treated 
cells in comparison to untreated cells is significant for all of these genes except 
RASA3 (p<0.05). Values are represented as mean ± SD. 
 
 
To investigate whether this binding is specific to HONE1-EBV cells, Zta ChIP 
qPCR was also performed in EBV positive HEK 293 Zta knock out (ZKO) 
epithelial kidney cells containing EBV induced into lytic cycle. Results can be 
seen in Figure 38 below and demonstrate that the level of enrichment of the 
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SCIMP promoter region is less significant in this cell line, although BCL2A1 is 
similar to HONE1-EBV. 
 
 
Figure 37: ChIP qPCR analysis showing the relative amount of HEK293 ZKO Chromatin bound by Zta when induced into lytic cycle through transfection with Zta. 
Figure 38: ChIP qPCR analysis showing the relative amount of HEK293 ZKO 
chromatin bound by Zta when induced into lytic cycle through transfection 
with Zta. Chromatin was immunoprecipitated with an antibody specific to Zta or 
a negative control IgG antibody. ChIP sequencing data analysis has revealed 
MACS peaks in the promoter region of the BCL2A1 gene of the HONE1-EBV 
genome. The amount of ChIP DNA in this region, and in a flanking negative 
control region, were quantified. The fold change of binding to these sites is 
represented in the graph. The enhanced binding of Zta to the peak in comparison 
to the flanking region is significant (p<0.005). Values are represented as mean ± 
SD. 
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4.4 Investigation of the mechanism of action by which Zta controls epithelial 
cells 
In order to investigate the mechanism of action through which EBV may be 
controlling the epithelial host cell, via the viral transcription factor Zta, the binding 
motif of the protein was investigated. For this purpose we utilised the Multiple 
Expectation Maximization for Motif Elicitation (MEME) -ChIP binding analysis 
platform [118] to seek common motifs in FASTA files, obtained from the UCSC 
Table browser (Figure 35), of all HONE1-EBV Zta ChIP MACS peak sequences. 
As can be seen in Figure 39, the most common binding motif identified is a 
previously characterised Zta binding site in B cells which strongly resembles the 
non CpG Zta response element (ZRE) [79]. 
A CA repeat element was also identified as a Zta binding motif with a significant 
p-value of 1.4x10-382. This motif has also been previously identified during similar 
experiments in a B cell background (data not published). 
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Figure 38: MEME-ChIP analysis of Zta binding motifs. 
Figure 39: MEME-ChIP analysis of Zta binding motifs. A: Most significant Zta 
binding motif identified in a Zta ChIP sequencing experiment using HONE1-EBV 
cells induced with 10μM SAHA for 48 hours. B: Non CpG ZRE previously 
identified in a Zta ChIP sequencing experiment using EBV positive B cells in lytic 
cycle. C: A CA repeat element was also identified as a Zta binding motif with a 
significant p-value of 1.4 x 10-382. This motif has also been previously identified 
during similar experiments in a B cell background.  
 
To investigate the mechanism of action of Zta on the epithelial cell genome 
further, we cross-referenced the genes associated with HONE1-EBV Zta ChIP 
MACS peak obtained from GREAT, with sites of histone modifications and human 
transcription factor ChIP data in a range of different cell types using the gene list 
enrichment analysis tool EnrichR [119] which utilises the Encyclopaedia of DNA 
Elements (ENCODE) database. The list of genes associated with Zta binding 
peaks in HONE1-EBV cells is too large to be included in this thesis. However, as 
mentioned previously, the Zta ChIP sequencing data will be publicly available on 
GEO from 01.01.2019.   
The analysis showed a co-association of Zta binding sites with H3K27me3, most 
significantly in other epithelial cell types (Table 6). H3K27me3 is associated with 
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inactive gene promoters and shutting down the transcription process. 
Remarkably, H3K27me3 has only one methyltransferase, namely EZH2, which 
is part of the PRC2 complex [135]. 
 
 
Table 6:Table showing the co-associations of Zta ChIP sequencing data of HONE1-EBV cells. 
Table 6: Table showing the co-associations of Zta ChIP sequencing data 
of HONE1-EBV cells. Lytic cycle was induced with 10μM SAHA for 48 hours. 
Histone modification data derived from the ENCODE database. Gene list 
enrichment analysis performed by the EnrichR tool. 
 
EnrichR analysis also showed a significant co-association between Zta and a 
range of host cell “transcription factors” in B cells and other cell types (Table 7). 
While these proteins are classified in the transcription factor data base, most of 
the proteins listed here do not bind DNA directly.  
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Notably, EZH2 and SUZ12 are part of the same PRC2 complex which is involved 
in H3K27 trimethylation. 
 
 
Table 7:Table showing the overlap of Zta ChIP sequencing data of HONE1-EBV cells. 
Table 7: Table showing the overlap of Zta ChIP sequencing data of HONE1-
EBV cells. Lytic cycle was induced with 10μM SAHA for 48 hours, and human 
transcription factor ChIPs in various cell types. Human transcription factor ChIP 
data derived from the ENCODE database. Gene list enrichment analysis 
performed by the EnrichR tool. 
 
Using the Genomic Regions Enrichment of Annotations Tool (GREAT) [120], we 
found that most of the Zta binding sites on the epithelial cell genome are more 
than 2kb away from transcription start sites (Figure 40). To generate the graph, 
we analysed the data repeatedly, changing the parameter of the two nearest 
transcription start sites within a certain kilo base distance from the peak. The 
resulting number of peaks was plotted. This showed that Zta may act through 
distal regulatory elements to control host cell gene as has been shown to be the 
case in B cells [105]. 
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Figure 39: Graph showing the number of genes, within a certain distance (in kb), associated with Zta ChIP sequencing MACS peaks. 
Figure 40: Graph showing the number of genes, within a certain distance 
(in kb), associated with Zta ChIP sequencing MACS peaks. Lytic cycle was 
induced in HONE1-EBV cells with 10μM SAHA for 48 hours. To generate the grap 
the data was analyzed repeatedly, changing the parameter of the two nearest 
transcription start sites within a certain kilo base distance from the peak. The 
resulting number of peaks was plotted. Graph shows that most of the Zta binding 
sites on the epithelial cell genome are more than 2kb away from transcription 
start sites. 
 
With the help of GREAT we were able to identify pathways which might be 
associated with Zta host cell binding sites. For this purpose, GREAT utilises 
different databases containing the Protein ANalysis THrough Evolutionary 
Relationships (PANTHER) classification system [136] and the Gene Ontology 
(GO) enrichment analysis tool [137]. Identified pathways include the notch 
signalling pathway (p-value: 1.84x10-8), negative regulation of receptor activity 
(p-value: 1.06x10-7), positive regulation of steroid biosynthesis (p-value: 1.15 x 
10-7) and steroid metabolic processes (p-value: 3.55 x 10-6). Considering binding 
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sites within 2kb of the transcription start site only, which is regarded as the 
promoter region, we discovered associations with the negative regulation of 
receptor activity  (p-value: 1.06 x 10-7), positive regulation of steroid biosynthesis 
(p-value: 1.15 x 10-7) and steroid metabolic processes (p-value: 3.44 x 10-6). The 
list of genes associated with Zta peaks within 2kb of their promoter region has 
been included in Appendix A of this thesis (Supplementary Figure 1). 
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Table 8:Top five most significant gene ontologies linked to genes associated with Zta ChIP sequencing MACS peaks in 
HONE1-EBV cell. 
Table 8: Top five most significant gene ontologies linked to genes 
associated with Zta ChIP sequencing MACS peaks in HONE1-EBV cell. Lytic 
cycle was induced with 10μM SAHA for 48 hours. All gene ontologies (GOs) are 
at a low level of significance. A recurring theme in GOs linked to genes associated 
with Zta MACS peaks in HONE1-EBV cells seems to be oxygen transport related. 
 
EnrichR was used to further explore the function of Zta controlling the host cell. 
This tool enabled us to investigate gene ontologies (GO) which may be linked to 
genes associated with Zta MACS peaks in the context of biological processes, 
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cellular components and molecular functions (Table 8). All of the obtained results 
are at a very low level of significance. A recurring theme in GOs linked to genes 
associated with Zta MACS peaks in HONE1-EBV cells seems to be oxygen 
transport related. 
 
4.5 Comparison of Zta peaks 
To investigate cell type specific properties of Zta, the Zta ChIP sequencing results 
obtained in HONE1-EBV cells were compared with Zta CHIP sequencing results 
in Akata cells. MACS peaks for Zta binding to the human genome, which are 
common to HONE1-EBV and Akata cells, will be among the data published on 
GEO (as stated in section 4.2). 
 
Figure 40: Comparison of Zta peaks in Akata and HONE1-EBV cells. 
Figure 41: Comparison of Zta peaks in Akata and HONE1-EBV cells. The Zta 
ChIP sequencing results obtained in HONE1-EBV cells were compared with Zta 
CHIP sequencing results in Akata cells. This Figure describes the analysis step 
undertaken during this process. 
 
Figure 41, 43 and 46 highlight specific processes shown in Figure 35. Figure 41 
focuses on how the Zta peak data of binding to the host genome of epithelial and 
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B cells were processed to find binding sites which are common to both cells types 
or unique to either. 
 
Figure 42 illustrates the overlap of Zta MACS peaks in HONE1-EBV cells with 
Zta MACS peaks in the B cell line Akata. This demonstrates that approximately 
2/3 of Zta MACS peaks in HONE1-EBV cells (NPC) are unique to this cell type in 
comparison to Zta peaks in Akata B cells, and 3704/5020 Zta peaks in Akata cells 
are also identified in HONE1-EBV.  
 
 
Figure 41: Venn Diagram showing the overlapping pieces of Zta MACS peaks between HONE1-EBV nasopharyngeal carcinoma cells (NPC) and Akata B cells. 
Figure 42: Venn Diagram showing the overlapping pieces of Zta MACS 
peaks between HONE1-EBV nasopharyngeal carcinoma cells (NPC) and 
Akata B cells. Zta MACS peaks in HONE1-EBV cells at a p-value of 10-9 and Zta 
MACS peaks in the B cell line Akata at a p-value of 10-7. This demonstrates that 
approximately 2/3 of Zta MACS peaks in HONE1-EBV nasopharyngeal 
carcinoma cells (NPC) are unique to this cell type in comparison to Zta peaks in 
Akata B cells. 
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Figure 43 summarises how specific Zta were analysed further to obtain binding 
motifs, gene associations and gene list enrichments described in the following 
section.  
 
 
Figure 42: Analysis of Zta peaks in Akata and HONE1-EBV cells. 
Figure 43: Analysis of Zta peaks in Akata and HONE1-EBV cells. Results 
obtained from further analysis of Zta peak files are indicated with the analysis tool 
used stated in boxes.  
 
Oxygen transport related GO analysis results can also be observed linked to Zta 
MACS peaks present in HONE1-EBV cells only, not present in Akata B cells. 
However, looking at genes associated with Zta MACS peaks present in both cell 
types does not yield oxygen transport related GOs, indicating that this analysis 
might point to a particular Zta function specific to epithelial cells. The list of genes 
associated with Zta peaks in HONE1-EBV and Akata cells is too large to be 
included in this thesis.  
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Focusing in more closely on Zta MACS peaks which NPC and B cells have in 
common, ChIP-MEME analysis was performed on the intersecting peak FASTA 
files. This analysis revealed that the most significant Zta binding motif associated 
with MACS peaks present in NPC and B cells is a CA repeat element (7.1x10-
169). The Non-CpG ZRE described earlier, as well as a CpG ZRE were identified 
(Figure 44). The p-values for these motifs are substantially less significant than 
those obtained for motifs found in HONE1-EBV cells (Figure 39) because the 
number of peaks put in to this analysis is much lower. 
 
Figure 43: MEME-ChIP analysis of Zta binding motifs. 
Figure 44: MEME-ChIP analysis of Zta binding motifs. A: Significant Zta 
binding motif identified in Zta ChIP sequencing MACS peaks in HONE1-EBV 
cells, induced with 10μM SAHA for 48 hours, intersected with Akata B cell peaks 
induced with 0.125% IgG for 24 hours. B: Significant Zta binding motif identified 
in Zta ChIP sequencing MACS peaks in HONE1-EBV cells, induced with 10μM 
SAHA for 48 hours, intersected with Akata B cell peaks induced with 0.125% IgG 
for 24 hours. C: Non CpG ZRE previously identified in a Zta ChIP sequencing 
experiment using EBV positive B cells in lytic cycle. D: CpG ZRE previously 
identified in a Zta ChIP sequencing experiment using EBV positive B cells in lytic 
cycle. 
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Using GREAT, we found that most of the Zta binding sites present on the NPC 
cell as well as the B cell genome are more than 2kb away from a transcription 
start sites. The number of genes, within a certain distance (in kilo bases), 
associated with Zta ChIP sequencing MACS peaks in epithelial and B cells 
resemble that shown in Figure 40. GREAT analysis of the associated genes 
shows that pathways which might be involved in the mechanism of Zta action 
include cell regulation and differentiation gene sets like cell differentiation in the 
spinal cord (3.68x10-19), positive regulation of protein serine/threonine kinase 
activity (2.32x10-18) and negative regulation of osteoblast differentiation (7.38x10-
18). A list of genes, associated with Zta peaks common to HONE1-EBV and Akata 
cells, within 2kb of the transcription start site, is included in Appendix A of this 
thesis (Supplementary Figure 2). 
 
Genes associated with HONE1-EBV Zta ChIP MACS peaks shared with B cells 
were cross-referenced with sites of histone modifications and human 
transcription factor ChIP data from ENCODE, in a range of different cell types, 
using EnrichR (Figure 43) [119]. The histone modifications analysis showed a 
most significant association of Zta binding sites with H3K4me1, which has a 
higher p-value than the most relevant histone modification in the complete set of 
Zta peaks in NPC cells. H3K4me1 is characterised by post-transcriptional 
modifications and associated with active enhancers [138]. 
A less significant association with H3K27me3 is present, when compared to 
results from the complete set of Zta peaks in NPC cells. This data could suggest 
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that Zta fulfils a role specific to NPC cells, which differs from its mechanism of 
action in B cells, making H3K27me3 more relevant in this cell type. 
In addition, a significant co-association with the same top three transcription 
factors as in the previous analysis was revealed (Table 9). The overlap with BCL3 
seems to be even more significant with Zta peaks common to NPC and B cells 
(3.18 x 10-52), this could suggest a cell type independent role of this particular 
transcription factor binding site to the lytic cycle of EBV. Interestingly, BCL3 has 
been shown to interact with CREB during its role as transcription repressor and 
the CREB binding protein (CBP) has also gained in relative significance during 
this particular co-association analysis.  
 
 
Table 9:Table showing co-association of Zta ChIP sequencing data in HONE1-EBV cells intersected with Akata cells, 
and human transcription factor ChIPs in various cell types. 
Table 9: Table showing co-association of Zta ChIP sequencing data in 
HONE1-EBV cells intersected with Akata cells, and human transcription 
factor ChIPs in various cell types. Lytic cycle in HONE1-EBV was induced with 
10μM SAHA for 48 hours. Lytic cycle in Akata cells was induced with 0.125% IgG 
for 24 hours. Human transcription factor ChIP data derived from the ENCODE 
database. Gene list enrichment analysis performed by the EnrichR tool. 
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4.6 A closer look at Zta peaks at host transcription factor promoter regions 
 
Based on the EnrichR analysis, we investigated the link between the viral 
transcription factor (TF) Zta and the human TFs BCL3, EZH2 and SUZ12 further. 
The MACS peak binding profile of Zta in the region of genes encoding these TFs 
is shown in Figure 45. The presence of binding sites near the genes suggests the 
possibility of a feedback mechanism between Zta and these host cell TFs in all 
three cases for epithelial cells, and for EZH2 also in B cells. 
 
Figure 44: Zta MACS peak binding sites in the region of significant human TF genes. 
Figure 45: Zta MACS peak binding sites in the region of significant human 
TF genes. HONE1-EBV cells were induced with 10μM SAHA for 48 hours (10-9 
hone) and Akata cells induced with 0.125% IgG for 24 hours (combined Zta 10-
7). 
 
 
Having found significant co-associations of Zta binding peaks with a range of 
other protein and histone modification peaks, the possibility of an absolute 
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overlap of ChIP sequencing peaks was investigated. Figure 46 further expands 
on the analysis steps by showing how transcription factor and histone 
modification data from ENCODE were included to extend the investigation of the 
mechanism of action of Zta on the host cell genome.  
 
 
Figure 45: Comparison of Zta peaks in Akata and HONE1-EBV cells with other transcription factor and histone modification ChIP-Seq data. 
Figure 46: Comparison of Zta peaks in Akata and HONE1-EBV cells with 
other transcription factor and histone modification ChIP Seq data. The Zta 
ChIP sequencing results obtained in HONE1-EBV cells were compared with Zta 
CHIP sequencing results in Akata cells. The resulting common peaks were 
compared to other published ChIP sequencing peaks for transcription factors and 
histone modification. This Figure describes the analysis step undertaken during 
this process. 
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Zta peaks found in epithelial cells, Akata B cells, and both cell types were 
intersected with the BCL3, SUZ12 and EZH2 binding sites, as well as H3K27me3 
sites. The results of these intersections are summarised in Table 10. 
 
 
* Data not available in GM12878 cells, values relate to H1hESC cells 
Table 10: Percentage of Zta peaks in HONE1-EBV NPC cells which overlap with indicated cellular factors or sites of 
H3K27me3. 
Table 10: Percentage of Zta peaks in HONE1-EBV NPC cells which overlap 
with indicated cellular factors or sites of H3K27me3. Lytic cycle in HONE1-
EBV cells was induced with 10μM SAHA for 48 hours. Lytic cycle in or Akata B 
cells was induced with 0.125% IgG for 24 hours. 
 
A high number of sites which overlap with Zta and a human transcription factor 
can be seen for BCL3. SUZ12 has similarly high overlap with Zta binding sites in 
NPC and B cells, as does H3K27me3. Though EZH2 has only a small amount of 
overlap with Zta peaks. 
The actual numbers of BCL3 peaks in GM12878 cells which overlap with Zta 
peaks in HONE1-EBV, Akata cells, and Zta peaks common to both is pictured in 
the Venn Diagrams in Figure 47.  
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Figure 46: BCL3 peaks intersected with Zta peak. 
Figure 47: BCL3 peaks intersected with Zta peak. BCL3 ChIP sequencing 
peaks in GM12878 cells were intersected with Zta peaks in HONE1-EBV, Akata 
and common binding peaks. 
 
In order to investigate the link between BCL3 and Zta further, ChIP-MEME 
analysis was carried out to identify the BCL3 binding motif. For this purpose 
publicly available ChIP sequencing data was used in the GM12878 and K562 cell 
backgrounds. K562 are EBV negative erythroleukaemia cells while GM12878 is 
an EBV positive lymphoblastoid cell line. Results of this analysis can be seen in 
Figure 48. 
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Figure 47: MEME-ChIP analysis of indirect BCL3 binding motifs. 
Figure 48: MEME-ChIP analysis of indirect BCL3 binding motifs. A: BCL3 
binding motif identified in BCL3 ChIP sequencing MACS peaks in EBV negative 
K562 cells in the factorbook repository. B: CA rich motif identified in BCL3 ChIP 
sequencing MACS peaks in EBV positive GM12878 cells by ChIP-MEME 
analysis. C: Most significant BCL3 binding motif identified in BCL3 ChIP 
sequencing MACS peaks in EBV positive GM12878 cells by ChIP-MEME 
analysis. D: Non CpG ZRE previously identified in a Zta ChIP sequencing 
experiment using EBV positive B cells in lytic cycle. 
 
The BCL3 binding motif in GM12878 cells, an EBV positive lymphoblastoid cell 
line, is similar to the Non CpG ZRE, further supporting the proposal that BCL3 
could play an important role in the regulation of the host cell by EBV. A CA rich 
motif was also discovered in the GM12878 BCL3 binding region. The Non CpG 
ZRE cannot be identified in the EBV negative K562 cell line. 
 
4.7 Discussion 
The mapped ChIP sequence reads initially suggest a relatively poor transcription 
factor enrichment on the bamFingerprint graph. However, this is due to a 
clustering of Zta binding peaks which leads to an enrichment pattern more 
134 
 
characteristic of broad histone modification peaks, rather than high, narrow peaks 
associated with most transcription factors [139]. In addition, MACS peaks were 
called at a high significance with a p-value of 10-9, which point to ample 
enrichment of the sequence reads. Peaks were also called at a lower significance 
with a p-value of 10-7, which yielded more peaks, however, visual inspection of 
genome alignments confirm that these are lower quality peaks. Further 
investigations focused on the more significant peaks only. While some relevant 
peaks might be missed at the higher significance, there is still a large number of 
more significant peaks to examine which are more likely to be pertinent. 
Several HONE1-EBV Zta MACS peaks were confirmed, with the help of ChIP 
qPCR, at locations which are known Zta binding sites in Akata cells [105]. 
Enrichment of the same regions can also be observed in a second epithelial cell 
line, HEK293 ZKO, though the effect was somewhat less substantial.  
Motif analysis of Zta binding sites revealed the non CpG ZRE, which was 
previously shown to be a Zta binding motif in Akata cells [18]. However, the CpG 
ZRE could not be detected, even at a low significance, for Zta binding in epithelial 
cells. This could point to a B cell specific function of Zta linked to CpG ZREs. 
To investigate if the binding of Zta to the epithelial cell genome has an effect on 
gene transcription, the RNA levels of associated genes were quantified. This 
analysis showed a significant up-regulation of several RNA levels in comparison 
to uninduced cells. This result is an average of the whole cell population, in which 
only approximately 21% of the cells are actually expressing Zta (Chapter 3).  
A closer look at gene associations revealed that the majority of Zta peaks are 
further than 2kb away from a transcription start sites, suggesting that Zta acts 
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through distal regulatory elements in epithelial cells, as it does in B cells [105]. 
The pathways linked to Zta gene associations should be further investigated, with 
a closer look at the possible regulation of common genes.  
The oxygen transport related GOs outlined, together with the positive regulation 
of steroid biosynthesis and steroid metabolic processes, might point to an 
increase in cell metabolism. This set of GOs seems specific to EBV infection in 
epithelial cells, as oxygen transport related results can also be found for Zta 
peaks unique to epithelial cells, but not for peaks common to both cell types. In 
addition, these metabolic and biosynthetic pathways are not associated with 
peaks common to both cell types. However, as is shown, the number of significant 
peaks in B cells, even at a lower significance of 10-7, is smaller than that in 
epithelial cells. This is due to a lower sequencing depth in B cells, which may 
have led to the exclusion of some relevant peaks in this cell type. 
Gene association analysis indicates a significance of H3K27me3 linked to the 
role of Zta in controlling the epithelial host cell. In addition, we also found a 
significant co-association between Zta, EZH2 and SUZ12, which are part of the 
PRC2 complex responsible for H3K27 trimethylation [140]. HE327me3 is 
associated with silenced regions of the genome. The relationship between 
methylated DNA and H3K27me3 is still poorly defined. In embryonic stem cells, 
H3K27me3 is located almost exclusively at CpG islands which are generally not 
associated with DNA methylation. However, in cancer cell lines H3K27me3 is a 
lot less restricted to CpG islands and there are extensive overlap between 
H3K27me3 and methylated DNA [141, 142]. Interestingly, it has previously been 
shown that the viral transcription factor, Zta, is able to bind to methylated DNA 
[76].  
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The most significant transcription factor co-association has been found to be with 
BCL3. For peaks common to both, epithelial and B cells, the repressive chromatin 
mark H3K27me3 drops in significance. The most significance histone 
modification for this set of peaks is the active chromatin mark H3K4me1. EZH2 
and SUZ12 also drop in significance for common peaks, in comparison to all 
HONE1-EBV cell peaks, while BCL3 gains in significance. This data could 
suggest that Zta fulfils a role specific to epithelial cells, which differs from its 
mechanism of action in B cells, making H3K27me3 more relevant in this cell type. 
Zta binding sites can be found at the promoter regions of BCL3, EZH2 and SUZ12 
in epithelial cells and at EZH2 in B cells. This points to a possible feedback 
mechanism between Zta and these proteins. Table 8 shows that there is a 
significant absolute overlap between Zta binding sites on the human genome and 
the binding sites of BCL3 and SUZ12, as well as H3K27me3 sites. EZH2 shows 
no significant direct overlap, however, it is possible that the binding regions are 
very close to each other as opposed to direct overlaps, especially as it forms a 
complex with SUZ12 . 
BCL3 has been shown to associate with the same non CpG ZRE binding motif 
as Zta, in GM12878 cells. GM12878 cells are infected with EBV, but the virus is 
reportedly latent and does not express Zta. The EBV negative cell line K562 has 
not been found to contain this binding motif. Further investigation is needed to 
determine if there is a link between EBV infection and BCL3 activity. Outlined 
results suggest that BCL3 could be acting as a repressor during EBV infection, 
being involved in the establishment of a repressive chromatin environment, which 
is overturned by Zta during the lytic cycle. 
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The p-value of the presence of the non-CpG ZRE related motif under BCL3 ChIP 
sequencing peaks in GM12878 cells is 1.9x10-325. The p-value of this same Zta 
binding motif in HONE1-EBV cells is 9.7x10-401. However, when looking only at 
peaks which are bound by Zta in HONE1-EBV cells as well as Akata cells, the 
significance falls to 1.3x10-68. This 5.9 fold decrease in significance might indicate 
that the combination of BCL3 and the non-CpG ZRE play a more prominent role 
in promoting the control of the epithelial host cell by EBV than they do in B cells. 
This fall in significance is, at least partially, linked to the decrease of the overall 
number of peaks bound by Zta in both cell types. However, despite this we also 
found a 2.6 fold increase in the significance of CA repeat regions in sites bound 
by Zta in both cell types in comparison to all sites bound by Zta in HONE1-EBV 
cells. The significance of CA repeat regions under BCL3 ChIP sequencing peaks 
is 16.4 fold lower than that of the Zta binding sites common to NPC and B cells. 
This could indicate a central role of CA repeat regions to EBV infection, unrelated 
to BCL3. 
Further investigations into the role of BCL3 linked to the early lytic cycle of EBV 
infection are outlined in the following chapter.  
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Chapter 5: BCL3 
 
5.1. Introduction 
This chapter will focus on the relevance of the B-cell lymphoma 3 protein (BCL3) 
for lytic cycle reactivation of EBV by Zta. As discussed in the previous chapter, 
BCL3 binds to 64% of the sites also bound by Zta in epithelial and B cells. In 
addition, BCL3 binding sites were shown to resemble non CpG ZREs in cells 
infected with EBV. 
BCL3 is located at the chromosomal site 19q13, which frequently translocates 
into the immunoglobulin alpha-locus in some cases of B cell leukaemia (e.g. 
chronic lymphocytic leukaemia and some lymphomas) [143, 144]. The BCL3 
gene itself consists of 9 exons, spanning 11.5kb. There are nine splice variants 
of BCL3, seven of which are non-protein coding. The two protein coding, variant 
BCL3 proteins are 308aa and 454aa in length [145]. BCL3 is a phosphoprotein 
and has a molecular weight of 32kDa (308aa variant) – 47kDa (454aa variant) 
[144]. In addition, the BCL3 protein also differs in its phosphorylation states, 
mainly at the serine-rich carboxyl terminus [144].  
Both variants of BCL3 contain seven ankyrin repeats. This structure is 
characteristic for family members of the Inhibitor of κ-B (IκB) proteins, to which 
BCL3 has close homology. Both IκB and BCL3 interact with the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) via their ankyrin tandem 
repeat motif. The NFκB protein family is central to inflammation. It is present in 
the cytoplasm of all cells, where it is generally complexed to IκB. In response to 
inflammatory signals, IκB is phosphorylated and degraded, which leads to the 
translocation of NFκB to the nucleus where it binds to DNA and activates genes 
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leading to inflammatory response [146]. In mammals, the NFκB family consists 
of p65 (RelA), RelB, c-Rel, p50 (p105, NFKB1), and p52 (p100, NFKB2). The 
subunits associate with each other to form homo- and heterodimers which control 
gene transcription. All five family members share a conserved 300aa long amino-
terminal Rel homology domain, which is required for interaction with IκB, 
dimerization, DNA binding and nuclear translocation [147].   
Unlike IκB, that inhibits NFκB activity, BCL3 can function as a transcriptional co-
activator of NFκB target genes, either directly via its proline-rich amino terminus 
and proline-/serine-rich carboxyl terminus or indirectly, by removing repressive 
p50 or p52 homodimers from κB sites [144, 148, 149]. In addition, BCL3 is also 
able to enhance the binding of p50 and p52 homodimers to certain target sites, 
leading to transcriptional repression [150, 151]. The mechanisms which lead to 
either effect of BCL3 are currently still poorly understood, but the effect of BCL3 
on transcription activation or repression depends, at least partly, on post-
transcriptional modification [144, 147]. BCL3 contributes to the regulation of cell 
proliferation and is required for the attenuation of pro-inflammatory action of 
activated macrophages and the survival of activated T cells [144, 152].  
BCL3 has also been proposed to have a lymphocyte specific role as an essential 
negative regulator of Toll-like Receptors (TLRs). It has been proposed that BCL3 
may play a role in B cell development by allowing immature B cells to resist 
apoptosis caused by the DNA damage undergone during immunoglobulin class 
switch recombination and somatic hypermutation [153].  
The varied functions described for BCL3 can partly be attributed to its ability to 
form complexes with a range of binding partners. Figure 49 shows the BCL3 
140 
 
STRING Interaction Network with 25 known binding partners, including CBP 
(CREBBP) [15]. Furthermore, BCL3 has been shown to form complexes with the 
NFκB p52-p52 (NFKB2) homodimer and the NFκB p50-p50 (NFKB1) homodimer 
[9]. Unlike the other subunits of NFκB, the p50 and p52 proteins lack a 
transactivation domain. When bound to DNA, these homodimers usually inhibit 
gene transcription [2]. TNFα, IL1β and phorbolester trigger the formation of BCL3-
p50 complexes [10]. Tethering of BCL3 to DNA via the p50 homodimers can allow 
BCL3 to activate gene transcription [11]. It also interacts with proteins outside of 
the NFκB family including the transcription factor AP1 (c-Fos and c-jun) whose 
effect it can increase. Other interactions include Tip60 (histone 
acetyltransferase), histone deacetylase and CYLD [143, 154, 155]. 
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Figure 48: BCL3 STRING Interaction Network 
Figure 49: BCL3 STRING Interaction Network. Diagram shows BCL3 with its 
25 binding partners [140]. 
 
In addition to CBP, BCL3 has also been shown to interact with the transducer of 
regulated CREB activity 3 (TORC3) during infection with the human T cell 
leukaemia virus 1 (HTLV-1) [156]. HTLV-1 enters a long period of latency in CD4+ 
lymphocytes which results in asymptomatic, live-long infection in ~90% of 
patients. It is associated with adult T cell leukaemia and lymphoma, myelopathy, 
dermatological conditions, uveitis and subclinical immune suppression which can 
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result in increased opportunistic infections [157]. The HTLV-1 Tax protein 
activates the virus’ lytic cycle by association with CREB from the viral long 
terminal repeat which contains multiple cyclic AMP response elements flanked 
by GC-rich sequences. TORC1, 2 and 3 significantly enhance this Tax-mediated 
transcription in a manner dependent on a ternary complex composed of Tax, 
CREB and TORCs. The interaction of BCL3 with TORC3 significantly inhibits the 
reactivation from latency of HTLV-1. Tax can modulate its own transcription by 
interacting with CREB, which activated the long terminal repeat [156]. The 
expression of BCL3 is enhanced by Tax via an NFκB binding site in the second 
intron of the BCL3 gene [158]. The suppression of transcription by BCL3 is due 
to the inhibition of TORC3 function, but not inhibition of Tax itself. The amount of 
CREB recruited to Tax response elements is not altered by increased BCL3 
expression [156]. Figure 50 shows a model the activation of transcription by Tax 
in conjunction with CREB and TORC from the long terminal repeat (LTR) of 
HTLV-1 (Figure 50 A) and how BCL3 may disrupt the transcription activation 
activity of Tax by interacting with TORC as part of the Tax-TORC-CREB complex 
(Figure 50 B), or by inhibiting the binding of TORC and hence the formation of 
the ternary complex (Figure 50 C). 
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Figure 49: Model of transcription activation by HTLV-1 Tax 
Figure 50: Model of transcription activation by HTLV-1 Tax. A: Activation of 
transcription by Tax in conjunction with CREB and TORC from the long terminal 
repeat (LTR) of HTLV-1. The bottom row shows how BCL3 may disrupt the 
transcription activation activity of Tax by interacting with TORC as part of the Tax-
TORC-CREB complex (B), or by inhibiting the binding of TORC and hence the 
formation of the ternary complex (C). 
 
 
Evidence indicates that deregulated BCL3 contributes to some types of Hodgkin 
and non-Hodgkin lymphoma, as well as nasopharyngeal carcinoma and ovarian 
cancer, where it has been found to be over-expressed without a translocation 
[143]. The constitutive expression of BCL3 has been shown to suppress DNA 
A 
B                                                              C 
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damage-induced p53 activation and consequent p53-induced apoptosis [159]. 
Additionally BCL3 inhibits apoptosis by blocking Bim activation [160].  
The deregulation of BCL3 has also been shown to be associated with a number 
of other diseases affecting the immune system, including autoimmune type 1 
diabetes in mice [161], atopic dermatitis [162] and Crohn’s disease [163]. 
 
BCL3 abundancy can be regulated at the post-transcriptional level. The 
translation of BCL3 mRNA transcripts is regulated by Micro-RNAs (miRNAs) or 
RNA-binding proteins. For example, the translation of BCL3 mRNA is down-
regulated by miRNA-125 in human ovarian cancer cells [164].  
Surprisingly, transgenic mice, which over-express BCL3 in T and B cells, do not 
develop a lymphoid neoplasm. However, they do develop a lymphoproliferative 
disorder. During these experiments, BCL3 was shown to increase the signal-
specific survival of follicular B cells as well as the incidence of antibodies to self-
antigens. Interestingly, a statistically significant increase in IgA antibodies was 
also observed [165, 166]. Unfortunately these studies did not include further 
mouse crosses against oncogenes or knock-outs to test whether BCL3 
predisposes to cancer.  
BCL3 is expressed in most areas of the human body, but the main defects of 
BCL3 knock-out mice relate to their immune response. BCL3 deficient mice 
appear developmentally normal but have an altered spleen and lymph node 
microarchitecture, including a lack of germinal centre formation. They are unable 
to form B cell follicles and are not able to form proper follicular dendritic cell 
networks following antigenic challenge [167]. These knock-out studies in mice 
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show that the animals have compromised production of antigen-specific B and T 
cells which makes them vulnerable to certain kinds of pathogens [144].  
Epstein–Barr virus latent membrane protein 1 (LMP1) may lead to the 
deregulation of BCL3 in infected cells. It has been shown that LMP1 expression 
induces multiple distinct NFκB forms including abundant p50 dimers, p50/p52 
dimers and p65. LMP1- carboxy-terminal activating region 1, which is the 
activating domain of LMP1, also induces formation of a complex containing the 
p50 dimer and BCL3 on the EGFR promoter. Cells expressing LMP1 have 
increased levels of phosphorylated STAT3, not only on the BCL3 promoter, but 
also on the HS3 and HS4 intronic enhancers, resulting in induced BCL3 
expression [168]. Indeed, expression of LMP1 is thought to result in p50/BCL3 
which is the major form for NFκB detected in Nasopharyngeal Carcinoma [169].  
 
5.2 Expression of BCL3 in a Range of EBV Positive Cell Lines 
Western blotting was performed to query whether BCL3 is expressed in HONE1-
EBV and Akata cells, which the Zta ChIP sequencing results outlined in the 
previous chapter are based on. This shows a clear increase in BCL3 protein 
levels in protein extracts and chromatin of cells containing EBV induced into lytic 
cycle in comparison to un-induced controls. The detected BCL3 band 
corresponds to the 47kDa (454aa variant) variant of the BCL3 protein. cDNA 
qPCR experiments to quantify BCL3 RNA levels did not show an increase in 
induced samples, suggesting that BCL3 is regulated at the translational level as 
a result of EBV lytic cycle reactivation or induction.  
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(47kDa) 
As the ChIP sequencing results for BCL3 from ENCODE were not based on 
HONE1-EBV or Akata B cells as the Zta ChIP sequencing results, the expression 
of BCL3 in these, and other EBV positive cells, was investigated. Figure 51 shows 
the expression of BCL3, Zta and Actin in HONE1-EBV cell protein extract and 
chromatin. The Figure shows that BCL3 expression appears to increase when 
EBV is induced into lytic cycle.  
 
Figure 50: Western Blot showing the expression of Zta, host cell actin and the host transcription co-factoraBCL3 in HONE1-EBV cells 
Figure 51: Western Blot showing the expression of Zta, host cell actin and 
the host transcription co-factor BCL3 in HONE1-EBV cells. Blot shows 
protein extracts and reverse cross-linked chromatin derived from HONE1-EBV 
cells un-induced (-SAHA) or induced (+SAHA) into lytic cycle with 10μM SAHA 
for 48 hours. Blot was performed using the Santa Cruz BCL3 (c-14) antibody. 
 
The corresponding amount of BCL3 RNA in HONE1-EBV cells is shown in Figure 
52, along with the RNA level of p50 and p52. There is no significant difference in 
the amount of BCL3 or p52 RNA, suggesting that any difference in BCL3 protein 
is likely due to post-transcriptional processing. It is known that BCL3 can be 
(42kDa) 
(33kDa) 
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regulated at the post-transcriptional level by Micro-RNAs (miRNAs) or RNA-
binding proteins (eg. miRNA-125) [164].  
The amount of p50 RNA increases significantly in HONE1-EBV cells when lytic 
cycle is induced. This hints at a mechanism of action of lytic cycle reactivation 
which may involve NFκB, with which BCL3 is known to interact.  
 
 
Figure 51: qPCR result showing the fold change of BCL3, p50 and p52 RNA expression in HONE1-EBV cells 
Figure 52: qPCR result showing the fold change of BCL3, p50 and p52 RNA 
expression in HONE1-EBV cells. Lytic cycle was induced in HONE1-EBV cells 
with 10μM SAHA for 48 hours (+SAHA) or not induced (-SAHA). Values are 
represented as mean ± 95% Confidence Interval (p<0.05 for p50). 
 
Due to the limitations of the HONE1-EBV cell line, including the fact that it is not 
fully identified and the drastic decrease in adherent cell numbers when EBV lytic 
cycle is induced, it was decided to carry out further experiments in alternative cell 
lines.  
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Previous Zta ChIP sequencing was also performed in Akata B cells. The last 
chapter showed a substantial overlap with BCL3 binding sites in this cell type. 
The expression of BCL3 in Akata cells, as well as HEK293 ZKO cells, can be 
seen on the western blot in Figure 53. EBV lytic cycle in Akata cells was induced 
via the activation of a doxycycline inducible promoter, which leads to the 
expression of Zta, or by crosslinking of the B cell receptor with anti-
immunoglobulin [170]. Lytic cycle in  
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Figure 52: Western Blot showing the expression of Zta, host cell actin and the host transcription co- factor BCL3 in Akata or HEK 293ZKO protein 
extracts 
Figure 53: Western Blot showing the expression of Zta, host cell actin and 
the host transcription co-factor BCL3 in Akata or HEK 293ZKO protein 
extracts. Akata cells were un-induced or induced into lytic cycle with 0.125% IgG 
or 500 ng/ml doxycycline for the indicated time. HEK293 ZKO cell were induced 
into lytic cycle by transfection with Zta or not induced by transfection with a 
pcDNA3 vector. Blot was performed using the Santa Cruz BCL3 (c-14) antibody. 
 
HEK293 ZKO cells was induced through transfection of a Zta expression plasmid. 
As in HONE1-EBV, the BCL3 protein levels appears to increase when EBV lytic 
cycle is induced with anti-IgG in Akata cells. The observed band is not based on 
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the IgG antibody used in Akata induction as the molecular weight of the rabbit 
F(ab')2 fragment antibody is approximately 110kDa (supplier information) and the 
BCL3 band is present just below the 49kDa marker. This is consistent with the 
BCL3 band seen in cells not induced with anti-IgG (e.g. HONE1-EBV). 
 
The increase of BCL3 in Akata cells containing EBV induced into lytic cycle with 
anti-IgG in comparison to untreated cells was confirmed. The band intensity and 
corresponding amounts of Zta and BCL3 normalised to actin levels were 
quantified (Figure 54).  
 
  
     
Figure 54: Western Blot (A) and band quantification (B) showing the 
expression of Zta, host cell actin and the host transcription factor BCL3 in 
Akata cells. Akata cells were induced into lytic cycle with 0.125% IgG for 24 
hours, or not induced. Blot was performed using the Santa Cruz (c-14) x antibody. 
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Figure 53: Western Blot (A) and band quantification (B) showing the expression of Zta, host cell actin and the host transcription factor BCL3 in Akata cells 
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As in HONE1-EBV cells, the amount of BCL3, p50 and p52 RNA, corresponding 
to the increase in BCL3 protein level, was investigated in Akata cells. This 
confirmed the absence on an increase in BCL3 transcription (Figure 55). 
However, as opposed to HONE1-EBV, the level of p50 RNA does not increase. 
This may suggest an epithelial-specific response of p50 to EBV lytic cycle.  
 
 
Figure 54: qPCR result showing the amounts of BCL3, p50 and p52 RNA in Akata cells 
Figure 55: qPCR result showing the amounts of BCL3, p50 and p52 RNA in 
Akata cells. The lytic cycle was induced with 0.125% IgG for 24 hours, or 
unindicted. Values are represented as mean ±95% Confidence Interval. 
 
Previous results, including MACS peak intersection of BCL3 and Zta peaks, have 
largely focussed on the human genome. Arvey et al. have mapped the binding of 
BCL3 in latently infected B95-8 LCLs to the EBV genome [25]. This shows a clear 
binding peak for BCL3 at the BHLF1 promoter (OriLyt). The western blot in Figure 
56A shows the expression of BCL3 in reverse cross-linked chromatin of Akata 
cells containing lytic EBV. The results of a corresponding ChIP qPCR experiment 
for Zta, BCL3 and a negative control IgG antibody are shown in Figure 56B. The 
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(47kDa) 
(42kDa) 
(33kDa) 
enrichment for OriLyt is significantly higher when immunoprecipitation was 
performed with an antibody specific for Zta or BCL3 in comparison to a non-
specific IgG control. This suggests that BCL3 binds to OriLyt in Akata cells and 
that overlapping binding sites for BCL3 and Zta can be extended to the viral 
genome.  
 
 
Figure 56: BCL3 association with OriLyt in Akata cells. Western Blot (A) 
showing the expression of Zta, host cell actin and the host transcription factor 
BCL3 in Akata cells. Blot shows reverse cross-linked chromatin derived from 
Akata cells induced into lytic cycle with 0.125% IgG for 24 hours. Blot was stained 
using the Santa Cruz BCL3 (c-14) x antibody. The corresponding ChIP qPCR 
analysis (B) shows the amount of OriLyt bound by Zta, BCL3 or a negative control 
IgG antibody. The binding of Zta and BCL3 to OriLyt is significantly higher than 
that of IgG (p<0.05). Values are represented as mean ± SD. 
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Figure 55: BCL3 
association with 
OriLyt in Akata cells 
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5.3 Binding of BCL3 to the Human Genome 
The previous section demonstrated that BCL3 is expressed in the same cell types 
in which the Zta ChIP sequencing experiments were performed when EBV is 
induced into lytic cycle. Based on these results and BCL3 ChIP sequencing 
results in GM12878 cells obtained from the ENCODE database, it was decided 
to investigate whether some of the BCL3 binding peaks correspond to BCL3 
binding in the EBV immortalized B-lymphoblastoid cell line 3 (LCL3). These cells 
were derived from a person infected with the B95-8 strain of EBV [24]. LCL3 cells 
do not require induction of EBV into lytic cycle.  In this section, results are 
presented which show binding of both, Zta and BCL3 to regions of binding peak 
overlaps on the human genome. The possibility of BCL3 and Zta binding to the 
same region of the human genome at the same time was further investigated 
using ChIP reChIP qPCR. This involved a first round of ChIP with a Zta-specific 
antibody followed by a second round of ChIP of the same sample with a BCL3-
specific antibody. As is shown in this section, this approach yielded no evidence 
of co-binding. 
An example of MACS peak overlaps for Zta in epithelial cells and Akata B cells, 
as well as BCL3 in GM12878 B cells at the promoter regions of THRA, SCIMP 
and BCL2A1 can be seen in Figure 57.  
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Figure 56: Example of ChIP sequencing MACS peaks around the BCL2A1, SCIMP and THRA gene 
Figure 57: Example of ChIP sequencing MACS peaks around the BCL2A1, 
SCIMP and THRA gene. Peaks were visualised with the help of the UCSC 
genome browser. 
 
The presence of BCL3, Zta and Actin in the sonicated LCL3 chromatin is 
presented in Figure 58.  
Figure 59 shows that the percentage of the LCL3 cell population which are 
expessing Zta is relatively low, at ~2%. As stated in chapter 3, any effects of Zta, 
during experiments based on the average of the whole population, actually only 
represent a fraction of Zta positive cells (~2%). These experiments include the 
EBV copy number per cell, RNA levels, and western blots. ChIP qPCR 
experiments select BCL3 or Zta positive cells with the relevant antibody. 
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However, it does point to the necessity to increase the number of cells used for 
ChIP experimentsm,  which are shown in the following section, in comparison to 
other cells lines which can be induced more efficiently.  
 
 
Figure 58: Western Blot showing the expression of BCL3 (A) in reverse 
cross-linked LCL3 chromatin together with a re-blot for Zta and host cell 
actin. The blot (A) was re-stained for the EBV early lytic cycle protein Zta and 
host cell actin (B). Blot was stained using the Santa Cruz BCL3 (c-14) antibody. 
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Figure 57: Western 
Blot showing the 
expression of BCL3 
(A) in reverse cross-
linked LCL3 
chromatin together 
with a re-blot for 
Zta and host cell 
actin 
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Figure 58: Overlay Histogram showing LCL3 cells containing Zta 
Figure 59: Overlay Histogram showing LCL3 cells containing Zta. Cells were 
not stained (black), stained with a negative control IgG antibody (red), showing 
background fluorescence, or Zta (blue). 
 
Based on this overlap, a ChIP qPCR experiment was performed in LCL3 with 
primers specific for the peak overlap region or a flanking negative control region 
(Figure 60). No binding could be confirmed to the THRA peak region. This may 
be due to primer design. SCIMP and BCL2A1 are knows Zta binding sites and, 
as expected, a significantly higher amount of binding is observed for the peak 
region. The amount of binding to the BCL2A1 peak in comparison to its flanking 
region is also increased for BCL3. 
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Figure 59: ChIP qPCR analysis showing the relative amount of LCL3 DNA bound by Zta, BCL3 or a negative control IgG antibody 
Figure 60: ChIP qPCR analysis showing the relative amount of LCL3 DNA 
bound by Zta, BCL3 or a negative control IgG antibody. Zta is known to bind 
to the promoter region of SCIMP and BCL2A1. These sites have previously been 
shown to be enriched during Zta ChIP experiments in comparison to 3’ flanking 
regions. ChIP sequencing data analysis has revealed overlapping BCL3 MACS 
peaks in these regions of the human genome. The amount of ChIP DNA in the 
promoter region of BCL2A1, SCIMP and THRA peak two (THRA #2), and in 
corresponding flanking negative control regions, were quantified. The qPCR 
result shows significantly enhanced binding of Zta and BCL3 to the BCL2A1 peak 
in comparison to the flanking region (p<0.05). The increased binding of Zta, but 
not BCL3, to SCIMP is also significant (p<0.05). Values are represented as mean 
± SD. 
An intragenic binging peak for Zta and BCL3 in the EGFR gene has been 
visualised in Figure 61 below. In addition to probing for binding at gene 
promoters, this region was also examined in LCL3 (Figure 62). Both Zta and 
BCL3, but not negative control IgG, are shown to be enriched at this EGFR 
binding peak in comparison to the flanking region.  
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Figure 60: Example of ChIP sequencing reads around the EGFR gene 
Figure 61: Example of ChIP sequencing reads around the EGFR gene. Zta 
and BCL3 binding site visualised, in the form MACS peaks, in the UCSC genome 
browser. 
 
Figure 61: ChIP qPCR analysis showing the relative amount of LCL3 DNA bound by Zta, BCL3 or a negative control IgG antibody 
Figure 62: ChIP qPCR analysis showing the relative amount of LCL3 DNA 
bound by Zta, BCL3 or a negative control IgG antibody. EGFR is a new Zta 
binding region. This sites has not previously been shown to be enriched during 
Zta ChIP experiments in comparison to a 5’ flanking region. ChIP sequencing 
data analysis has revealed overlapping BCL3 MACS peaks in this region of the 
human genome. The binding of Zta and BCL3 to EGFR peak is significantly 
higher than binding to the 5’ Flanking region (p<0.05). Values are represented as 
mean ± SD. 
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To investigate if BCL3 and Zta are present at their common binding sites at the 
same time, a ChIP re-ChIP experiment was performed which involved a first 
round of ChIP with Zta or negative control IgG followed by a second round of 
ChIP for BCL3 and Zta (Figure 63). A very similar enrichment for binding to the 
BCL2A1 peak in comparison to the flank can be seen for samples 
immunoprecipitated with Zta followed by Zta or BCL3. This result suggests that 
Zta and BCL3 may both be present at the same binding site at the same time. 
Alternatively it is possible that Zta antibody was carried over after the first round 
of ChIP. 
 
 
160 
 
 
 
Figure 62: ChIP reChIP qPCR analysis showing the relative amount of LCL3 DNA bound by Zta and a negative control IgG antibody (A) including a second round of ChIP for BCL3 and Zta (B) 
Figure 63: ChIP reChIP qPCR showing the relative amount of LCL3 DNA 
bound by Zta and a negative control IgG antibody (A) including a second 
round of ChIP for BCL3 and Zta (B). Zta is known to bind to the promoter region 
of BCL2A1. This site has previously been shown to be enriched during Zta ChIP 
experiments in comparison to 3’ flanking regions in this cell line. ChIP sequencing 
data analysis has revealed overlapping BCL3 MACS peaks in this regions of the 
human genome. The amount of ChIP DNA in the promoter region of BCL2A1 and 
in its corresponding flanking negative control region, were quantified. The binding 
of Zta to the BCL2A1 peak is significantly higher than to the flanking region 
(p<0.05). Values are represented as mean ± SD. 
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It was decided to follow this result up further with the aim to perform a ChIP re-
ChIP sequencing experiment for sites bound by Zta and BCL3. For this purpose, 
a large scale chromatin preparation was performed. The quality of this chromatin 
was checked by southern blot and qPCR. The resulting fragment size can be 
seen in Figure 64.  
 
 
 
 
 
 
 
Figure 64: Agarose Gel showing the size, in base pairs (bp), of sonicated 
LCL3 chromatin fragments. The ideal fragment size is 100-300bp 
 
In addition to the control first round IgG ChIP, a first round Zta, followed by a 
second round IgG ChIP was performed as a control to confirm whether or not 
BCL3 bind together with Zta. Figure 65 shows the qPCR results for the first round 
of ChIP with antibodies specific for BCL3, Zta or a negative control IgG with 
enhanced binding to the BCL2A1 peak in comparison to the flank. Following this 
first round of Zta ChIP, a second round of ChIP was performed using Zta as a 
positive control, IgG as a negative control, and BCL3 (Figure 66). 
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Figure 64: qPCR results of a ChIP experiment showing IgG, Zta and BCL3 binding to BCL2A1 in comparison to a 3’ flanking region 
Figure 65: qPCR results of a ChIP experiment showing IgG, Zta and BCL3 
binding to BCL2A1 in comparison to a 3’ flanking region. This experiment 
was performed using the same antibodies on the same chromatin, at the same 
time in the same qPCR run as the ChIP reChIP experiment. Data represented as 
percentage of Input. The enhanced binding of Zta and BCL3, but not IgG, to the 
BCL2A1 peak in comparison to the flanking region is significant (p<0.05). Values 
are represented as mean ± SD. 
 
The negative control re-ChIP with IgG appears to show the same enrichment as 
the re-ChIP with BCL3 (Figure 66). As IgG has been shown to be a suitable 
negative control in previous ChIP qPCR experiments, this result suggests that 
BCL3 and Zta may not bind to the promoter region of BCL2A1 together, but rather 
that the enrichment of this region is caused by carry-over of the Zta antibody from 
the first-round of ChIP. To investigate the possibility that the enrichment of 
binding to the peak in comparison to the flank after the first round of Zta ChIP is 
based on inefficient removal of the first round antibody, a ChIP was performed 
using Zta antibody denatured in the same way as after the first round of ChIP. 
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Figure 65: ChIP reChIP qPCR analysis showing the relative amount of LCL3 Zta ChIP DNA also bound by IgG, BCL3 or Zta 
Figure 66: ChIP reChIP qPCR analysis showing the relative amount of LCL3 
Zta ChIP DNA also bound by IgG, BCL3 or Zta. This site has previously been 
shown to be enriched during Zta and BCL3 ChIP experiments in comparison to 
3’ flanking regions in this cell line. ChIP sequencing data analysis has revealed 
overlapping Zta and BCL3 MACS peaks in this regions of the human genome. 
Following a first round of Zta ChIP, the increase in DNA precipitated by  Zta and 
IgG, but not BCL3, to the BCL2A1 peak in comparison to the flanking region is 
significant (p<0.05). Data represented as percentage of input. Values are 
represented as mean ± SD. 
 
As can be seen in Figure 67, a reduced, but significant enrichment of the BCL2A1 
promoter region is still achieved when performing ChIP using the denatured Zta 
antibody. The fold change of binding to the peak in comparison to the flanking 
region is very similar to the previously shown second round of ChIP with IgG or 
BCL3 (Figure 66). If BCL3 generally bound to the same regions as Zta, a higher 
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enrichment, similar to that seen for a second round Zta ChIP, would be expected. 
These results demonstrate that a Zta ChIP, BCL3 re-ChIP sequencing 
experiment is unlikely to be valuable. 
 
Figure 66: qPCR results of ChIP experiment showing the binding of a negative control IgG antibody, Zta and denatured Zta to BCL2A1 in comparison to a 3’ flanking region 
Figure 67: qPCR results of ChIP experiment showing the binding of a 
negative control IgG antibody, Zta and denatured Zta to BCL2A1 in 
comparison to a 3’ flanking region. The enhanced binding to the peak in 
comparison to the flanking region of BCL2A1 is significant in all cases (p<0.05). 
Data represented as percentage of Input.Values are represented as mean ± SD. 
 
5.4 BCL3 Protein Levels 
To investigate the upregulation of BCL3 as a result of lytic cycle induction more 
closely, FACS was performed to determine the percentage of BCL3 positive cells. 
Figure 68 shows the amount of Akata cells positive for BCL3 or a negative control 
antibody. The BCL3 antibody seems to have a higher amount of background 
staining. The amounts of both control and BCL3 positive cells appear to increase 
when lytic cycle is induced. The induction process requires a rabbit IgG antibody 
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and, both, control and BCL3, antibodies used for FACS are also of rabbit origin. 
To detect them, a rabbit specific, fluorescent antibody is used which leads to false 
positive results in induced cells.  
 
Figure 67: Akata FACS showing percentage of BCL3 positive cells 
Figure 68: Akata FACS showing percentage of BCL3 positive cells. Akata 
cells were not induced (top row) or induced with 0.125% rabbit IgG for 48 hours 
(bottom row). Cells were fixed and stained with rabbit negative control (left 
column) or rabbit BCL3 antibodies (right column) followed by a rabbit specific 
fluorescent secondary antibody.  
 
Overlay histograms were generated to directly compare the control to the BCL3 
specific antibody (Figure 69). In conjunction with BCL3 staining, the amount of 
viral capsid antigen (VCA) positive cells was also investigated. This protein is 
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used as a marker of cells containing EBV in late lytic cycle. This reveals that 
about 5% of induced cells are VCA positive (Figure 70). For direct comparison of 
VCA levels in induced and non-induced cells, Figure 71 shows these results in 
an overlay histogram. As opposed to BCL3, the VCA antibody and control are of 
mouse origin, so the induction of lytic cycle with rabbit IgG should not directly 
affect the result. 
As the percentage of VCA positive cells only represents the amount of cells 
containing EBV in late lytic cycle, FACS was repeated including a Zta (BZ1) 
specific antibody for cells containing EBV in early lytic cycle. In addition the lytic 
cycle was induced using a doxycycline inducible plasmid containing Zta, or a 
negative control reverse plasmid, instead of the rabbit IgG antibody, to prevent 
false positive staining. Induction was undertaken for both 24 and 48 hours. Table 
11 summarises the percentage of cells positive for the indicated targets. This 
reveals a greater increase of BCL3 amount (~15%) in cells containing EBV 
induced for 48 hours and thus in more established lytic cycle in comparison to 24 
hour induction. VCA staining did not increased with longer induction. This may be 
due to cell lysis. The amount of cells containing EBV in early lytic cycle (BZ1) is 
shown to have almost halved at the longer induction time. 
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Figure 68: FACS overlay histograms showing the amount of BCL3 positive cells 
Figure 69: FACS overlay histograms showing the amount of BCL3 positive 
cells. Akata cells were not induced (top) or induced (bottom) with 0.125% rabbit 
IgG for 48hours. Cells were fixed and stained with a control (black) or BCL3 
antibody (red) followed by a specific fluorescent secondary antibody. 
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Figure 69: Akata FACS showing percentage of VCA positive cells 
Figure 70: Akata FACS showing percentage of VCA positive cells. Akata 
cells were not induced (top row) or induced with 0.125% rabbit IgG for 48 hours 
(bottom row). Cells were fixed and stained with mouse negative control (left 
column) or mouse VCA antibodies (right column) followed by a mouse specific 
fluorescent secondary antibody. 
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Figure 70: FACS overlay histogram showing the amount of VCA positive cells 
Figure 71: FACS overlay histogram showing the amount of VCA positive 
cells. Akata cells were not induced (black) or induced with 0.125% rabbit IgG for 
48 hours (red). Cells were fixed and stained with a mouse VCA antibody followed 
by a mouse specific fluorescent secondary antibody.  
 
 
 
 
 
 
 
 
 
170 
 
Target Non-induced Induced 
24hrs 48hrs 24hrs 48hrs 
Mouse Control 1.06 1.08 0.80 1.32 
Rabbit Control 1.10 1.04 2.33 1.93 
BCL3 (Rabbit) 76.11 47.04 83.64 62.15 
VCA (Mouse) 0.28 0.44 7.13 6.34 
BZ1 (Mouse) 0.35 0.18 10.99 5.65 
Table 11: Table showing the percentage of Akata cells positive for a specific FACS antibody target. 
Table11: Table showing the percentage of Akata cells positive for a specific 
FACS antibody target. Akata cells containing either a Zta doxycycline inducible 
plasmid or a negative control reverse plasmid were treated with 500 ng/ml 
doxycycline for 24hrs or 48hrs. Cells were fixed and stained with a BCL3, VCA, 
BZ1 or control antibody followed by a specific fluorescent secondary antibody. 
 
The previous experiment was repeated using Akata cells induced with rabbit IgG 
antibody instead of the Zta doxycycline inducible plasmid (Table 12). This shows 
that there is a substantial increase in the amount of cells stained with negative 
control, rabbit-specific secondary antibody when cells are induced with rabbit 
IgG, especially at 48 hours of induction (46.81%). The amount of BCL3 cannot 
be seen to increase during this experiment. As before, the amount of Zta (BZ1) 
is halved at 48 hours of induction in comparison to 24 hours. However, 
surprisingly staining for VCA appears higher at 24 hours. This might be because 
induction with IgG utilises a different mechanism to induction with doxycycline 
which leads to a faster progression to late lytic cycle.  
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Target Non-induced Induced 
24hrs 48hrs 24hrs 48hrs 
Mouse Control 1.39 1.02 0.40 0.93 
Rabbit Control 0.92 3.04 11.51 46.81 
BCL3 (Rabbit) 46.58 88.22 45.03 82.07 
VCA (Mouse) 0.36 0.38 8.23 0.57 
BZ1 (Mouse) 0.37 0.56 4.75 2.45 
Table 12: Table showing the percentage of Akata cells positive for a specific FACS antibody target. 
Table 12: Table showing the percentage of Akata cells positive for a specific 
FACS antibody target. Akata tet cells were not induced or induced into lytic cycle 
with 0.125% rabbit IgG for 24hrs or 48hrs. Cells were fixed and stained with a 
BCL3, VCA, BZ1 or control antibody followed by a specific fluorescent secondary 
antibody. 
 
To overcome the problem of false positive staining of the rabbit specific 
secondary antibody in Akata cells induced with rabbit IgG, a new fluorescent 
hamster BCL3 antibody with a hamster control florescent IgG antibody were used 
for FACS. As can be seen in Figure 72, this combination does not show the 
presence of BCL3 in Akata cells containing induced or non-induced EBV above 
the level of negative control staining. The inability to show an increase in BCL3 
levels as a result of lytic cycle induction using this method can be clearly seen in 
the overlay histogram in Figure 73. The corresponding amount of VCA positive 
cells is shown in Table 13, demonstrating that induction was successful. The 
Table also shows that it was not possible to detect any cells positive for both, 
BCL3 and VCA. 
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Figure 71: Histograms showing the percentage of Akata tet cells positive or negative for BCL3 expression 
Figure 72: Histograms showing the percentage of Akata tet cells positive or 
negative for BCL3 expression. Cells were not induced (top row) or induced 
(bottom row) into lytic cycle with 0.125% rabbit IgG for 24hrs, fixed and stained 
with a fluorescent control (left column) or fluorescent hamster BCL3 antibody 
(right column). 
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Figure 72: Overlay-histogram showing the expression of BCL3 in Akata tet cells non-induced (black) or induced (red) into lytic cycle 
Figure 73: Overlay-histogram showing the expression of BCL3 in Akata tet 
cells non-induced (black) or induced (red) into lytic cycle. Induction was 
performed with 0.125% rabbit IgG for 24hrs. Cells were fixed and stained with a 
fluorescent hamster BCL3 antibody. Figure shows that there is no evidence by 
FACS of BCL3 upregulation in Akata cells. 
 
 Non-induced Induced 
Mouse Control 1.08 0.89 
VCA (Mouse) 0.12 11.79 
VCA (Mouse) and 
BCL3 (Hamster) 
0.09 0.16 
Table 13: Table showing the percentage of VCA and “BCL3 and VCA” positive Akata tet cells corresponding to the above BCL3 
amounts. 
Table 13: Table showing the percentage of VCA and “BCL3 and VCA” 
positive Akata tet cells corresponding to the above BCL3 amounts. Cells 
were induced into lytic cycle with 0.125% rabbit IgG for 24hrs, fixed and double 
stained with a fluorescent rabbit BCL3 and a mouse VCA antibody followed by a 
mouse fluorescent secondary antibodies. 
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5.5 BCL3 Knock-Down 
To investigate the relevance of BCL3 for EBV lytic cycle reactivation, it was 
decided to use BCL3 specific siRNA to knock down its expression. To control for 
the transfection of siRNA, a Cy3 stained control siRNA was included in the 
transfection at a ratio of 3:1. Initial trials showed that, 72 hours after transfection 
with 750nM siRNA, 32.59% of cells are positive for the Cy3 marker (Figure 74). 
To optimise the transfection protocol, different concentrations of siRNA were 
used and the subsequent transfection efficiency was investigated with the help of 
the Cy3 marker siRNA.  
 
 
Figure 73: FACS histograms showing the percentage of siRNA transfected cells 
Figure 74: FACS histograms showing the percentage of siRNA transfected 
cells. Using the NEON, Akata cells were not transfected (A) or transfected (B) 
with 750nM siRNA at a 3:1 ratio of control siRNA to Cy3 stained siRNA. 72hrs 
after transfection cells were fixed and FACS was performed to show the amount 
of Cy3 positive cells. Cells that were not transfected show a background 
fluorescence of 0.98%. Transfected cells are 32.59% Cy3 positive, as detected 
in the FL2 channel. 
 
A                                  B 
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As can be seen in Figure 75, 24 hours after transfection, of the three tested 
concentrations, 200nM siRNA resulted in the highest amount of siRNA positive 
cells at 87.76%. Transfection with 750nM resulted in a similar percentage of Cy3 
positive cells as shown in the previous Figure (35.23%).The lowest amount of 
siRNA positive cells was achieved with the highest concentration of siRNA at 
5µM.  
 
Figure 74: FACS histograms showing the percentage of siRNA transfected cells 
Figure 75: FACS histograms showing the percentage of siRNA transfected 
cells. Akata cells were not transfected (A) or transfected with 200nM (B), 750nM 
(C) or 5μM (D) siRNA at a 3:1 ratio of control siRNA to Cy3 stained siRNA. 24hrs 
after transfection cells were fixed and FACS was performed to show the amount 
of Cy3 positive cells and demonstrate transfection efficiency at different 
concentrations. 
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In addition to testing for cells transfected with siRNA 24 hours after transfection, 
the amount of cells positive for the Cy3 siRNA marker was also quantified 72 
hours after transfection. The results of this experiment are summaries in Figure 
76 below, showing that, by this point, no substantial amount of siRNA can be 
detected in the Akata cells.  
 
Figure 75: FACS histograms showing the percentage of siRNA transfected cells 
Figure 76: FACS histograms showing the percentage of siRNA transfected 
cells. Akata cells were not transfected (A) or transfected with 200nM (B), 750nM 
(C) or 5μM (D) siRNA at a 3:1 ratio of control siRNA to Cy3 stained siRNA. 72hrs 
after transfection cells were fixed and FACS was performed to show the amount 
of Cy3 positive cells and demonstrate transfection efficiency at different 
concentrations. 
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The background fluorescence in the FL2 channel is at 4.42% (Figure 76 A). The 
highest signal in transfected cells is 2.03% above the background for cells 
transfected with 750nM siRNA. In contrast, the highest amount of positive cells 
transfected with 200nM siRNA by 24 hours was 82.62%.  
Figure 77 shows a comparison of the amount of cells positive for the Cy3 siRNA 
marker 24 or 72 hours after transfection in two overlay histograms. This clearly 
shows that the majority of cells have taken up the siRNA 24 hours after 
transfection but loose it over time.  
Unfortunately it was not possible to repeat this result. This may be due to a 
problem with the transfection, the Cy3 siRNA itself or the FACS procedure. To 
investigate if the problem could be resolved by not fixing the cells during FACS, 
Akata cells were transfected with 0, 200nM or 5μM siRNA and either fixed or not 
fixed before FACS was performed. Results of this experiment are shown in Figure 
78. No clear difference can be observed for transfection with 200nM and only a 
slight difference can be seen when transfection was performed with 5μM. The 
amount of Cy3 siRNA is 25 times higher during the transfection with 5μM in 
comparison to 200nM. As transfection was previously shown to be more efficient 
with 200nM siRNA, this result could point to a problem with the fluorescent siRNA 
marker. 
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Figure 76: Overlay histograms showing the amount of cells positive for Cy3 siRNA marker in Akata cells 
Figure 77: Overlay histograms showing the amount of cells positive for Cy3 
siRNA marker in Akata cells. Cells were not transfected (black) or transfected 
with 200nM (red) siRNA at a 3:1 ratio of control siRNA to Cy3 stained siRNA. 
Cells were fixed and FACS was performed to show the amount of Cy3 positive 
cells and demonstrate transfection efficiency 24 hour (A) or 72 hours (B) after 
transfection. 
A 
 
 
 
 
 
 
 
 
B 
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Figure 77: Overlay-histogram showing the amount of the siRNA marker Cy3 
Figure 78: Overlay-histogram showing the amount of the siRNA marker 
Cy3. Akata tet cells were transfected with no siRNA (black), 200nM (red) or 5μM 
(blue) of negative control siRNA at a 3:1 ratio of siRNA to Cy3 stained siRNA. 
Cells were fixed (A) or not fixed (B) before FACS was performed 24 hours after 
transfection. Lytic cycle was not induced. 
 
A 
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To investigate whether the knock-down of BCL3 has an impact on the switch from 
EBV latency to lytic cycle, Akata cells were transfected with 200nM siRNA, 
followed by the induction of lytic cycle. Based on the results shows in the previous 
Figures, induction of lytic cycle was undertaken 24 hours after siRNA transfection, 
at which point the highest amount of siRNA was detected in the cells. Three 
different BCL3 siRNAs were used in the attempt to knock down BCL3. No 
significant difference can be seen between EBV loads in cells treated with control 
siRNA in comparison to siRNA1-3 (Figure 79). As cells were harvested 24 hours 
after induction of lytic cycle, it is likely that this result is, at least partly, due to the 
fact that lytic cycle has not progressed far enough at this time. 
 
 
Figure 78: qPCR results showing the relative amount of EBV genome copies per human genome numbers 
Figure 79: qPCR results showing the relative amount of EBV genome 
copies per human genome numbers. Akata tet cells were transfected with 
200nM of the indicated siRNA. Lytic cycle was induced 24hrs after transfection 
with 0.125% rabbit IgG for 24hrs. There is no significant difference between EBV 
loads in cells treated with control siRNA in comparison to siRNA1-3. Averages 
are based on triplicate pipetting repeats. Values are represented as mean ± SD. 
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The amount of BCL3 RNA in Akata cells 24 hours after BCL3 siRNA knock down 
using 200nM siRNA were investigated with the help of a BCL3 revers transcribed 
cDNA qPCR (Figure 80). This revealed no significant decrease in BCL3 RNA 
levels of cells transfected with no, or non-specific, siRNA in comparison to BCL3 
siRNA. This result point to a possible problem with the siRNA. For this reason, 
new siRNA was used to investigate the effect of BCL3 knock-down on EBV’s 
reactivation from latency.  
 
 
Figure 79: qPCR result showing the difference in BCL3 expression relative to BCL3 siRNA2 
Figure 80: qPCR result showing the difference in BCL3 expression relative 
to BCL3 siRNA2. Akata cells were transfected, using the NEON, with 200nM of 
the indicated siRNAs for 24hrs. Values are represented as mean ± 95% 
Confidence Interval (p>0.05). 
 
Figure 81 shows results obtained using the DharmaFECT transfection reagent 
and corresponding BCL3 siRNA pool to transfected HEK293 ZKO cells. The cells 
were also treated with ionomycin and phorbol 12-myristate 13-acetate (PMA) to 
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activate the B cell receptor signalling pathway. As shown in the previous section, 
the detection of BCL3 by western blot in HEK293 ZKO cells is poor. Nonetheless, 
when BCL3 is knocked-down in these cells, an increase of Zta protein abundance 
with a fold change of 1.4 can be observed 24 hours after hisZta expression vector 
transfection. It was shown in the previous section that BCL3 levels increase when 
Zta is expressed in lytic cycle. Based on these results, it is possible that Zta and 
BCL3 affect each other’s protein levels. 
 
Figure 80: Western Blot (A) and corresponding band quantification (B) showing Zta and actin levels 
Figure 81: Western Blot (A) and corresponding band quantification (B) 
showing Zta and actin levels. HEK293 ZKO cells were transfected with a siRNA 
control or BCL3 specific siRNA followed by the hisZta expression vector and 
treatment with 1µM ionomycin and 20ng/ml PMA 24 hours later. Cells were 
harvested for western blotting a further 24 hours later. Blit was stained using the 
Santa Cruz BCL3 (c-14) antibody. 
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Figure 81: Western Blot (A) and corresponding band quantification for BCL3 (B) and Zta (C) 
Figure 82: Western Blot (A) and corresponding band quantification for 
BCL3 (B) and Zta (C). HEK293ZKO cells transfected with a siRNA control or 
BCL3 specific siRNA followed by a Zta expression vector 24 hours later. Cells 
were harvested for western blotting and qPCR a further 48 hours later. Blot was 
stained using the Santa Cruz BCL3 (c-14) antibody. 
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It is not possible to observe EBV genome copy number increases 24 hours after 
induction of lytic cycle. The above experiment was repeated without ionomycin 
or PMA, as these led to substantial cell death. Cells were harvested 48 hours 
after the induction of EBV lytic cycle. The protein levels in the resulting samples 
were quantified with the help of a western blot and are shown in Figure 82. 
Results indicate that the BCL3 knock-down was successful and also confirm that 
less BCL3 is present in cells expressing Zta. The amount of Zta in cells 
transfected with BCL3 specific siRNA is 1.25 fold higher than in those transfected 
with a control siRNA.  
 
The amount of EBV genome copy number in these cells was determined using 
qPCR (Figure 83). This shows a slightly higher amount of EBV in cells which 
received the BCL3 specific siRNA. However, this increase is not significant. It is 
possible that the increase in Zta abundance, detected when BCL3 is knocked 
down, correlates to an increase in EBV lytic cycle induction. 48 hours of induction 
may not be sufficient time to observe a significant effect on genome copy number. 
Harvesting cells 72 hours after transfection may make it possible to observe a 
more significant change.  
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Figure 82: qPCR results showing the relative amount of EBV genome copies per human genome numbers 
Figure 83: qPCR results showing the relative amount of EBV genome 
copies per human genome numbers. HEK293ZKO cells transfected with a 
siRNA control or BCL3 specific siRNA followed by the hisZta expression vector 
24 hours later. Cells were harvested for western blotting and qPCR a further 48 
hours later. Averages are based on triplicate pipetting repeats. Values are 
represented as mean ± SD. 
     
5.6 BCL3 Over-Expression 
To elucidate the effect of BCL3 on the reactivation of EBV from latency to lytic 
cycle by Zta, BCL3 was over-expressed in HEK293T cells with the help of a 
pcDNA3 plasmid expressing the 47kDa (454aa variant) isoform of the BCL3 
protein. 
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Figure 83: Luciferase assay results showing the expression of a BHLF1 or mutant reporter vector 
Figure 84: Luciferase assay results showing the expression of a BHLF1 or 
mutant reporter vector. The amount of luciferase intensity is proportional to the 
amount of Zta in each sample. HEK293T cells were transfected with increasing 
amounts of BCL3 flag (0.025µg, 0.1µg and 0.4µg), 0.1μg hisZta expression 
vectors and 0.5μg BHLF1 wild type or 0.5μg BHLF1 mutant Zta reporter vectors 
with a pcDNA3 vector to balance total transfect concentration to 2μg total. Cells 
were harvested 24hrs after transfection. The luciferase assay results were 
normalised to total protein concentration per sample as determined by BCA 
assay. 
 
HEK293 T cells were transfected with a BHLF1 mutant or BHLF1 wild type 
reporter vector which creates luciferase intensity relative to the amount of Zta 
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activity. The BHLF1 reporter vector and mutant BHLF1 vector, containing 
mutated ZREs, which are described in more detail in [111]. 
In cells transfected with mutant BHLF1 (Figure 84, samples 1-8), only a low 
background of luciferase activity can be observed. In cells transfected with wild 
type BHLF1 and increasing amounts of BCL3, but without Zta (Figure 84, 
samples 9-12), a similar background luciferase intensity is shown. When wild type 
BHLF1 is transfected together with Zta, increased luciferase activity is observed 
while increasing amounts of BCL3 clearly decrease the amount of Zta activity 
(Figure 84, samples 13-16).  
The western blot corresponding to the luciferase results is shown in Figure 85. 
The amount of Zta transfected into samples 5-8 and 13-16 was constant. 
However, as the amount of transfected BCL3 increases, the amount of Zta 
expressed appears to decrease, while overall cell number, as controlled for by 
Actin, remain constant.  
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Figure 84: Western blots showing the expression of Zta and BCL3 with Actin as a loading control 
Figure 85: Western blots showing the expression of Zta and BCL3 with 
Actin as a loading control. This blot corresponds to the luciferase assay in 
Figure 84. HEK293T cells were transfected with increasing amounts of BCL3 flag 
(samples 1-4, 5-8, 9-12 and 13-16), 0.1μg hisZta expression vectors (samples 5-
8 and 13-16) and 0.5μg BHLF1 wild type (9-16) or 0.5μg BHLF1 mutant (1-8) Zta 
reporter vectors with a pcDNA3 vector to balance total transfect concentration to 
2μg total. Cells were harvested 24hrs after transfection. Blot was stained using 
the Santa Cruz (c-14) antibody. 
 
The amounts of BCL3 and Zta were quantified and normalised relative to Actin 
levels. Figure 86 confirms that the amount of Zta protein decreases with 
increasing amounts of BCL3. The amounts of expression vector in each sample 
was normalised with a pcDNA3 vector.  
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Figure 85: BCL3 and Zta western blot band quantification 
Figure 86: BCL3 and Zta western blot band quantification. Graphs show the 
amount of BCL3 and Zta expressed in HEK293T cells transfected with increasing 
amounts of BCL3 flag (samples 1-4, 5-8, 9-12 and 13-16), 0.1μg hisZta 
expression vectors (samples 5-8 and 13-16) and 0.5μg BHLF1 wild type (9-16) 
or 0.5μg BHLF1 mutant (1-8) Zta reporter vectors with a pcDNA3 vector to 
balance total transfect concentration to 1μg total. Expression levels are 
normalised to Actin.   
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To investigate the effect that BCL3 may have on lytic cycle reactivation, HEK293 
ZKO cells were transfected with hisZta, BCL3, hisZta and BCL3, or a pcDNA3 
control. The western blot shown in Figure 87 demonstrates that the transfections 
were successful. Consequently, the relative amount of EBV genome copy 
numbers was determined in the same lot of cells. This revealed a significant 
decrease in the amount of EBV in cells transfected with both, BCL3 and Zta, in 
comparison to cells transfected with Zta only (Figure 88). This drop in EBV 
genome copy number appears to be higher than the corresponding decrease of 
Zta abundance, suggesting that BCL3 is not the only factor which affects lytic 
cycle reactivation. 
 
Figure 86: Western blot showing the expression of Zta and BCL3 
Figure 87: Western blot showing the expression of Zta and BCL3. 
HEK293ZKO cells were transfected with 100ng hisZta, BCL3, both or a pcDNA3 
control vector and harvested 72hrs later. An antibody specific for actin was used 
as a loading control. Blot was stained using the Santa Cruz BCL3 (c-14) x 
antibody. 
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Figure 87: qPCR results showing the relative amount of EBV genome copies per human genome numbers 
Figure 88: qPCR results showing the relative amount of EBV genome 
copies per human genome numbers. HEK293 ZKO cells were transfected with 
100ng hisZta, BCL3, both or a pcDNA3 control vector and harvested 72hrs later. 
pcDNA3 was used to balance total vector amount to 200ng for each sample. The 
decrease in viral load per cell is significant when comparing transfection with Zta 
and BCL3 to Zta only (p<0.05). Averages are based on triplicate pipetting 
repeats. Values are represented as mean ± SD.  
 
To determine what impact the BCL3 level has on the amount of lytic cycle 
inhibition, HEK293 ZKO cell were transfected with increasing amounts of BCL3 
without (Figure 89, samples 1-4), or with constant amounts of Zta (Figure 89, 
samples 4-8). This revealed that the viral load per cell is significantly lower in cells 
transfected with both, Zta and large amounts of BCL3 (sample 8), in comparison 
to cells transfected with Zta only. The corresponding amount of Zta, BCL3 and 
Actin protein are shown in the western blot (Figure 90). The location of the BCL3 
band corresponds to the expected size for the 47kDa isoform of the protein.  
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Figure 88: qPCR results showing the relative amount of EBV genome copies per human genome numbers 
Figure 89: qPCR results showing the relative amount of EBV genome 
copies per human genome numbers. HEK293 ZKO cells were transfected with 
increasing amounts of BCL3 (samples 1-4 and 5-8) and 0.1μg hisZta expression 
vectors (samples 5-8) with a pcDNA3 vector to balance total transfect 
concentration. The viral load per cell is significantly lower in cells transfected with 
both Zta and large amounts of BCL3 (sample 8) in comparison to cells transfected 
with Zta only (p≤0.05). The decrease in EBV load is not significant in samples 6 
and 7 when compared to sample 5. Cells were harvested 48hrs after transfection. 
Values are represented as mean ± SD. 
 
The bands shown in the western blot (Figure 90) were quantified and the amount 
of Zta and BCL3 relative to actin levels can be seen in the graphs in Figure 91. 
This demonstrates that the amount of Zta decreases with increasing amounts of 
BCL3 even though the transfected amount of Zta is constant and the overall 
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amount of transfected vectors is equalised across each sample with the help of 
a pcDNA3 vector.  
 
Figure 89: Western blot showing the expression of Zta and BCL3 
Figure 90: Western blot showing the expression of Zta and BCL3. HEK293 
ZKO cells were transfected with increasing amounts of BCL3 flag (samples 1-4 
and 5-8) and 0μg (samples 1-4) or 0.1μg hisZta (samples 5-8) expression vectors 
with a pcDNA3 vector to balance total transfect concentration to 2μg total. Cells 
were harvested 48hrs after transfection. An antibody specific for actin was used 
as a loading control. Blot was stained using the Santa Cruz BCL3 (c-14) antibody. 
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Figure 90: Western blot band quantification showing the amount of BCL3 and Zta 
Figure 91: Western blot band quantification showing the amount of BCL3 
and Zta. HEK293ZKO cells were transfected with increasing amounts of BCL3 
flag (samples 1-4 and 5-8) and 0μg (samples 1-4) or 0.1μg hisZta (samples 5-8) 
expression vectors with a pcDNA3 vector to balance total transfect concentration 
to 1μg total. Cells were harvested 48hrs after transfection. Expression levels are 
normalised to Actin.   
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To determine whether BCL3 has an impact on lytic cycle other than decreasing 
the Zta protein level, a Zta titration experiment was performed in which HEK293 
ZKO cells were transfected with a range of hisZta expression vector as well as a 
constant amount of Zta with BCL3 (Figure 92). This resulted in two samples which 
have very similar Zta protein levels, one transfected with Zta, whose expression 
is reduced by BCL3 (sample 6), and one transfected with a lower level of Zta to 
result in comparable protein levels (sample 3). The western blot showing BCL3, 
Zta and Actin protein levels in Figure 92 was quantified. The amount of Zta and 
BCL3 relative to Actin are shown in Figure 93.     
 
 
Figure 91: Western Blot showing the expression of Zta and BCL3 
Figure 92: Western Blot showing the expression of Zta and BCL3. HEK293 
ZKO cells were transfected with Zta (Samples 1 and 7: 0ng, samples 4-6: 280ng, 
sample 2: 30ng, sample 3: 60ng) and BCL3 (samples 1-4: 0ng, samples 5 and 7: 
70ng, sample 6: 110ng). A pcDNA3 vector was used to balance total transfect 
concentrations across all samples. Cells were harvested 48hrs after transfection. 
An antibody specific for actin was used as a loading control. Blot was stained 
using the Abcam BCL3 antibody. 
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Figure 92: Western blot band quantification showing the amount of BCL3 and Zta 
Figure 93: Western blot band quantification showing the amount of BCL3 
and Zta. HEK293ZKO cells were transfected, as shown in the western blot 
above, with increasing amounts of hisZta (samples 1-4), or the highest amount 
of hisZta equivalent to sample 4 and increasing BCL3 flag (samples 5 and 6). 
Sample 7 was transfected with BCL3 flag only. A pcDNA3 vector was used to 
balance total transfect concentrations across all samples. Cells were harvested 
48hrs after transfection. Zta levels were normalised to Actin levels.  
197 
 
The EBV genome copies per human genome were quantified corresponding to 
the protein levels in the previously described samples (Figure 94).  
 
Figure 93: qPCR results showing the relative amount of EBV genome copies per human genome numbers 
Figure 94: qPCR results showing the relative amount of EBV genome 
copies per human genome numbers. HEK293 ZKO cells were transfected with 
Zta (Samples 1 and 7: 0ng, samples 4-6: 280ng, sample 2: 30ng, sample 3: 60ng) 
and BCL3 (samples 1-4: 0ng, samples 5 and 7: 70ng, sample 6: 110ng). A 
pcDNA3 vector was used to balance total transfect concentrations across all 
samples. Cells were harvested 48hrs after transfection. In cells with the same 
expression level of Zta, viral load per cell is significantly higher when transfected 
with hisZta only (sample 3) in comparison to transfection with hisZta and BCL3 
flag (sample 6, p≤0.05). Values are represented as mean ± SD. 
 
The amount of Zta is comparable in samples 3, which was transfected with Zta 
only, and sample 6, whose Zta amounts were reduced to similar amounts by 
BCL3. Of these two samples, there is a small but significant difference in viral 
198 
 
load per cell when transfected with hisZta only in comparison to transfection with 
hisZta and BCL3. This result suggests that the attenuation of Zta function by 
BCL3 may relate to the decrease in Zta protein levels, but other factors are likely 
also involved in controlling EBV lytic cycle activation. This possibility was further 
explored in the following section.    
 
5.7 Zta, BCL3, TORC and CBP 
Data presented in the previous chapter showed that there is a high incidence of 
BCL3-Zta binding region overlap as well as a high incidence of H3K27me3 site 
overlap with Zta binding sites. To investigate whether these occurrences may be 
linked, the Zta binding sites common to Akata and HONE1-EBV cells were 
intersected with H3K27me3 sites in GM12878. A significant overlap of Zta binding 
sites which are also H3K27me3 sites and bound by BCL3 was discovered with 
almost 2/3 of the sites coinciding (Figure 95). 
These results suggest that BCL3 may be acting as a repressor at 2/3 of sites 
which are bound by Zta. Therefore BCL3 may be involved in the establishment 
of a repressive chromatin environment, which is overturned or promoted by Zta. 
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Figure 94: Venn Diagram showing the number of H3K27me3 sites in GM12878 cells bound by Zta in HONE1-EBV and Akata cells overlapping with sites bound by BCL3 in GM12878 and Zta in HONE1-EBV and Akata cells 
Figure 95: Venn Diagram showing the number of H3K27me3 sites in 
GM12878 cells bound by Zta in HONE1-EBV and Akata cells overlapping 
with sites bound by BCL3 in GM12878 and Zta in HONE1-EBV and Akata 
cells. HONE1-EBV cells were induced with 10μM SAHA for 48 hours. Akata cells 
were induced with 0.125% IgG for 24 hours. 
 
In order to further investigate the mechanism by which BCL3 may repress EBV 
lytic cycle activation, it was decided to investigate the possibility that one or more 
TORCs are involved in this process. It has been shown that both Zta and BCL3 
interact with a member of the TORC family [90, 156]. In addition, the interaction 
of HTLV-1 Tax with BCL3 involved TORC and CBP during this virus’ reactivation 
from latency [158] (see chapter introduction) and it is possible that the interaction 
of Zta with BCL3 occurs through a similar mechanism. CBP was one of the top 
five most significant factors which were shown to have common binding sites with 
Zta in epithelial and B cells. CBP, and its paralog p300, are transcriptional 
coactivators, central to eukaryotic transcription activation [14]. CBP provides a 
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scaffold for the interaction of a large variety of binding partners including >400 
transcription factors and regulatory proteins [15], which compete for limiting 
quantities of CBP [16].  
 
A series of western blots was performed to probe for the presence of TORC1-3. 
Unfortunately, it has not been possible to show BCL3, TORC1 or CBP expression 
by western blotting.  
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Figure 95: Western Blot showing the expression of TORC2 
Figure 96: Western Blot showing the expression of TORC2. Figure shows a 
range of cell types and corresponding TORC2 expression (top row). Cells were 
treated to induce the EBV lytic cycle or Zta expression (HEK293T) and incubated 
for 24-72hrs as indicated. An antibody specific for actin was used as a loading 
control (bottom row). 
The expression of TORC2 and TORC3, as well as Actin, in the indicated cell lines 
at various time points following induction are shown in Figure 96 and 97 
respectively. TORC 3 could not be detected in Akata or HONE1-EBV cells (data 
not shown).  
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Figure 96: Western Blot showing the expression of TORC3 
Figure 97: Western Blot showing the expression of TORC3. Figure shows a 
range of cell types and corresponding TORC3 expression (top row). Cells were 
treated to induce the EBV lytic cycle or Zta expression (HEK293T) and incubated 
for 48 or 72hrs as indicated. An antibody specific for actin was used as a loading 
control (bottom row). 
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Figure 97: Western Blot (A) and corresponding band quantification (B) showing TORC2 and actin levels 
Figure 98: Western Blot (A) and corresponding band quantification (B) 
showing TORC2 and actin levels. HEK293 ZKO cells transfected with a siRNA 
control, BCL3, CBP or TORC1-3 specific siRNAs followed by the pcDNA3 or Zta 
expression vector and treatment with 1 µM ionomycin and 20ng/ml PMA 24 hours 
later. Cells were harvested for western blotting a further 24 hours later. The 
siRNA used in each sample is indicated. The first four samples were transfected 
with pcDNA3, the last four samples were transfected with Zta, as indicated. 
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TORC2 and 3 could be detected in HEK 293 cells and this cell type was chosen 
to perform siRNA transfections to investigate the effect of BCL3, CBP and 
TORC1-3 knock-down on Zta and EBV lytic cycle reactivation. Figure 98 
suggests that transfection with BCL3 siRNA may reduce the abundance of 
TORC2 in HEK 293ZKO cells, which were treated with ionomycin and PMA to 
activate the B cell signalling pathway. The knock-down of TORC1-3 appears to 
have been successful in cells not transfected with Zta. A 3.7 fold reduction is 
shown (Figure 98 B). However, no decrease in TORC2/Actin can be observed 
when Zta is also present in the cells. Similarly CBP knock-down reduces 
TORC2/Actin abundance in cells not transfected with Zta. This reduction is not 
observed in the presence of Zta. However, a knock-down appears visible by eye. 
Due to the very low band intensity for TORC2 the signal:noise ratio may be too 
high to allow for dependable quantification of the relative signal intensity for 
TORC2/Actin.  
The band intensity for TORC3 is higher than that for TORC2. As is shown in 
Figure 99, the knock-down of TORC3 was successful with a fold reduction of 2.4 
in uninduced cells. Unlike TORC2, a decrease of TORC3/Actin is also observed 
in the presence of Zta, with a fold change of 3.3. Like TORC2/Actin, the 
abundance of TORC3/Actin is also reduced by CBP in the absence of Zta but not 
in its presence. Knock-down of BCL3 appears to reduce the level of TORC3/Actin 
to a greater extend in the presence of Zta.  
To investigate the impact on EBV lytic cycle reactivation, the experiment was 
repeated without ionomycin and PMA, which leads to cell death, and cells were 
harvested 48 hours after transfected of the Zta expression vector. Western blot 
results for TORC2 are shown in Figure 100 and those for TORC3 in Figure 101.  
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Figure 98: Western Blot (A) and corresponding band quantification (B) showing TORC3 and actin levels 
Figure 99: Western Blot (A) and corresponding band quantification (B) 
showing TORC3 and actin levels. HEK293ZKO cells transfected with a siRNA 
control, BCL3, CBP or TORC1-3 specific siRNAs followed by the pcDNA3 or 
hisZta expression vector and treatment with 1 µM ionomycin and 20ng/ml PMA 
24 hours later. Cells were harvested for western blotting a further 24 hours later. 
The siRNA used in each sample is indicated above the blot. The first four samples 
were transfected with pcDNA3, the last four samples were transfected with Zta, 
as indicated. 
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Figure 99: Western Blot (A) and corresponding band quantification (B) showing TORC2 and actin levels 
Figure 100: Western Blot (A) and corresponding band quantification (B) 
showing TORC2 and actin levels. HEK293ZKO cells transfected with a siRNA 
control, BCL3, CBP or TORC1-3 specific siRNAs followed by the pcDNA3 or 
hisZta expression vector 24 hours later. Cells were harvested for western blotting 
a further 48 hours later. The siRNA used in each sample is indicated above the 
blot. The first four samples were transfected with pcDNA3, the last four samples 
were transfected with Zta, as indicated. 
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The knock-down of TORC2 appears to have been successful in cells not 
transfected with Zta. However, the amount of TORC2 in cells containing Zta is 
much higher in cells transfected with TORC-specific siRNA in comparison to 
control siRNA. This experiment should be repeated. 
Results for TORC3 demonstrate a knock-down of protein levels. When BCL3 is 
knocked-down, TORC3 levels also appear reduced when Zta is not present. It is 
possible that Zta stabilises TORC3 in a similar way as BCL3 may do, allowing 
TORC3 protein levels to stay constant in the absence of BCL3.  
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Figure 100: Western Blot (A) and corresponding band quantification (B) showing TORC3 and actin levels 
Figure 101: Western Blot (A) and corresponding band quantification (B) 
showing TORC3 and actin levels. HEK293 ZKO cells transfected with a siRNA 
control, BCL3, CBP or TORC1-3 specific siRNAs followed by the pcDNA3 or 
hisZta expression vector 24 hours later. Cells were harvested for western blotting 
a further 48 hours later. The siRNA used in each sample is indicated above the 
blot. The first four samples were transfected with pcDNA3, the last four samples 
were transfected with Zta, as indicated. 
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To investigate whether the knock-down of TORC1-3 and CBP has any effect on 
Zta abundance or EBV reactivation from lytic cycle, a western blot was performed 
with cells harvested 24 hours after transfection of Zta (Figure 102 A) and the 
amount of Zta was normalised to actin levels (Figure 102 B). This showed a very 
slight reduction of Zta. When this experiment was repeated without ionomycin or 
PMA and protein levels were investigated 48 hours after transfection with a Zta 
expression plasmid, the reduction in Zta protein level as a result of CBP and 
TORC knock-down is much clearer (Figure 103).  
Figure 104 shows the impact on lytic cycle activation resulting from the 
transfection of CBP or TORC1-3 specific siRNAs. Knock-down of either CBP or 
TORC1-3 leads to a significant decrease of EBV lytic cycle activation 48 hours 
after transfection with Zta.  
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Figure 101: Western Blot (A) and corresponding band quantification (B) showing Zta and actin levels 
Figure 102: Western Blot (A) and corresponding band quantification (B) 
showing Zta and actin levels. HEK293 ZKO cells transfected with a siRNA 
control, CBP or TORC1-3 specific siRNAs followed by Zta expression vector and 
treatment with 1 µM ionomycin and 20ng/ml PMA 24 hours later. Cells were 
harvested for western blotting a further 24 hours later. The siRNA used in each 
sample is indicated.  
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Figure 102: Western Blot (A) and corresponding band quantification (B) showing Zta and actin levels 
Figure 103: Western Blot (A) and corresponding band quantification (B) 
showing Zta and actin levels. HEK293 ZKO cells transfected with a siRNA 
control, CBP or TORC1-3 specific siRNAs followed by hisZta expression vector 
24 hours later. Cells were harvested for western blotting a further 48 hours later. 
The siRNA used in each sample is indicated.  
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Figure 103: qPCR results showing the relative amount of EBV genome copies per human genome numbers 
Figure 104: qPCR results showing the relative amount of EBV genome 
copies per human genome numbers. HEK293ZKO cells were transfected with 
a siRNA control, CBP or TORC1-3 specific siRNAs followed by hisZta expression 
vector 24 hours later. Cells were harvested for western blotting a further 24 hours 
later. The siRNA used in each sample is indicated above the blot. The first four 
samples were transfected with pcDNA3, the last four samples were transfected 
with hisZta, as indicated. The difference in EBV load per cell is significantly 
smaller in cells transfected with CBP or TORC1-3 siRNA in comparison to 
transfection with the relevant control siRNA (p<0.05). Averages are based on 
triplicate pipetting repeats. Values are represented as mean ± SD. 
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5.8 Discussion 
This chapter summarises results which suggest that BCL3 plays a part in the EBV 
lytic cycle.  
It was demonstrated that BCL3 is expressed in the cell lines which Zta ChIP 
sequencing results were obtained in. In addition, an increase in BCL3 protein 
level was observed as a result of lytic cycle induction in a range of cell lines. No 
corresponding increase in BCL3 RNA levels could be observed, suggesting that 
post-transcriptional processing is responsible for the increase in BCL3 protein 
levels. On the other hand, the RNA level of p50 is significantly increased in the 
epithelial cell line HONE1-EBV but not in Akata cells when EBV is in lytic cycle. 
The p50/BCL3 heterodimer has been shown to be the major form for NFκB 
detected in Nasopharyngeal Carcinoma [148]. This suggests that there may be 
an epithelial specific mechanism during lytic cycle involving this NFκB subunits.  
ChIP sequencing data analysis discussed in the previous chapter suggested that 
BCL3 binds to many of the regions of the human genome that Zta also binds to. 
This was confirmed for several binding sites with the help of ChIP qPCR. 
Further ChIP experiments in LCL3, followed by a second round of ChIP and 
qPCR, did not show BCL3 and Zta binding to these common binding sites at the 
same time.  
In addition to investigating BCL3 and Zta on the human genome, BCL3 ChIP 
sequencing data mapped to the viral genome by Arvey et al. was investigated 
[171]. It was not possible to show clear evidence of BCL3 binding to the viral 
genome in Akata cells because of a lack of negative control flanking region. As 
there is no evidence for Zta and BCL3 binding at the same time, it is possible that 
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Zta displaces BCL3. Therefore BCL3 may not commonly bind to the viral genome 
during lytic cycle.  
It has proven challenging to quantify the increase in BCL3 protein levels observed 
in Akata cells as a result of lytic cycle induction using FACS. This is partly due to 
the lack of a suitable non-rabbit BCL3 antibody which would allow detection of 
BCL3 without interference of the rabbit IgG antibody used to induce lytic cycle in 
Akata cells. A different cell line with a different mode of EBV lytic cycle induction 
may also be an alternative in future experiments.  
In order to investigate the effect of BCL3 on the EBV lytic cycle, BCL3 specific 
siRNA was used to attempt to knock-down the expression of BCL3. Initial 
optimisation of the experiment showed promising transfection results, as shown 
via FACS with a fluorescent Cy3 marker siRNA 24 hours after transfection. 
However, it was not possible to show a knock-down of BCL3 RNA, possibly due 
to a degradation of the siRNA over time.  
Using a new siRNA and transfection system to knock-down BCL3 protein levels 
coincided with an increase in Zta abundance at 24 and 48 hours after transfection 
of HEK293 ZKO cells with a Zta expression vector. In addition, a slight increase 
in EBV genome copy numbers could be detected. While this increase is not 
significant, based on the increase in Zta levels, it is possible that it would be at a 
later time point when lytic cycle had progressed further as the effect of BCL3 
over-expression was shown to be significantly larger at 72 hours than 48 hours 
after transfection. However, it was not possible to clearly show that transfection 
with BCL3 specific siRNA lead to a knock-down of BCL3. More experiments are 
required to demonstrate this.  
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BCL3 was over-expressed in HEK293T and HEK293 ZKO cells. This showed a 
progressive decrease in Zta protein levels as a result of increasing BCL3 
amounts. The amount of EBV lytic cycle is decreased as a result of BCL3 
transfection. This effect is more prominent at 72 hours after transfection than at 
48 hours after transfection. The decreased abundance of Zta when BCL3 is over-
expressed may relate to the attenuation of EBV lytic cycle. However, Zta 
transfected without BCL3 results in significantly higher EBV genome copy 
numbers per cells than Zta co-transfected with BCL3 to obtain similar Zta protein 
levels. Furthermore, higher amounts of BCL3 do not seem directly proportional 
to lower amounts of lytic cycle. 
As both, Zta and BCL3 have been shown to interact with TORC, the possibility 
that TORC is involved in the mechanism by which BCL3 inhibits the lytic cycle 
was investigated by siRNA knock-down of TORC1-3. CBP was also included in 
this investigation as it is known that CBP is targeted by carcinogenic viruses to 
hijack the cellular regulatory machinery, which disrupts host signalling pathways 
[17]. In addition, CBP was shown to be one of the top five co-associations with 
Zta binding peaks common to HONE1-EBV and Akata cells (Chapter 4).  
BCL3 knock-down decreases TORC protein levels at 24 and 48 hours after Zta 
or pcDNA3 expression vector transfection, unless Zta is also present at 48 hours. 
The decrease of TORC2 and 3 can be seen in the presence of Zta at 24 hours, 
but not anymore by 48 hours. It is possible that both Zta and BCL3 stabilize TORC 
proteins. 
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The levels of TORC2 do not appear to decrease when cells are transfected with 
TORC2 specific siRNA when Zta is also expressed. More experiments are 
necessary to confirm if this result is reproducible. 
The impact of TORC and CBP knock-down on Zta protein levels is much higher 
at 48 hours after Zta transfection than at 24 hours, suggesting that these proteins 
may play an important role in the establishment of lytic cycle. Close attention to 
the timing of further investigations into this process will be essential.  
A model of how Zta interacts with TORC and CBP, and how BCL3 may interfere 
with this mechanism is shown in Figure 105. Zta has been shown to interact with 
CBP as well as TORC2 [90, 98]. CBP can also bind to cellular transcription factors 
including p65, p53 and the retinoic acid receptor [84, 85]. p65, p53 and the 
retinoic acid receptor inhibit Zta transcriptional activity, and the over-expression 
of CBP relieves the antagonistic interactions between different classes of 
activators such as nuclear receptors and AP1. It has been suggested that CBP 
availability may control the transcription output from a range of signal inputs [84].  
The mechanism by which BCL3 inhibits the lytic cycle of EBV may be similar to 
that described for HTLV-1 in the introduction of this chapter, which involves 
blocking the binding of CBP to the complex, thus decreasing transcription 
activation. Alternatively CBP may be present, but the binding of BCL3 to the 
complex may block the activation of gene transcription (Figure 105 C). As TORC 
is a tetramer, it is also possible that multiple BCL3 and Zta proteins could bind to 
the complex to either inhibit or promote its transcription activation function. 
However, if this is the case it would be expected that the level of BCL3 is more 
proportional to the level of attenuation, which has not been shown to be the case. 
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These versions of the model would involve BCL3 binding to Zta binding sites at 
the same time as Zta. ChIP reChIP experiments described in this thesis did not 
show any evidence of this. In addition, the ChIP sequencing data which shows 
BCL3 at Zta binding sites on the human and viral genome was obtained in cells 
which are reported to contain latent EBV infection.  
It may be the case that BCL3 associates with Zta binding sites during latency, 
possibly as part of a complex including TORC and CBP. BCL3 may recruit 
HDACs to this complex. This model (Figure 105 C) is supported by a large overlap 
of Zta binding sites, which are also H3K27me3 sites and bound by BCL3 with 
almost 2/3 of the sites coinciding. It is possible that Zta displaces BCL3 at such 
a site, thus activating gene transcription and the lytic cycle. As BCL3 does not 
bind DNA directly, this model would involve the presence of an additional factor 
(X) at Zta binding sites during latency. This factor may be CREB, p50 or p52 as 
BCL3 has been shown to interact with these proteins during its role as 
transcription repressor [156]. AP1 or a viral factor could also tether BCL3 to DNA 
at Zta binding sites. The fact that indirect BCL3 binding motif analysis in a EBV 
negative cell line (K562) did not reveal a non CpG ZRE, while the indirect BCL3 
binding motif in GM12878 did resemble a non CpG ZRE may point to a latent 
viral factor being involved in this process. Further research would be required to 
specify these details.  
BCL3 ChIP qPCR experiments in HEK293 ZKO cells, which are tightly latent 
unless transfected with Zta, may be able to reveal if BCL3 is present at certain 
binding sites, like OriLyt, in latency or in lytic cycle, or both. 
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BCL3 has been shown to interact with TORC3 via its ankyrin repeat region. 
Interestingly, Dryfus et all. suggest that Zta may also have an ankyrin-like region 
[155], so it would be possible that Zta may interact with TORC in this way instead 
of through the bZIP domain. This could be an alternative way of explaining how 
BCL3 is inhibiting Zta and lytic cycle activation by competing for limiting amounts 
of TORC outside of a complex bound to DNA. However, this model would not 
explain the presence of BCL3 at Zta binding sites.   
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Figure 104: Model of Zta, CBP and TORC interaction and how BCL3 may interfere with it 
Figure 105: Model of Zta, CBP and TORC interaction and how BCL3 may 
interfere with it. A: Model of classic target gene activation by Zta. B: Proposed 
model of Zta gene activation. C: Different possible mechanisms by which BCL3 
may block Zta transcription activation.  
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Chapter 6: General Discussion 
Since the discovery of EBV in 1964, our understanding of the virus has evolved 
from being a contributing factor in an obscure African cancer to its present leading 
role as a prime example of a human tumour virus. EBV infects a large majority of 
the human population and is linked to a very diverse range of diseases. 
Considering the significant global burden of EBV-associated malignancies, it is 
an important priority to find novel treatments with specific targets that exploit the 
presence of the virus in malignant cells [2]. Although the precise role of EBV in 
epithelial malignancies is still poorly understood, the fact that the virus is present 
in all tumour cells shows that there is opportunity for the development of novel 
therapeutic and diagnostic approaches [6].  
The EBV early lytic cycle protein Zta is a key regulator of the switch from latency 
to lytic cycle. This thesis presents new insights into the binding, and consequent 
control, of Zta on the host cell genome. For this purpose, a ChIP sequencing 
experiment was performed in epithelial cells. The challenges encountered during 
the large scale Zta ChIP and preparation of a library for sequencing enabled the 
writing of a comprehensive book chapter on the methods involved in ChIP 
sequencing for the analysis of Zta binding to the human and EBV genome 
(Appendix B) [172].  
Sequencing reads mapped to the human and EBV genome were analysed to 
obtain MACS peaks, binding motifs, gene associations and gene list enrichments. 
In addition, results were compared to those previously obtained in B cells. This 
revealed Zta binding sites which could be cell-type specific, and some that could 
be common. Further research is needed to ascertain the relevance of the 
common and unique binding peaks of each cell type. However, as the rapid 
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advance in sequencing technology resulted in epithelial cell ChIP sequencing 
data to be of higher quality in comparison to the results obtained in B cells several 
years earlier, it is likely that at least part of the unique peaks found in epithelial 
cells are lower significance peaks also present, but not identified, in B cells.  
Histone modification and transcription factor binding data, which is publicly 
available from the ENCODE database for binding to the human genome, were 
included in the Zta ChIP sequencing data analysis. This revealed a range of co-
associations, of which BCL3 had the notably highest significance. The 
intersection of Zta and BCL3 MACS peaks in GM12878 cells, which are reported 
to contain latent EBV infection, confirmed a high number of overlaps. 
Interestingly, this overlap is especially high for Zta peaks common to B and 
epithelial cells, which could point to a cell-type independent role of BCL3. 
In addition to ChIP sequencing data mapped to the human genome, BCL3 
binding mapped to the EBV genome (Arvey et al. [171]) showed a BCL3 binding 
peak at OriLyt, which is also known to be bound by Zta. BCL3 ChIP qPCR results 
in Akata cells, containing lytic EBV, showed enrichment of OriLyt by a BCL3-
specific antibody in comparison to an IgG control. However, while amplification 
above the IgG negative control can be seen for BCL3 in Akata cells, no negative 
control flanking region is available for BCL3 binding to this peak. Therefore, 
amplification could represent a false positive caused by non-specific binding of 
the BCL3 antibody used to perform the ChIP. Further experiments are necessary 
to validate this binding.  
In HONE1-EBV cells induced with SAHA, and Akata cells induced with anti-IgG, 
it was shown that BCL3 protein levels increase when EBV is in lytic cycle and Zta 
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is expressed. It is not clear if this effect is due to the direct impact of Zta on BCL3 
stability and/or translation, or due to the impact of SAHA and anti-IgG on both, 
Zta and BCL3 expression. On the other hand, results obtained with the help of 
luciferase assays in HEK 293T cells show that Zta transcription activation of a 
BHLF1 reporter vector is decreased when BCL3 is over-expressed. Furthermore, 
EBV genome copy number qPCRs performed in HEK 293ZKO cells showed that 
EBV lytic cycle activation is also decreased by BCL3 over-expression. Both of 
these consequences of BCL3 over-expression correlate with a decrease in Zta 
protein levels. This may be caused by BCL3 impacting on the expression and/or 
stability of Zta. However, further experiments are necessary to investigate this 
correlation. Zta and BCL3 were both transfected and expressed in HEK 293 cells 
with the help of pcDNA3 Zta and pcDNA3 BCL3 expression vectors. It is possible 
that native Zta expression is not affected in the same way. Future work should 
question the impact of BCL3 on Zta expression and stability. 
As outlined in the introduction for Zta and BCL3, both proteins have been shown 
to interact with a member of the TORC family. In addition, BCL3 and TORC are 
involved in the reactivation from lytic cycle of the human T cell leukaemia virus 
HTLV-1. HTLV-1 is a lymphotropic virus, like EBV, and also causes life long, 
latent infections. The HTLV-1 protein Tax acts as a switch from latency to lytic 
cycle. This process involves the association of Tax with CREB. It is not clear to 
what degree TORC1, TORC2 and TORC3’s functions are similar or 
interchangeable. While they are not homologs, all three members of the TORC 
family significantly enhance Tax-mediated transcription by forming a complex 
with Tax and CREB. Low-level expression of each TORC is present in all human 
tissues, however, TORC2 and TORC3 are predominantly found in T and B 
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lymphocytes [3]. The interaction of BCL3 with TORC3 significantly inhibits the 
HTLV-1 reactivation from latency via the inhibition of TORC3 function [25]. As 
outlined in the first chapter of this thesis, Zta is known to interact with TORC2 and 
this interaction promotes reactivation from latency [90].  
First experiments in HEK293 ZKO cells transfected with BCL3 specific siRNA hint 
at a possible interaction of TORC, BCL3 and Zta. However, while an effect can 
be observed, it has not been possible to prove a convincing knock-down of BCL3 
in these samples as BCL3 expression levels in HEK293 cells are low in 
comparison to other cell types. In addition, the BCL3 antibody used in earlier 
western blotting was discontinued and it has not been possible to find a satisfying 
replacement during the course of this PhD. Future work should clarify the knock-
down of BCL3 in the relevant samples.  
Unlike Zta, Tax is not a bZIP protein itself, but promotes dimerization of bZIP 
proteins in the absence of DNA. The elevated concentration of the bZIP 
homodimer facilitates DNA binding and activation of target sites [173]. TORCs 
have a conserved N-terminal coiled-coil domain which allows them to interact 
with the bZIP domain of CREB [174], leading to the induction of cAMP responsive 
genes. As Zta also contains a bZIP domain [72], it is possible that Zta and CREB 
interact with TORC in a similar fashion. Furthermore, Zta does not form 
heterodimers with other bZIP proteins [81], so it is possible that CREB and Zta 
are competing for the same binding sites. Zta has been shown to decrease 
transactivation of CREB target sites. This effect is relieved by CBP over-
expression, but it has been suggested that Zta does not decrease the amount of 
CREB-CBP complexes [97].  
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Knock-down of TORC2 has been shown to reduce the levels of lytic proteins 
following induction, including Zta [90]. This result was confirmed in this thesis. 
CBP has been suggested to stabilize a complex containing CREB and HTLV-1 
Tax to activate gene transcription. The binding of BCL3 to the CREB/Tax complex 
inhibits the binding of CBP and represses gene activation. Interestingly, CBP was 
one of the top five most significant co-associated cellular factor found when 
intersecting ChIP sequencing MACS peaks, available from ENCODE, with the 
overlapping Zta ChIP sequencing peaks of HONE1-EBV cells and Akata cells. 
Knock-down of CBP needs to be validated in further experiments, but treatment 
of HEK293 ZKO cells with CBP specific siRNA leads to a reduction in Zta protein 
levels in a similar range to knock-down of TORC1- 3. Further research is needed 
to examine whether findings relating to CREB, TORC and BCL3 obtained for 
HTLV-1 Tax can be extended to EBV Zta, and perhaps other lymphotropic viruses 
like HIV.  
ZRE2 contains a CREB binding region and herpes simplex virus type 1 infection 
has been shown to activate EBV lytic cycle via a CREB dependant mechanism 
[175]. Perhaps the activation of the B cell receptor, which leads to the activation 
of CREB’s transcriptional activity, results in the induction of the EBV lytic cycle 
by activating target sites through a similar mechanism later utilised by Zta.  
Based on the high overlap of Zta and BCL3 peaks with H3K27me3, the ability of 
BCL3 to recruit histone deacetylases that inhibit transcription [176] and the fact 
that Zta has been shown to significantly increases CBP-mediated acetylation of 
nucleosomal histones [99], a further possible model includes BCL3 involved in 
the establishment of a repressive chromatin environment during latency, which is 
overturned through Zta expression and activation at onset of lytic cycle.  
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Cells expressing the latent EBV protein LMP1 have increased levels of 
phosphorylated STAT3, resulting in induced BCL3 expression [168]. The 
expression of LMP1 is thought to result in the p50/BCL3 complex which is the 
major form for NFκB detected in Nasopharyngeal Carcinoma [169]. In this thesis, 
results indicate that BCL3 protein levels in EBV-associated cancer cell lines may 
also increase in response to EBV lytic cycle activation. The constitutive 
expression of BCL3 has been shown to suppress DNA damage-induced p53 
activation and consequent p53-induced apoptosis [159]. BCL3 also inhibits 
apoptosis by blocking Bim activation [160]. The over-expression of BCL3 has 
been shown to contribute to the development of some types of Hodgkin and non-
Hodgkin lymphoma, as well as nasopharyngeal carcinoma and ovarian cancer 
[143].  
The success of EBV associated cancer therapies is directly linked to the 
susceptibility for lytic cycle activation. In addition to the anti-apoptotic effect of 
BCL3, results presented in this thesis raise the question whether increased BCL3 
levels are also responsible for the tight latency of EBV associated cancers.  
BCL3 has previously been suggested to be a useful diagnostic or prognostic 
marker for different types of cancers including colorectal cancer [177]. Research 
presented in the thesis suggests that BCL3 may also be able to fulfil this role for 
EBV associated cancers. In addition, research at the University of Cardiff has 
investigated the potential for BCL3 as a new, alternative therapeutic target for 
HER-2 positive breast cancer [178] and research led by Dr Dafydd Jones at 
Cardiff University is currently in the process of attempting to develop BCL3 
targeted cancer therapies. While more extensive research is required to 
investigate the model of lytic cycle activation presented in this thesis, BCL3-
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targeted cancer therapies could have the potential to improve treatment 
outcomes for patients with EBV associated cancers.  
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Appendix A 
 
Supplementary Figure 1: List of Genes with Zta MACS peaks in HONE1-EBV 
cells within 2kb of the transcription start site. List was obtained using GREAT 
version 2.0.2, Species assembly: hg19 and the association rule: Two nearest 
genes: 2000 bp max extension, curated regulatory domains included. 
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 Chapter 14 
 The Use of Chromatin Precipitation Coupled to DNA 
Sequencing (ChIP-Seq) for the Analysis of Zta Binding 
to the Human and EBV Genome 
 Anja  Godfrey ,  Sharada  Ramasubramanyan , and  Alison  J.  Sinclair 
 Abstract 
 Determining which components of the transcription machinery associate with the viral and cellular 
genome, and how this changes at specifi c stages of the viral life cycle is paramount to understanding how 
the distinct transcriptional programs associated with primary infection, latency, and disease are established 
and how they are reprogrammed during initiation and execution of the viral lytic replication cycle. 
Chromatin precipitations linked to next generation DNA sequencing (ChIP-Seq) allow for the interac-
tions of proteins with DNA to be mapped across both viral and cellular genomes. This can be applied to 
viral and cellular transcription factors, coactivators and corepressors, modifi ed histones, and modulators of 
chromatin. 
 Key words  Chromatin ,  Immunoprecipitation ,  DNA ,  ChIP ,  DNA sequencing ,  Transcription factor 
1  Introduction 
 Every cell in an organism has an identical genome, which contains 
all of the information required for the lifetime of that organism, 
but many genes are required only in specialized cells or in response 
to particular conditions. Highly controlled mechanisms that regu-
late the expression of such genes are paramount to the specializa-
tion of cells, thus allowing for the complexity and survival of the 
organism. This is achieved through a myriad of controls that ensure 
that an environment that is either favorable or unfavorable to tran-
scriptional activation exists surrounding the transcriptional start 
site of each gene [ 1 ]. 
 The Epstein Barr virus (EBV) has highly controlled and distinct 
programs of  gene expression . The EBV genome consists of ~170 kb 
of double strand DNA.  Following infection of cells the genome is 
transported to the nucleus, where it becomes associated with  his-
ton es and so resembles cellular DNA. During viral latency one of the 
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four distinct patterns of viral gene expression is  established (termed 
latency 0 to latency III) [ 2 ]. These have relevance for viral  persis-
tence a nd for virus-associated disease. Cells exhibiting these latency 
patterns can be activated to initiate the viral lytic  replicatio n cycle, 
during which most viral genes are expressed. In addition, an impor-
tant but currently less well-defi ned pattern of gene expression occurs 
immediately following infection of B-cells, and during some dis-
eases, which is termed pre-latency or abortive lytic replication. 
 The relevant proteins include  histones, specifi c posttransla-
tional modifi cations of histones, transcription factors, coactivators 
and corepressors, and proteins that enable and change chromatin 
architecture. Several EBV genes encode transcription factors that 
either interact directly (e.g., Zta (Zebra) and Rta), or indirectly 
(e.g.,  EBNA1 , -2, - 3 and -LP) with DNA [ 2 ]. 
 ChIP-Seq has been valuable in determining information about 
the binding sites of individual EBV transcription factors with the 
human, and in some cases viral, genomes [ 3 – 9 ]. In addition, the 
Encyclopedia of DNA elements (ENCODE)  project [ 10 ] includes 
an EBV-infected cell displaying latency III pattern of  gene expres-
sion , and the wealth of data available from ENCODE has been 
mapped to the EBV genome. This generated an atlas of interac-
tions in Latency III [ 11 ]. 
 The ChIP-Seq technique takes a genome-wide approach to 
determine the interactions of proteins with DNA. This involves the 
use of cross-linkers to “fi x”  adjacent protein-protein and  protein- 
DNA interactions  within live cells, followed by isolation of a spe-
cifi c protein, together with any other proteins, and DNA that 
protein is associated with. The precipitated DNA and a sample of 
the starting DNA are then isolated, the cross-links are reversed and 
samples are prepared for sequencing. The libraries are then subject 
to next generation  sequencing . The resulting DNA sequencing 
reads are mapped to genome sequences. For virus-infected cells, 
this can be undertaken for both the viral genome and the host cell 
genome from the same sequence library as shown for the viral tran-
scription factor Zta [ 9 ,  12 ]. 
2  Materials 
  1.  Formaldehyde: 37 % (v/v). 
  2.  Glycine: 1 M. 
  3.  PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM 
KH 2 PO 4 . 
  4.  Cell Lysis Buffer: 85 mM KCl, 0.5 % (v/v) NP-40, and 5 mM 
PIPES pH 8.0. 
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  5.  SDS lysis buffer: 1 % (w/v) SDS, 10 mM EDTA, 50 mM Tris 
pH 8.0. 
  6.  IP Dilution Buffer: 0.01 % (w/v) SDS, 1.1 % (v/v) Triton 
X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.0, 167 mM NaCl. 
  7.  Low salt wash buffer: 0.1 % (w/v) SDS, 1 % (v/v) Triton 
X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 150 mM NaCl. 
  8.  High salt wash buffer: 0.1 % (w/v) SDS, 1 % (v/v) Triton 
X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 500 mM NaCl. 
  9.  LiCl wash buffer: 250 mM LiCl, 1 % (v/v) NP-40, 1 % (w/v) 
Na- deoxycholate, 1 mM EDTA, 10 mM Tris pH 8.0. 
  10.  Elution buffer: 10 mM Tris–HCl, 1 mM EDTA, 1 % (w/v) 
SDS. 
  11.  Protein A sepharose beads. 
  12.  Protein G sepharose beads. 
  13.  Blocking buffer: PBS, 0.5 % (w/v) BSA (fraction V), passed 
through a 0.2 μm fi lter). 
  14.  RNase A: 20 mg/mL. 
  15.  Proteinase K (20 mg/mL). 
  1.  Library preparation kits: NEB Next ChIP-Seq Library  Prep 
 Reagent Set for Illumina, NEBNext Multiplex Oligos for 
Illumina (Index Primers Set 1). 
  2.  Deoxynucleotide (dNTP) solution mix: Kit component, 
10 mM dATP, 10 mM dGTP, 10 mM dCTP, 10 mM dTTP, 
supplied in Milli-Q water (Millipore Corporation) as a sodium 
salt at pH 7.5. 
  3.  Phosphorylation reaction buffer (10×): Kit component, 
500 mM Tris–HCl, 100 mM MgCl2, 100 mM DTT, 10 mM 
ATP, pH 7.5 at 25 °C. 
  4.  Enzymes: Kit components, T4 DNA Polymerase, DNA poly-
merase I: Large (Klenow) fragment, T4 Polynucleotide Kinase, 
Klenow Fragment (3′→5′exo–), quick T4 DNA ligase, USER 
enzyme. 
  5.  NEBuffer 2 for Klenow fragment (3′ → 5′exo–): Kit compo-
nent, 50 mM NaCl, 10 mM Tris–HCl, 10 mM MgCl 2 , 1 mM 
DTT, pH 7.9 at 25 °C. 
  6.  Deoxyadenosine 5′- Triphosphate (dATP): Kit component, 
1 mM, supplied in Milli-Q water as a sodium salt at pH 7.5. 
  7.  Quick ligation reaction buffer (2×): Kit component, 132 mM 
Tris–HCl, 20 mM MgCl 2 , 2 mM dithiothreitol, 2 mM ATP, 
15 % (v/v) Polyethylene glycol (PEG 6000), pH 7.6 at 25 °C. 
  8.  NEBNext Adaptor: Kit component, 15 μM, 5′-/5Phos/GAT 
CGG AAG AGC ACA CGT CTG AAC TCC AGT C/
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ideoxyU/A CAC TCT TTC CCT ACA CGA CGC TCT TCC 
GAT C*T-3′, where the * indicates a phosphorothioate bond. 
  9.  High-Fidelity 2× PCR Master Mix: Sample kit component. 
  10.  Universal PCR primer: Kit component, 25 μM ( see  Note  1 ), 
5′-AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT 
CTT TCC CTA CAC GAC GCT CTT CCG ATC*T-3′, 
where the * indicates a phosphorothioate bond. 
  11.  NEBNext Multiplex Oligos for Illumina:  Kit component, e.g., 
Index 1: 5′-CAA GCA GAA GAC GGC ATA CGA GAT CGT 
GAT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG 
ATC-s-T-3′, where -s- indicates a phosphorothioate bond ( see 
 Note  2 ). 
  12.  Qiagen MinElute PCR Purifi cation and Gel Extraction Kits. 
  13.  PB buffer: Kit component, high concentration of guanidine 
hydrochloride and isopropanol. 
  14.  MinElute Columns: Kit component. 
  15.  QIAquick spin columns: Kit component. 
  16.  2 mL collection tubes: Kit component. 
  17.  PE buffer: Kit component. 
  18.  EB buffer: Kit component, 10 mM Tris-Cl, pH 8.5. 
  19.  QG buffer: Kit component. 
  20.  Thermal cycler. 
  21.  Agarose. 
  22.  TAE buffer (1×): 4.84 g Tris base, 1.14 mL acetic acid, pH 8.0. 
Make up to 1 L with sterile water. 
  23.  Loading buffer: 50 mM Tris, pH 8.0, 40 mM EDTA, 40 % w/v 
sucrose. 
  24.  100 bp DNA ladder (New England Bio Labs Quick-Load 
100 bp DNA Ladder). 
  25.  1 kb DNA ladder (Bioline HyperLadder). 
  26.  Electrophoresis equipment (Bio-Rad Mini-Sub Cell GT 
System #170-4467 and power source). 
  27.  Dark Reader Transilluminator (Clare Chemical Research). 
  28.  Disposable scalpels. 
  29.  96–100 % (v/v) ethanol. 
  30.  Isopropanol. 
  31.  Microcentrifuge. 
  32.  Agilent 2100 Bioanalyzer. 
  33.  Agilent High Sensitivity DNA Kit. 
  34.  High Sensitivity DNA Chip: Kit component. 
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  35.  Electrode Cleaner: Kit component. 
  36.  Syringe: Kit component. 
  37.  Spin Filters: Kit component. 
  38.  High Sensitivity DNA Ladder: Kit  component , 13 DNA frag-
ments from 50 to 7000 bp. 
  39.  High Sensitivity DNA Markers: Kit component, lower marker 
at 35 bp, upper marker at 10,380 bp. 
  40.  High Sensitivity DNA Dye Concentrate: Kit component. 
  41.  High Sensitivity DNA Gel Matrix: Kit component. 
  42.  IKA MS3 vortex mixer with chip adaptor (Agilent). 
  43.  Electrode cleaner (Agilent). 
3  Methods 
  1.  Centrifuge 1 × 10 8 cells at 1710 ×  g for 5 min, resuspend in 
5 mL of cell culture medium to 2 × 10 7 /mL. 
  2.  Add formaldehyde to cell culture medium to a fi nal concentra-
tion of 1 % and incubate for 15 min at 20 °C while rocking. 
  3.  Add 625 μL of 1 M glycine, to a fi nal concentration of 0.125 M. 
  4.  Centrifuge cells at 1710 ×  g for 5 min resuspend in 5 mL of 
PBS. 
  5.  Centrifuge cells at 1710 ×  g for 5 min resuspend cells in 3 mL 
of Cell Lysis Buffer. 
  6.  Incubate on ice for 10 min. 
  7.  Centrifuge at 1710 ×  g 5 min, and discard supernatant ( see 
 Note  3 ). 
  8.  Resuspend nuclei in 2 mL SDS lysis buffer. 
  9.  Sonicate nuclear lysate on ice (e.g., using a Branson Model 
250 Microtip sonicator) 10 × 10 s pulses, in a volume of 100 μL 
with a 21 % output, vortexing the sample after every minute 
( see  Note  4 ). 
  10.  Snap freeze and store nuclear chromatin extracts at −80 °C. 
  11.  Mix 1 mL of Protein-A Sepharose beads with 1 mL of 
Protein- G Sepharose beads ( see  Note  5 ) and 10 mL of IP 
Dilution Buffer ( see  Note  6 ). 
  12.  Centrifuge beads at 1710 ×  g for 5 min, and discard 
supernatant. 
  13.  Add 10 mL of IP Dilution Buffer,  centrifug e beads at 1710 ×  g 
for 5 min and discard supernatant. 
  14.  Resuspend beads in 5 mL of blocking buffer and incubate at 
4 °C while rotating for 30 min. 
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  15.  Centrifuge beads at 1710 ×  g for 5 min and discard 
supernatant. 
  16.  Resuspend beads in 2 mL of IP dilution buffer. 
  17.  Defrost 2 mL of chromatin and transfer it to a 50 mL falcon tube. 
  18.  Add 18 mL IP dilution buffer. 
  19.  Remove 400 μL and freeze. Label as “input chromatin.” 
  20.  Add 1 mL of the blocked protein A-G beads to the remaining 
19.4 mL and incubate for 30 min at 4 °C. 
  21.  Centrifuge beads at 1710 ×  g for 5 min and transfer superna-
tant into a new 50 mL tube. 
  22.  Add 40 μg of antibody and incubate for 1 h on a rotator. 
  23.  Add 1 mL of blocked protein A-G beads and rotate tubes 
overnight. 
  24.  Centrifuge beads at 1710 ×  g for 5 min and add 20 mL low salt 
wash buffer. Incubate for 10 min on a rotator. 
  25.  Centrifuge beads at 1710 ×  g for 5 min and add 20 mL high 
salt wash buffer. Incubate for 10 min on a rotator. 
  26.  Centrifuge beads at 1710 ×  g for 5 min and add 20 mL LiCl 
wash buffer. Incubate for 10 min on a rotator. 
  27.  Centrifuge beads at 1710 ×  g for 5 min and add 20 mL TE buf-
fer. Incubate for 10 min on a rotator. 
  28.  Centrifuge beads at 1710 ×  g for 5 min and discard 
supernatant. 
  29.  Add 3 mL of TE/1 % (v/v) SDS at room temperature and 
incubate the solution at 65 °C for 20 min. 
  30.  Centrifuge beads at 1710 ×  g for 5 min. Transfer the superna-
tant to a new tube. 
  31.  Defrost the “input chromatin” control and add 3 mL of 
TE/1 % (w/v) SDS at room temperature. 
  32.  Incubate the input chromatin and the precipitated  chromatin 
at 65 °C overnight to reverse the cross-links. 
  33.  Add 60 μL of RNAse A and 3 mL of TE to each and incubate 
at 37 °C for 2 h ( see  Note  7 ). 
  34.  Add 60 μL of proteinase K to each tube and incubate at 55 °C 
for 2 h ( see  Note  7 ). 
  35.  Purify DNA using the Qiagen MinElute PCR purifi cation kit 
( see  Note  11 ). Add ethanol (96–100 %) to buffer PE before 
use. All centrifugation steps are carried out in a microcentri-
fuge set to 11,710 ×  g at room temperature ( see  Note  12 ). 
  36.  Add 15 mL PB buffer to the samples and mix. 
  37.  Place the MinElute column in a provided 2 mL collection tube. 
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  38.  Apply 700 μL of the samples to the column and centrifuge for 
1 min. 
  39.  Discard the fl ow-through and place the MinElute column back 
into the same tube. 
  40.  Repeat  steps 38 and  39 until all of the sample has been 
centrifuged. 
  41.  Add 750 μL PE buffer to the column, let it stand for 3 min, 
and centrifuge for 1 min. 
  42.  Discard the fl ow-through and place the column back into the 
same tube. Centrifuge the column for an additional minute. 
  43.  Place the MinElute column into a sterile 1.5  mL  microcentri-
fuge tube. 
  44.  Add 42 μL EB buffer to the center of the membrane, let the 
column stand for 1 min, then centrifuge for 1 min. 
  45.  Add the eluate back to the center of the column, let it stand for 
1 min, then centrifuge for 1 min. 
  1.  The NEBNext ChIP-Seq Library Prep Reagent Set is used in 
combination with the NEBNext Multiplex Oligos for Illumina 
(Index Primers Set 1), the MinElute PCR purifi cation kit 
(Qiagen), and the Gel Extraction kit (Qiagen) to prepare the 
input and ChIP libraries. 
  2.  To end-repair the ChIP and input DNA, measure the concen-
tration of your ChIP and input samples ( see  Note  8 ). 
  3.  Suspend 10 ng ( see  Note  9 ) of ChIP or input DNA in sterile 
water to a fi nal volume of 40 μL. 
  4.  Dilute DNA polymerase I, Large (Klenow) Fragment by mix-
ing 1 μL of enzyme with 4 μL of sterile water. 
  5.  Mix the following components in a sterile microcentrifuge 
tube:
  (a)  20 μL of Phosphorylation Reaction Buffer (10×). 
  (b)  4 μL of T4 DNA Polymerase. 
  (c)  4 μL of T4 polynucleotide kinase. 
  (d)  8 μL of dNTP mix. 
  (e)  4 μL  of  diluted DNA Polymerase I, Klenow Fragment. 
  6.  Add 10 μL of this mix to each sample of the 40 μL ChIP and 
input DNA. 
  7.  Incubate in a thermal cycler at 20 °C for 30 min ( see  Note  10 ). 
  8.  Purify DNA using the Qiagen MinElute PCR purifi cation kit 
( see  Note  11 ). Add ethanol (96–100 % (v/v)) to buffer PE 
before use. All centrifugation steps are carried out in a micro-
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centrifuge set to 11,710 ×  g at room temperature ( see  Note 
 12 ). 
  9.  Add 250 μL PB buffer to the samples and mix. 
  10.  Place the MinElute column in a provided 2 mL collection tube. 
  11.  Apply all traces of the samples to the column and centrifuge for 
1 min. 
  12.  Discard the fl ow-through and place the MinElute column back 
into the same tube. 
  13.  Add 750 μL PE buffer to the column, stand for 3 min, and 
centrifuge for 1 min. 
  14.  Discard the fl ow-through and place the column back into the 
same tube. Centrifuge the column for an additional minute. 
  15.  Place the  MinElute  column into a sterile 1.5 mL microcentri-
fuge tube. 
  16.  Add 35 μL EB buffer to the center of the membrane, let the 
column stand for 1 min, then centrifuge for 1 min. 
  17.  Add the eluate back to the center of the column, let it stand for 
1 min, then centrifuge for 1 min. 
  18.  For dA-tailing of end-repaired DNA, mix the following com-
ponents in a sterile microcentrifuge tube:
  (a)  20 μL NEBuffer 2 (10×). 
  (b)  40 μL Deoxyadenosine 5′-Triphosphate. 
  (c)  4 μL Klenow Fragment (3′→5′ exo–). 
  19.  Add 16 μL of this mix to the 34 μL of DNA sample ( see  Note  13 ). 
  20.  Incubate in a thermal cycler for 30 min at 37 °C. 
  21.  Repeat  steps 8–17 , but using 11 μL EB buffer. 
  22.  For the adaptor ligation, dilute the NEBNext Adaptor for 
Illumina (15 μM) 10-fold in sterile water to a fi nal concentra-
tion of 1.5 μM. 
  23.  Mix the following components in a sterile microcentrifuge 
tube:
  (a)  60 μL  of  Quick Ligation Reaction Buffer (2×). 
  (b)  4 μL of Diluted NEBNext Adaptor (1.5 μM). 
  (c)  16 μL of Quick T4 ligase. 
  24.  Add 20 μL of this mix to the 10 μL end-repaired, dA-tailed 
DNA. 
  25.  Incubate the reaction in a thermal cycler for 15 min at 20 °C 
( see  Note  10 ). 
  26.  Add 3 μL USER enzyme, mix by pipetting up and down, and 
incubate at 37 °C for 15 min. 
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  27.  Repeat  steps 8–17 , but using 150 μL PB and 24 μL EB 
buffer. 
  28.  To PCR enrich the adaptor ligated DNA, mix the following 
components in a sterile microcentrifuge tube:
  (a)  23 μL adaptor ligated DNA. 
  (b)  25 μL NEBNext High-Fidelity 2× PCR Master Mix. 
  (c)  1 μL  universal PCR primer (25 μM). 
  (d)  1 μL Index Primer (one of 12 per sample, e.g., Input: 
Index 4, ChIP1: Index 6, ChIP2: Index 12). 
  29.  PCR cycling conditions (Table  1 ):
  30.  Repeat  steps 8–17 , but using 16 μL EB buffer. 
  31.  To size select the library, prepare the required number of 2 % 
(w/v) agarose gels with 1× TAE buffer ( see  Note  14 ). 
  32.  Add 6 μL loading buffer to the samples and to 15 μL of the 
100 bp DNA ladder. 
  33.  Use 1× TAE buffer as running buffer. Load the sample and 
marker ladders onto the gel(s), leaving at least one space 
between ladder and samples ( see  Note  15 ). 
  34.  Run the gel at 120 V until the marker dye has reached the bot-
tom of the gel (approximately 60 min). 
  35.  Weigh out three sterile microcentrifuge tubes and label them 
with their weight. 
  36.  View the gels on the Dark Reader Transilluminator ( see  Note  16 ). 
  37.  Excise the 175–225 bp region of the gel with a clean, dispos-
able scalpel ( see  Note  17 ). Minimize the size of the gel slice by 
removing excess agarose. Place the selected gel slice into a 
labeled microcentrifuge tube. 
  38.  Use the Qiagen gel extraction kit to purify the DNA from the 
agarose slice. All centrifugation steps are carried out in a micro-
centrifuge set to 11,710 ×  g at room temperature ( see  Note  12 ). 
 Table 1 
 PCR cycling conditions 
 Cycle step  Temperature (°C)  Time (s)  Cycles 
 Initial denaturation  98  30  1 
 Denaturation  98  10  15 
 Annealing  65  30 
 Extension  72  30 
 Final extension  4  hold  1 
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  39.  Weigh the tubes containing the gel slice and calculate the 
weight of the agarose. 
  40.  Add three volumes of QG buffer to one volume of gel (i.e., 
add 300 μL of QG to 100 mg of gel). For gel slices over 
400 mg, use more than one tube. 
  41.  Incubate on bench ( see  Note  18 ) for at least 10 min until the 
gel slice has completely dissolved. Vortex the tube every 2 min 
during the incubation time. 
  42.  Heat  EB buffer to 50 °C. 
  43.  Add one gel volume of isopropanol to the sample (i.e., if the 
gel slice weight 100 mg, add 100 μL) and mix ( see  Note  19 ). 
  44.  Place the QIAquick spin column in a provided 2 mL collection 
tube. 
  45.  Apply the sample to the column and centrifuge for 1 min. The 
maximum volume of the column is 750 μL. For higher sample 
volumes, load the spin column again after centrifugation. 
  46.  Discard fl ow-through and place the column back into the same 
collection tube. 
  47.  Add 500 μL QG buffer to the column and centrifuge for 1 min. 
  48.  Discard fl ow-through. 
  49.  Add 750 μL of PE buffer to the column and let it stand for 
3 min, then centrifuge for 1 min. 
  50.  Discard fl ow-through  a nd centrifuge the column for an addi-
tional minute. 
  51.  Place the column into a sterile 1.5 mL microcentrifuge tube. 
  52.  Add 55 μL of EB buffer directly to the center of the column 
membrane and let the column stand for 1 min, then centrifuge 
for 1 min. 
  53.  Repeat  steps 8–17 , but using 14 μL EB buffer. 
  54.  Use 1 μL of the purifi ed library sample for quality control on a 
Bioanalyzer ( see  Note  20 ) using the Agilent High Sensitivity 
DNA Kit: 
  55.  Let the High Sensitivity DNA dye concentrate and High 
Sensitivity DNA gel matrix equilibrate to room temperature 
( see  Note  21 ). 
  56.  Vortex the vial with High Sensitivity DNA dye concentrate for 
10 s and spin down. Making sure that the DMSO is completely 
thawed. 
  57.  Pipette 15 μL of the dye concentrate into a High Sensitivity 
DNA gel matrix vial ( see  Note  22 ). 
  58.  Return the dye concentrate to 4 °C to store, protecting it from 
light. 
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  59.  Cap the tube, vortex for 10 s. Make sure that the gel and dye 
are mixed properly. 
  60.  Transfer the gel—dye mix to the top receptacle of the spin fi lter. 
  61.  Spin for 10 min at 2400 × g at room temperature in a 
microcentrifuge. 
  62.  Discard the  fi lter  and label the tube ( see  Note  23 ). 
  63.  Ensure that the base plate of the chip priming station is in posi-
tion C and that the adjustable clip is set to the lowest position. 
  64.  Place a new High Sensitivity DNA chip onto the chip priming 
station. 
  65.  Placing the pipette tip at the center of the well, pipette 9 μL of 
the gel—dye mix (which is at room temperature) to the bottom 
of the well located in the right (fourth) column and third row. 
  66.  Set a timer to 1 min and make sure that the plunger is posi-
tioned at 1 mL. Then close the chip priming station. 
  67.  Press the syringe plunger down until it is held by the clip, then 
start the timer. 
  68.  Release the plunger after exactly 1 min. 
  69.  Make sure that the plunger moves back at least to the 0.3 mL 
mark. 
  70.  Wait 5 s before slowly pulling back the plunger to the 1 mL 
position. 
  71.  Open the chip priming station and pipette 9 μL of the gel—dye 
mix into the three empty wells of the right (fourth) column. 
  72.  Return the gel—dye mix to 4 °C to store, protecting it from 
light. 
  73.  Pipette 5 μL of the High Sensitivity DNA marker into each of 
the empty wells (fi rst three columns) ( see  Note  24 ). 
  74.  Pipette  1 μL of the High Sensitivity DNA ladder into the well 
marked with the ladder symbol (third column, fourth row). 
  75.  Pipette 1 μL of sample ( see  Note  25 ) or 1 μL of marker (for 
otherwise empty wells) into each well of the fi rst three col-
umns, except the well with the ladder symbol. 
  76.  Carefully place the chip horizontally into the vortex adapter 
and vortex for 1 min at 2400 rpm. 
  77.  Place the chip carefully into the receptacle of the Bioanalyzer, 
making sure that the run is started within 5 min. 
  78.  Carefully close the lid ( see  Note  26 ) and start the chip run. Use 
the dsDNA assay and fi ll in the sample name table. 
  79.  After the run is fi nished dispose of the chip. 
  80.  Slowly fi ll one of the wells of the electrode cleaner ( see  Note  27 ) 
with 350 μL sterile water. 
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 Fig. 2  Agarose gel showing the size, in base pairs (bp), of sonicated chromatin 
fragments, using two different chromatin sonication protocols ( left and  right ) 
 Fig. 1  Bioanalyzer  Electropherogram showing fl uorecense units [FU] on the  y -axis and seconds [s] on the 
 x -axis, with numbers above peaks indicating the fragment size in base pairs (bp). A single high peak around 
200 bp and no peak in the 100 bp Adapotor region has been detected 
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  81.  Place the electrode cleaner in the Bioanalyzer, then close the 
lid and leave it for about 10 s. 
 82.  Remove the electrode cleaner and wait another 10 s to allow 
the water on the electrodes to evaporate. 
  83.  For a good quality sample, the electropherogram should show 
no peak in the 100 bp region, with a high peak around 200 bp 
( see Fig.  1 ). If there is a peak in the adaptor region (as indicated 
by the blue box),  the sample is contaminated and sequencing 
may not yield successful results.
4  Notes 
  1.  Concentrations of universal PCR Primer and the Index Primers 
contained in the NEB kit have changed from 25 to 10 μM. Refer 
to the most recent protocol for use. 
  2.  12 Index Primers are included in the NEBNext Multiplex 
Oligos for Illumina (Index Primers Set 1) kit for producing 
barcoded libraries. Refer to the manual for sequence informa-
tion. If fewer than 2 indexes per lane are used, NEB recom-
mends the combination of the following indexes for best 
demultiplexing results:
  (a)  Pool of 2 samples: Index 6 and 12. 
  (b)  Pool of 3 samples: Index 4, 6, and 12. 
  (c)  Pool of 6 samples: Index 2, 4, 5, 6, 7, and 12. 
  3.  After the addition of cell lysis buffer all steps are undertaken at 
4 °C unless specifi ed. 
  4.  Sonication is critical. The ideal fragment size for ChIP sequenc-
ing is 200 bp. Appropriate conditions will vary with each soni-
cator and can be checked by undertaking a time course of 
sonication, incubating at 65 °C overnight to reverse the cross- 
links. This is followed by purifying the DNA and analyzing size 
distribution on an agarose gel. Figure  2 shows the results of 
two different sonication protocols. The gel on the left shows a 
sub- ideal chromatin sonication for ChIP-Seq purposes. The 
gel on the right, using the second chromatin sonication proto-
col, shows a good fragmentation around 200 bp. 
  5.  Protein A and Protein G sepharose beads should be stored at 
4 °C in 70 % (v/v) ethanol, then washed with IP dilution buffer 
prior to use. 
  6.  Add protease inhibitor cocktail (Sigma) and 1 mM PMSF to all 
buffers just before use. 
  7.  Proteinase K and RNAase can be stored as aliquots at −20 °C. 
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  8.  We found that the Qubit Fluorometer worked well for this 
step. The concentration of our ChIP samples was too low to be 
measured accurately using a NanoDrop Spectrophotometer. 
  9.  The kit calls for 10 ng of DNA, but we have previously used 
18 ng to ensure maximum library concentration. In our experi-
ence, this did not seem to impair the quality of the fi nal library. 
  10.  Our laboratory tends to be around 20 °C. We incubate this 
reaction on the bench rather than in a thermal block cycler and 
still get good results. 
  11.  If using the Qiagen kit, it is important for the effi ciency of this 
purifi cation process that centrifugation steps are actually car-
ried out at room temperature. 
 Alternatively, it is possible to clean up  the sample using AMPure 
XP Beads (Beckman Coulter, Inc.). 
  12.  Qiagen suggests that buffer QG from the GelExtraction kit 
may be used to remove salt and proteins from samples. Do not 
use buffer QG outside of the gel extraction during the library 
preparation. 
  13.  The sample was eluted in 35 μL, but a small amount will 
remain in the column; hence, the DNA is already in the correct 
34 μL volume required for the following step. 
  14.  Make sure that the comb creating the sample wells in the aga-
rose gel is precisely straight to ensure that the sample and 
markers run exactly vertically on the gel. If the samples and 
markers run at an angle, it is more diffi cult to be sure of the 
exact size to select on the gel, which can lead to adaptor 
contamination. 
  15.  It is important to select the correct sample size, we suggest 
running each sample with two markers on each side, as shown 
in the scheme below.
 Marker 1  Marker 2  Sample  Marker 1  Marker 2 
  16.  The Dark Reader Transilluminator allows the visualization of 
the DNA on the gel for excision of the desired size while avoid-
ing UV exposure that may be harmful to the DNA sample. 
  17.  Make sure not to cut out any of the light adaptor band (below 
150 bp). It is advisable to take a photograph of the gel before 
and after the excision. 
  18.  Do not heat the samples to 55 °C as stated in the GelExtraction 
kit protocol. 
  19.  Do not  centrifuge the sample at this point. 
  20.  If you are unable to perform quality control of your sample 
using a bioanalyzer, your sequencing facility may be able to 
perform this step for you. In this case, we recommend per-
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forming a  qPCR analysis of a target that is known/thought to 
be enriched before sending your samples off. 
  21.  Make sure to protect the DNA dye concentrate from light. 
  22.  Use the indicated volumes. Different volumes at the same ratio 
can produce inaccurate results. 
  23.  Shield the gel—dye mix from light and store at 4 °C. It is suf-
fi cient for fi ve chips. Use within 6 weeks of preparation. 
  24.  Even if you have less than 11 samples, do not leave any wells 
empty; otherwise, the chip will not run properly. 
  25.  Samples should be dissolved in 10 mM Tris and 1 mM EDTA 
for optimal results. However, we have achieved good results 
with our samples in EB buffer. 
  26.  Never use force to close the lid or drop the lid onto the chip. 
This may damage the electrodes or cause liquid spills leading 
to bad results. 
  27.  A more thorough  c lean may be required when switching 
between different types of assay. 
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